Coming into view: Renal iron handling in human health and disease by Raaij, S.E.G. van
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/200691
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Sanne van Raaij
Coming into view: 
Renal iron handling in
human health and disease
R
IM
L
S
2
0
19
-0
3
Paranimfen
Manon Engels 
mengels91@hotmail.com
Iris van Raaij
ivanraaij92@gmail.com
Promotie Sanne van Raaij 
Uitnodiging 
voor het bijwonen van 
de openbare verdediging
van mijn proefschrift
Coming into view: 
Renal iron handling 
in human health and disease
op dinsdag 19 februari 2019
om 16.30 uur precies
in de aula van de
Radboud Universiteit Nijmegen,
Comeniuslaan 2 te Nijmegen.
U bent van harte welkom
bij deze plechtigheid
en de aansluitende receptie.
Sanne van Raaij
segvanraaij@gmail.com
C
o
m
in
g in
to
 v
iew
: R
en
a
l iro
n
 h
a
n
d
lin
g in
 h
u
m
a
n
 h
ea
lth
 a
n
d
 d
isease      San
n
e van
 R
aaij
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 1
Sanne van Raaij
Coming into view: 
Renal iron handling in
human health and disease
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 2
 
 
 
 
 
 
 
 
 
 
 
 
The research presented in this thesis was performed at the Translational Metabolic Laboratory, part 
of department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud 
university medical center, Nijmegen, the Netherlands. Publication of this thesis was financially 
supported by the Radboud University Nijmegen, the Netherlands.  
 
 
ISBN: 978-94-028-1342-5 
 
Thesis number: RIMLS 2019-03 
 
 
Cover painting: Sanne van Raaij 
Cover design: Promotie In Zicht, Arnhem  
Lay out: Promotie In Zicht, Arnhem 
Print: Ipskamp printing, Enschede  
 
 
About the cover: Artistic representation of ferroportin immunohistochemistry staining in healthy 
human kidney biopsy, based on Figure 2f in van Raaij ?????? ?????????????????? 2018 (Figure 5.2f on 
page 102 in this thesis). 
 
 
Copyright © 2019 Sanne van Raaij, Nijmegen, the Netherlands  
 
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by 
any means without prior written permission of the author. 
 
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 3
 
 
 
???????????????????????????????????????
????????????????????????????
 
 
 
 
 
 
 
Proefschrift 
 
 
 
 
 
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken, 
volgens besluit van het college van decanen 
 
in het openbaar te verdedigen op 
dinsdag 19 februari 2019 
om 16.30 uur precies 
 
 
door 
 
 
???????????????????????????????????
geboren op 4 februari 1990 
te Nijmegen 
 
 
 
  
Coming into view: 
Renal iron handling in
human health and disease
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 4
???????????
Prof. dr. D.W. Swinkels 
Prof. dr. R. Masereeuw (Universiteit Utrecht) 
 
???????????
Dr. R.P.L. van Swelm 
 
????????????????????
Prof. dr. J.G.J. Hoenderop 
Prof. dr. J.F.M. Wetzels 
Prof. dr. C.A.J.M. Gaillard (Universiteit Utrecht) 
 
?
 
 
  
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 5
 
 
Doctoral thesis 
 
 
 
 
 
to obtain the degree of doctor 
from Radboud University Nijmegen 
on the authority of the Rector Magnificus prof. dr. J.H.J.M. van Krieken, 
according to the decision of the Council of Deans 
 
to be defended in public on 
Tuesday, February 19, 2019 
at 16.30 hours  
 
 
by 
 
 
???????????????????????????????????
born in Nijmegen 
on February 4, 1990 
 
 
 
  
Coming into view: 
Renal iron handling in
human health and disease
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 6
????????????
Prof. Dr. D.W. Swinkels 
Prof. Dr. R. Masereeuw (Utrecht University) 
 
??????????????
Dr. R.P.L. van Swelm 
 
??????????????????????????
Prof. Dr. J.G.J. Hoenderop 
Prof. Dr. J.F.M. Wetzels 
Prof. Dr. C.A.J.M. Gaillard (Utrecht University) 
  
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 7
 
?
?
??????????
?????????????????????????
  
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 8
 
 
 
 
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 9
TABLE OF CONTENTS 
 
Chapter 1  General introduction       11 
 
Chapter 2 Iron handling by the human kidney: Glomerular filtration and  33 
tubular reabsorption both contribute to urinary iron excretion 
 
Chapter 3 Iron uptake by ZIP8 and ZIP14 in human proximal tubular epithelial  53 
cells  
 
Chapter 4 Inhibition of Nrf2 alters cell stress induced by chronic iron exposure  75  
In human proximal tubular epithelial cells  
 
Chapter 5 Tubular iron deposition and iron handling proteins in human healthy  95 
kidney and chronic kidney disease 
 
Chapter 6 General discussion      117 
 
Chapter 7 Summary       139 
  Samenvatting        143 
 
Chapter 8 List of publications      151 
  List of abbreviations      153 
  Research data management     157 
  Curriculum Vitae       159 
  PhD portfolio       161 
 
Chapter 9 Dankwoord ? Acknowledgements     163 
   
 
 
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 10
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 11
1
General introduction
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 12
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 13
IRON HOMEOSTASIS  
The metal iron 
Iron is the most abundant metal on earth.1 Iron itself is insoluble in water and, therefore, 
it needs to be complexed to ligands to become bioavailable to living organisms.1 In the 
mammalian systemic circulation, iron is incorporated in hemoglobin in erythrocytes to 
transport oxygen throughout the body.2 At the cellular level, iron is incorporated in 
various enzymes and functions in a large variety of cell processes ranging from cell 
proliferation and the mitochondrial respiratory chain, to cellular electron transport and 
DNA synthesis.3 
 Iron functions in many processes via its reversible shifting between two redox 
states: the oxidized ferric iron (Fe3+) and the reduced ferrous iron (Fe2+).4 Most iron in the 
body is in the ferric form, since physiological oxygen concentrations readily oxidize ferrous 
iron to ferric iron. As a result, reducing agents are critical, to provide ferrous iron that is 
required for cellular transport, storage and heme synthesis.4 These redox shuttling 
properties can also be harmful. In presence of oxygen, iron redox cycling is prone to 
catalyze the production of highly reactive oxygen species (ROS), generated in the Fenton 
and Haber-Weiss reactions (Figure 1.1).5,6 Iron-induced ROS, particularly hydroxyl 
radicals,7 are known to cause injury to cellular structures including membranes, DNA and 
proteins.8 Therefore, iron levels are carefully balanced and tightly regulated at both the 
systemic and cellular level.9 
 
Systemic iron homeostasis 
The human body contains 3-4 g of iron, the majority of which is incorporated in the form 
of hemoglobin in circulating erythrocytes or in immature erythrocytes residing in the bone 
marrow (1-2g) (Figure 1.2).2 Tissues such as the liver and muscle also contain relatively 
high iron levels (~1000 mg, and ~300 mg, respectively). In contrast, plasma iron levels are 
rather low, only 2-3 mg. In the circulation, iron is bound to the glycoprotein transferrin 
(transferrin-bound iron, TBI), which binds two molecules of iron with a very high affinity 
(Kd = ~10
-23 M).10 In the form of TBI, iron is transported to all cells of the body. Plasma iron 
levels are predominantly maintained by erythrocyte turnover in reticuloendothelial 
macrophages in the spleen and replenished by iron absorption from the diet by duodenal 
enterocytes.11 Iron transport towards the plasma is mainly controlled by hepcidin. This 
iron-regulatory peptide hormone is produced in hepatocytes and secreted into the blood 
stream where it functions via inactivation of ferroportin (SLC40A1), which is the only 
known mammalian cellular iron exporter. Binding of hepcidin to ferroportin at the plasma 
membrane causes ferroportin internalization and lysosomal degradation.12 This way, 
hepcidin controls dietary, stored and recycled iron transport into the blood stream in  
13
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Figure 1.1: Iron can induce reactive oxygen species formation in the Fenton and Haber-Weiss reaction 
 
enterocytes, hepatocytes and macrophages, respectively.2 As a result, in case of low 
plasma iron, decreased hepcidin production enables the elevation of circulating iron levels 
to meet erythropoiesis demand, whereas high hepcidin levels halt iron export into the 
blood stream when systemic iron levels are high. However, once iron is reabsorbed, the 
body has limited physiological mechanisms to regulate iron excretion.9 Daily iron loss is 
minimal, only 1-2 mg/day, in order to ensure availability of this scarce metal for body iron 
demand. As a consequence, duodenal enterocytes absorb only 1-2 mg of iron/day. 
However, iron loss is not actively regulated, and takes place via uncontrolled processes 
like sloughing of enterocytes, desquamation of skin and urinary cells, bleeding (including 
menstruation) and sweating.13,14 Consequently, in physiological conditions, mammalian 
total body iron levels are mainly regulated through dietary iron uptake at the level of the 
intestine.11 
 
Cellular iron homeostasis 
Mammalian cells have evolved strategies to safely acquire, distribute, store and use iron 
species (Figure 1.3). Most cell types acquire iron via transferrin receptor 1 (TfR1) at the cell 
surface. At physiological pH (7.4), TfR1 effectively binds diferric transferrin 
(holotransferrin) and ferric transferrin (monotransferrin), whereas the affinity of iron 
deficient transferrin form (apotransferrin) for TfR1 is two magnitudes lower.15 The TBI-
TfR1-complex is internalized into an endosome, where acidification via a V-ATPase proton 
pump lowers the pH to ~5.6, and iron is released from the holotransferrin-TfR1 
complex.15,16 The apotransferrin-TfR1 complex is returned to the cell surface, where the 
physiological pH now enables dissociation of apotransferrin from its receptor.15 In the 
endosome, iron is reduced by a reductase, for example STEAP3 (six-transmembrane 
epithelial antigen of prostate 3) in erythrocyte precursors,17 and transported over the 
endosomal membrane into the cytosol by a divalent metal transporter. Divalent metal 
transporter 1 (DMT1, SLC11A2) has been reported  to transport iron into the cytosol in 
erythroid precursors, hepatocytes and macrophages.18-21 However, cellular iron import  
14
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Figure 1.2 Iron uptake, distribution and recycling to maintain sufficient systemic iron levels  
The amount of iron bound to transferrin (Tf) in the systemic circulation is maintained by iron absorption in the 
duodenum to compensate for daily iron loss. Most body iron is used for production of hemoglobin in 
erythrocytes. Senescent erythrocytes are recycled by reticuloendothelial macrophages, replenishing plasma iron 
levels. Moreover, iron is stored in hepatocytes (liver), muscle tissue and reticuloendothelial macrophages. 
Systemic iron homeostasis is regulated by the peptide hormone hepcidin that is produced by hepatocytes  when 
body iron levels are high, causing iron to be sequestered in macrophages, and duodenal iron absorption to be 
reduced.  
 
redundancy was observed for DMT1, since DMT1 knockout mice become anemic, but 
maintain liver iron stores.18 Moreover, divalent metal transporters ZIP8 (SLC39A8) and 
ZIP14 (SLC39A14) are candidates for endosomal iron transport towards the cytosol in 
hepatocytes and neuronal cells.22-24 In the cytosol, iron is either stored in ferritin, utilized 
by iron-requiring processes, like respiration in the mitochondria, or exported into the 
blood stream by ferroportin.25 Ferritin is a large intracellular iron storage protein, where 
iron is oxidized by the ferroxidase H-ferritin for storage as ferrihydrite aggregates within 
the L-ferritin core.26 How iron is transported throughout the cell, i.e. from the endosomes 
to the ferritin molecules or towards ferroportin, is not well known. These transport 
processes are suggested to be mediated by iron chaperones, like poly(rC) binding proteins 
(PCBPs), monothiol glutaredoxin (Grx) proteins or cytosolic molecules like glutathione.27,28  
 The above described cellular iron transport mechanisms are tightly regulated to 
balance cellular iron homeostasis without potential harmful effects. Posttranscriptional 
iron-responsive element – iron responsive protein (IRE-IRP) regulation has emerged as a 
central coordinating system to regulate the expression of iron uptake, storage and export 
proteins.29 Depending on the cellular iron content, IRP proteins 1 and 2 (IRP1 and IRP2, 
respectively) bind to IRE mRNA motifs and increase or decrease protein translation, 
depending on the location of the IRE in the mRNA. Binding of IRPs to single IREs in the 
15
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Figure 1.3 Cellular iron handling 
Overview of cellular iron handling based on processes described in hepatocytes, enterocytes and macrophages. 
Iron (in red) bound to transferrin (in blue) (transferrin-bound iron, TBI) is internalized by endocytic transporter 
transferrin receptor 1 (TfR1). In the endosome, acidification by a V-ATPase proton pump results in release of iron 
from the TBI-TfR1 complex, which is reduced by a ferrireductase and subsequently transported into the cytosol 
by potential divalent metal transporters ZIP8, ZIP14 and divalent metal transporter 1 (DMT1). The remaining 
transferrin-TfR1 receptor complex is returned to the cell surface. Iron bound to small ligands (non-transferrin-
bound iron) can potentially be internalized into the cytosol by divalent metal transporters ZIP8, ZIP14 and DMT1. 
Once in the intracellular labile iron pool, iron can be either utilized in iron-requiring processes in mitochondria, 
stored in the ferritin protein shell or exported through the cellular iron exporter ferroportin.  
 
5’UTR, for example in L-ferritin, H-ferritin and ferroportin, represses mRNA translation. In 
contrast, binding of IRPs to multiple IREs located in the 3’UTR in TfR1 and DMT1 results in 
mRNA stabilization and, as such, inhibits mRNA decay and enhance mRNA translation.30 In 
case of low intracellular iron levels, IRPs can freely bind IRE mRNA elements. This results in 
decreased iron export by ferroportin and reduced iron storage in ferritin, and iron is 
released from ferritin via NCOA4-mediated autolysosomal ferritin degradation.31,32 
Moreover, TfR1 translation is prolonged, further increasing intracellular iron levels.29 In 
contrast, with high intracellular iron levels, iron is incorporated in IRP1 to form an iron 
sulfur cluster that functions as an intracellular aconitase in the Krebs cycle with the 
assistance of FAM96A, whereas iron binding in IRP2 results in proteosomal degradation 
mediated by FBXL5.33,34 This leaves the IREs unbound, resulting in L-ferritin, H-ferritin and 
ferroportin translation, increasing iron storage and iron export, while TfR1 mRNA are no 
longer stabilized and will be degraded, decreasing cellular iron uptake.29 All together, this 
decreases intracellular iron levels. To date, IRE-IRP regulation of DMT1 is not fully 
resolved, as this seems life-stage dependent35 and some DMT1 isoforms lack mRNA IREs.36 
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IRON AND KIDNEY INJURY  
 
Current understanding of systemic and cellular iron homeostasis is mainly derived from 
studies in hepatocytes, erythrocyte precursors, enterocytes and macrophages. Knowledge 
of physiological iron homeostasis in the kidney is limited,25 despite observations made 
decades ago that iron could play a role in renal injury.37-39 The kidney expresses many 
proteins that are not only essential for maintaining renal cellular iron balance,40,41 but are 
also likely involved in maintaining systemic iron balance by renal reabsorption of filtered 
iron species.25 However, the localization of several iron handling proteins in renal tubular 
epithelial cells in physiological conditions is still unclear. This includes their detailed 
intracellular localization, i.e. presence at the plasma membrane and/or in intracellular 
structures such as endosomes, as well as their localization in different tubular segments of 
the renal filter units, termed nephrons.25 Moreover, human-based studies examining renal 
iron handling are scarce,41 despite the fact that differences in systemic iron handling 
between animal models and human physiology have been recognized.42 Although the 
kidney’s primary function is to remove waste products from the circulation by urinary 
excretion,43 evidence is growing that renal nephrons may function in iron homeostasis by 
preventing urinary iron and transferrin excretion regardless of systemic iron levels.44 As 
such, renal iron handling may differentiate from iron handling in other cell types. Renal 
tubular cells express additional proteins that are shown to play a role in renal iron 
handling, i.e. the megalin:cubilin:amnionless receptor complex and NGAL receptor 
(NGALR, SLC22A17).25 Moreover, iron handling differs between distinct segments of the 
renal nephron, e.g. between proximal and distal tubules (PTs and DTs, respectively).25 
Renal tubuli could be exposed to high iron levels in systemic iron overload disorders or 
kidney disease, which may have deleterious consequences in terms of iron toxicity. A 
better understanding of the mechanisms of human renal tubular iron handling and 
subsequent toxicity will be essential in dissecting the role of iron in kidney injury.  
 
Renal iron homeostasis 
Plasma molecules can enter the nephron by glomerular filtration into the renal tubular 
lumen. Subsequently, essential molecules are reabsorbed back into the circulation by 
reabsorption by renal tubules, whereas waste products are excreted in urine.43 TBI in the 
systemic circulation is suggested to be at least partly filtered by the glomerulus. In vivo 
studies have demonstrated the presence of transferrin in the primary urine, and showed 
that ~0.4 mg of iron is daily filtered by the rat kidney, of which only 0.7% is daily excreted 
in the final urine.40,45,46 Indeed, hardly any iron or transferrin is found in urine in human 
healthy volunteers,14,47-49 suggesting that filtered TBI is almost completely reabsorbed by 
the renal tubular epithelium. Although proteins filtered by the glomerulus are 
predominantly reabsorbed by PTs,25 micropuncture studies in rats demonstrated that both 
17
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PTs and DTs can reabsorb TBI.45,46 The TBI uptake transporter TfR1 is found in the kidney, 
but its intracellular localization in renal tubules remains controversial. Studies in mice, rats 
and human kidney tissues showed TfR1 immunostaining in PTs and DTs at both the apical 
and basolateral tubular membranes.44,50-54 TBI uptake in PTs can also be mediated by the 
endocytic megalin:cubilin:amnionless receptor complex.55 Studies in megalin deficient 
mice and dogs with deficient cubilin surface expression showed that transferrin is a ligand 
for the cubilin receptor, but transferrin endocytosis requires cooperation of both megalin 
and cubilin.56 Function of this receptor complex also requires the transmembrane protein 
amnionless, which is essential for cubilin trafficking towards the apical membrane.57,58 In 
addition, TBI uptake by this receptor complex is supported by findings of increased urinary 
transferrin levels in patients with Fanconi syndrome, a disorder characterized by 
compromised PT reabsorption by the megalin:cubilin:amnionless receptor complex,48,59 or 
Donnai-Barrow/Facio-Oculo-Acustico-Renal syndrome, an extremely rare disorder 
characterized by megalin deficiency.60 Internalization of fluorescently labeled TBI was also 
shown in mouse distal tubular epithelial cells, facilitated by the NGALR.61 Subsequent to 
endocytosis by any of the abovementioned endocytic transporters, iron is transported 
from the endosome towards the cytosolic, but this process has not yet been studied in 
renal tubular epithelial cells. Although DMT1 and ZIP14 protein expression have been 
detected in murine kidney (DMT1;40,62-68 ZIP1469) and ZIP8 was found in mice and human 
kidney,69-71 functional studies on their role in renal tubular TBI-derived iron uptake are 
absent. Similar to other cell types, intracellular iron is stored in ferritin and iron is 
exported by ferroportin. Although ferroportin was localized to the tubular basolateral 
membrane by several studies in mice and rats,65,72-74 this has not been examined in the 
human kidney before. Interestingly, a study in mice detected ferroportin on the apical 
tubular membrane and suggested a role of this protein in iron import.75  
 
DISORDERS OF SYSTEMIC IRON OVERLOAD 
Renal injury as a result of chronic iron exposure is an emerging avenue of interest in iron 
overload disorders. Disturbed intestinal iron uptake is known to result in systemic iron 
overload, which may cause injury to organs including the liver and heart,9 but has also 
been  associated with renal injury.41 Increased iron levels reside in the systemic circulation 
but are also deposited in parenchymal tissues.9 In hereditary hemochromatosis (HH), 
unrestricted iron uptake that is inappropriate to body iron stores usually results from 
inherited defects in proteins involved in hepcidin regulation.76 The most common form in 
Caucasians (>90%) is related to a homozygous variant in the human hemochromatosis 
gene (HFE, HFE-HH) on chromosome 6 (p.Cys282Tyr/p.Cys282Tyr, abbreviated 
C282Y/C282Y).77 HFE-HH affects 1 in 200-300 individuals of Northern European descent,78-
80 but its clinical penetrance is low, only 13.5% in a meta-analysis of 19 epidemiological 
18
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studies,78 indicating many individuals carry the genotype without experiencing iron 
overload symptoms. In practice, patients are mostly males between 40-60 years of age.78 
HFE-HH results in innate low hepcidin levels,81 which can lead to iron loading in the liver, 
heart, pituitary and pancreas and subsequent liver cirrhosis, hepatocellular carcinoma and 
cardiac myopathy.82,83 Treatment for patients with HFE-HH usually consists of phlebotomy 
(venesection), when large quantities of iron in erythrocytes are removed.78,80 
Subsequently, circulating iron is replenished by iron stored in tissues to provide iron for 
erythropoiesis, leading to a gradual decline in body iron stores.81 
Systemic iron overload can also be secondary to other disorders (acquired), which 
is the case for inherited hemoglobin disorders, including thalassemia syndromes, sickle 
cell disease, sideroblastic anemia or other forms of anemia characterized by ineffective 
erythropoiesis.84 In thalassemia ??????????? ???????? ??????????? ??? ?- ??? ?-globin chains, 
?????????- ????-thalassemia, respectively, results in disturbed hemoglobin synthesis and, 
as such, impaired erythropoiesis.85 The epidemiology of thalassemia disorders is not 
completely defined, although a relevant high prevalence is found in the Mediterranean 
area, Middle East, sub-Sahara Africa, Indian subcontinent and Southeast Asia.86,87 Patients 
????? ?-thalassemia are typically classified according to their level of globin production, 
anemia severity and clinical presentation.84 ????????? ????? ?-thalassemia minor carry a 
????????????? ?????????? ???? ???? ??????????? ?????????????? ???????? ?-thalassemia 
intermedia can present with variable mutations and treatment requirements, patients 
?????????? ????? ?-thalassemia major usually present with severe anemia in infancy and 
become transfusion dependent for life.84 ??? ?-thalassemia major, ineffective 
erythropoiesis cause anemia and, as such, lower hepatic hepcidin production triggers 
increased intestinal iron uptake and increased iron release from reticuloendothelial 
macrophages.88 Moreover, additional frequent red blood cell transfusions as treatment of 
anemia further add to systemic iron levels.84 Iron loading in the heart, liver and endocrine 
organs causes complications of cardiomyopathy, chronic hepatitis and endocrine 
problems.89 Iron re?????? ???????? ??? ????????? ????? ?-thalassemia consists of treatment 
with iron chelation medication.84 Several iron chelators are available that bind iron in the 
circulation and subsequently cause urinary and/or fecal excretion of the iron-chelator 
complexes, reducing systemic iron levels.90 When chelation therapy is initiated at an early 
age, this treatment is successful in reducing iron-related complications.91 
In systemic iron overload, the amount of iron that is bound to circulating 
transferrin (transferrin saturation, expressed as percentage) is used as measure for 
circulating iron overload.76 Whereas transferrin is saturated for 20-45% with iron in health, 
this value usually exceeds 60% in patients with systemic iron overload.80 Plasma ferritin 
levels correlate with body iron stores, and are, therefore, used as diagnostic tool to 
determine iron stored in parenchymal tissues and reticuloendothelial macrophages.80,84 
When transferrin is for at least 70% saturated with iron, also non-transferrin-bound iron  
19
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Table 1.1: Iron overload phenotype and treatment in ???-???????? ??????????? ???????????????? ???? ?-
thalassemia major summarized 
 
???-related hereditary 
hemochromatosis 
?-thalassemia major 
Cause of iron loading 
Unrestricted intestinal iron 
uptake due to innate low 
hepcidin levels  
Unrestricted intestinal iron uptake due 
to ineffective erythropoiesis + red 
blood cell transfusions  
Main localization of iron 
deposition  
Liver, heart, endocrine organs Heart, liver, endocrine organs 
Age of onset 40 – 60 years Infancy  
Predominant treatment to 
reduce systemic iron levels 
Phlebotomy Iron chelation 
 
(NTBI) where iron is bound to  low-molecular weight carrier molecules, can be 
detected.92,93Although the exact nature of NTBI remains to be determined and is 
suggested to vary based on the degree and duration of iron overload,92-94 iron in NTBI is 
predominantly bound to citrate, but can also bind to acetate or albumin.95-97 Iron binds its 
ligands in NTBI with a much lower affinity than in TBI, rendering it potentially reactive.92 
Specific laboratory analyses are designed to determine the labile and redox active fraction 
of NTBI, termed labile plasma iron (LPI).8,98  
The iron phenotype and treatment options of patients with HFE-HH ??? ?-
thalassemia major are summarized in Table 1.1.  
 
Renal dysfunction in systemic iron overload  
?????????????????????????????????????????-thalassemia major was limited as a result of severe 
cardiomyopathy, which is attributed to the limited ability of cardiomyocytes to cope with 
internalized LPI and subsequent iron accumulation and ROS production.99 Since the 
?????????? ??? ????? ?????????? ???????? ??? ?????? ????? ?????????? ???? ?????????? ?????? ??? ?-
thalassemia have seriously declined.91,100,101 However, extending patient survival with the 
current treatment possibilities has resulted in reports of renal dysfunction in patients with 
thalassemia syndromes.102 This includes glomerular anomalies of increased urinary 
creatinine clearance and proteinuria103 but also tubular dysfunction, manifested by 
hypercalciuria, hyperuricosuria and renal glycosuria.104-106 More specifically, tubular 
dysfunction was localized to PTs, by reports of increased urinary excretion of N-acetyl-?-D-
???????????????? ?????? ???? ?-2-microglobulin, indicators of PT dysfunction.104,105,107-110 
Multiple clinical and preclinical studies show that these renal injury findings could be 
associated with chronic exposure to increased renal iron concentrations. Indeed, in 
???????????????-thalassemia syndromes, histological staining of MRI imaging showed iron 
accumulation in the kidney.109,111,112 Moreover, increased urinary iron levels were also 
observed,113-116 indicating the nephrons are exposed to high iron levels. ?????????????????-
?????????????????????????????????????????-thalassemia intermedia, severe systemic iron 
20
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loading induced renal iron accumulation.117 In other systemic iron overload mouse 
models, iron was also found to deposit in the kidney. In HFE or HFE2 knockout mice, 
mouse models for HH, increased iron levels were detected in the kidney24 Moreover, 
when systemic iron overload was induced in control mice by long term high iron diet, iron 
dextran injection or administration of radioactive iron (59TBI and 59Fe-NTBI), iron 
accumulated in the kidneys, as shown by Perls’ staining, iron quantification or radioactive 
signal detection.118-125 Reports in patients with HFE-HH seem to confirm the above 
mentioned ????????findings, since renal iron accumulation and enhanced urinary iron levels 
were reported in these patients.126-133 All together, this evidence supports an association 
between chronic exposure to increased renal iron levels and renal injury in systemic iron 
overload. 
Currently, it remains unknown which molecular mechanisms are involved in 
human renal iron loading during systemic iron overload and potential subsequent iron-
induced  injury. Similar to observations in cardiomyocytes and hepatocytes,134,135 chronic 
exposure to high iron concentrations is shown to induce oxidative stress in renal tubular 
epithelial cells. Moreover, in human and porcine tubular epithelial cells, 72h iron exposure 
was found to reduce cell viability and decrease cell proliferation, respectively.136,137 
Studies in rats have shown that a long term iron diet can result in tubular atrophy, iron 
deposition and enhanced malondialdehyde (MDA) formation, a byproduct of lipid 
peroxidation induced by oxidative stress, in the renal tubular epithelium.122,138 Moreover, 
iron-induced lipid peroxidation and kidney dysfunction were ameliorated in iron-
overloaded rats by administration of antioxidant compounds,139-141 suggesting that 
oxidative stress may cause iron overload-induced renal injury. Patients with HFE-HH ????-
thalassemia major also showed increased MDA levels and decreased levels of antioxidants 
vitamin E and ascorbic acid in plasma, as well as increased oxidized RNA products in 
urine.107,142-146 These findings suggest that chronically increased renal tubular iron 
exposure can induce oxidative stress-related renal tubular injury. Mechanistically, uptake 
of TBI (as described above) and NTBI can contribute to renal iron loading and subsequent 
renal injury. Divalent metal transporters ZIP8, ZIP14 and DMT1 are implicated in NTBI 
transport at the plasma membrane in hepatocytes, pancreatic cells and neurons (Figure 
1.3),21,23,147-151 but the role of these transporters in NTBI uptake has not been studied in 
renal tubular epithelial cells.  
CHRONIC KIDNEY DISEASE 
In chronic kidney disease (CKD), iron is suggested to play a detrimental role in the onset or 
progression of renal injury.152 CKD is a heterogeneous group of kidney disorders 
characterized by a decrease in glomerular filtration rate (GFR) <60 ml/min/1.73m2 in 
combination with pathologic kidney abnormalities on biopsy, imaging or urinary sediment 
or proteinuria for 3 months or more.153 In these patients, valuable serum proteins are lost 
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in urine as a result of glomerular leakage whereas waste products from the human body 
are not properly removed from the circulation by the renal tubular epithelial cells.43 
Currently, CKD affects 13% of the population worldwide.154 As kidney function gradually 
decreases over time, these patients can progress to end stage renal disease, which has a 
yearly mortality rate above 20%.155 Current treatment for patients with CKD is mainly 
aimed at ameliorating the symptoms of nephropathy, including proteinuria, which is the 
major risk factor for CKD progression.156 Treatment to reduce proteinuria consists of 
medication for blood pressure control, for instance by use of angiotensin-converting 
enzyme (ACE) inhibitors.157 Unfortunately, this treatment is not effective in reducing 
proteinuria in a large proportion of CKD patients, and progression to end stage renal 
disease or the emergence of cardiovascular complications cannot be prevented.158 
Therefore, new treatment modalities are required for patients with CKD, preferably aimed 
at the underlying pathological mechanisms.  
 
Iron-mediated injury in chronic kidney disease 
In many pathologies of CKD, renal disease is initiated by injury to the glomerulus, which 
manifests as proteinuria.159 As a result, increased levels of circulating TBI are filtered into 
the tubular lumen and result in high iron exposure for renal tubular epithelial cells. 
Indeed, increased urinary transferrin levels have been detected in patients with various 
CKD pathologies.38,48,49,160 However, in renal tubulointerstitial disorders, also called 
tubulopathy, renal disease originates from abnormalities in the renal tubuli. These 
disorders may affect TBI handling, ???? TBI uptake, based on the increased urinary 
transferrin excretion found in patients with Fanconi syndrome, a PT tubulopathy 
disorder.48 Injury to both the glomerulus and tubulointerstitium are recognized as part of 
the progression of CKD.161 As such, both glomerular TBI filtration and TBI reabsorption can 
be disturbed in disorders of CKD.  
Accumulating evidence suggests that renal iron accumulation may be involved in 
the onset and/or progression of CKD. The first reports of a potential role of iron in the 
pathogenesis of CKD date from the 1980s, when iron reduction by a low iron diet or by 
infusion of an iron chelator was shown to prevent renal function deterioration in 
nephrotoxic serum nephritis.37 This evidence was extended with the finding that iron 
reduction was also able to ameliorate renal tubular injury in an animal model of 
membranous nephropathy.162 In the years that followed, increased renal iron 
accumulation and urinary iron excretion were also reported in various other CKD animal 
models, such as puromycin aminonucleoside- and adriamycin-induced nephrotic 
syndrome, 5/6 nephrectomy, hypertension nephropathy, diabetic nephropathy, and 
passive Heymann nephritis.163-169 More recently, renal iron accumulation was also found in 
an animal model of lupus nephritis.170 Altogether, this illustrates that renal tubular 
epithelial cells are likely to be exposed to high iron concentrations and develop 
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tubulointerstitial injury in a large variety of CKD pathologies. Interestingly, administration 
of an iron chelator or low-iron diet was reported to reduce proteinuria and halt the loss of 
kidney function in multiple animal models of CKD.162,165-168,170,171 These findings suggests a 
relation between renal iron deposition, urinary iron excretion and tubular injury in several 
CKD animal models. Increased urinary iron excretion has also been observed in patients 
with CKD.38,49,160,172-178 Moreover, iron deposition was found in biopsies of various 
nephrotic CKD disorders, including IgAN nephropathy, membranous nephropathy and 
diabetic nephropathy.39,179,180 More specifically, iron deposition was localized to PTs 
lysosomes in nephrotic CKD, which was present in higher levels in damaged renal tubuli 
than in tubules with less damage.181 Although this suggests that increased iron exposure 
may be deleterious for renal tubuli in patients with nephrotic CKD, insights in the 
molecular mechanisms of tubular iron handling in response to enhanced iron supply in 
human CKD are lacking. 
In addition to the uncertainties of renal iron handling, our insights in the 
mechanisms of iron toxicity are far from complete. Increased oxidative stress production 
and decreased mRNA expression of antioxidant enzymes were reported in mouse models 
of diabetic nephropathy and protein-overload induced tubulointerstitial injury,166,182,183 as 
well as production of inflammatory cytokines, ultimately leading to renal fibrosis.168,184 An 
iron-restricted diet ameliorated oxidative stress formation and inflammation in several 
studies,166,168,182 indicating that both oxidative stress and inflammation are key processes 
involved in iron-induced renal injury during CKD. However, the molecular mechanisms 
involved in these detrimental processes, as well as potential interaction between these 
pathways during iron-mediated tubular injury remain elusive. 
 ?
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AIM AND OUTLINE OF THIS THESIS  
 
The aim of this thesis was to gain insights into the molecular mechanisms of renal tubular 
iron handling in health and disease and to improve our understanding of the detrimental 
role of iron in renal injury.  
To this end, we performed studies to assess tubular iron handling in human 
health, systemic iron overload and CKD. In Chapter 2, we describe human renal iron 
handling for which we measured urinary iron excretion and tubular injury in healthy 
controls, patients with tubular dysfunction and patients with systemic iron overload. In 
Chapter 3, we characterized the molecular mechanisms involved in TBI and NTBI uptake in 
conditionally immortalized proximal tubular epithelial cells (ciPTECs), focusing on divalent 
metal transporters ZIP8 and ZIP14. In Chapter 4, we describe our studies into the potential 
of chronic iron overload to induce cytotoxicity in ciPTECs and investigated the molecular 
mechanisms involved. Lastly, in Chapter 5, we examined the extent and localization of iron 
deposition in renal biopsies of patients with various CKD pathologies. Here, we also 
characterized the presence and localization of proteins involved in iron handling in healthy 
controls and CKD patients, as well as injury related to iron accumulation. The implications 
and future prospects of the findings described in this thesis are discussed in Chapter 6 and 
summarized in Chapter 7. 
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ABSTRACT 
Background: In physiological conditions, circulating iron can be filtered by the glomerulus 
and is almost completely reabsorbed by the tubular epithelium to prevent urinary iron 
wasting. Increased urinary iron concentrations have been associated with renal injury. 
However, it is not clear whether increased urinary iron concentrations in patients are the 
result of increased glomerular iron filtration and/or insufficient tubular iron reabsorption 
and if these processes contribute to renal injury.  
Methods: We measured plasma and urine iron parameters and urinary tubular injury 
markers in healthy human subjects (n=20), patients with systemic iron overload (n=20) 
and patients with renal tubular dysfunction (n=18).  
Results: Urinary iron excretion parameters were increased in both patients with systemic 
iron overload and tubular dysfunction, whereas plasma iron parameters were only 
increased in patients with systemic iron overload. In patients with systemic iron overload, 
increased urinary iron levels associated with elevated circulating iron, as indicated by 
transferrin saturation (TSAT), and increased body iron, as suggested by plasma ferritin 
concentrations. In patients with tubular dysfunction, enhanced urinary iron and 
transferrin excretion were associated with distal tubular injury as indicated by increased 
urinary glutathione s-transferase-pi-1-1 (GSTP-1-1) excretion. In systemic iron overload, 
elevated urinary iron and transferrin levels were associated with increased injury to 
proximal tubules, indicated by increased urinary kidney injury marker 1 (KIM-1) excretion.  
Conclusion: Our explorative study demonstrates that both glomerular filtration of 
elevated plasma iron levels and insufficient tubular iron reabsorption could increase 
urinary iron excretion and cause renal injury. 
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INTRODUCTION 
In physiological conditions, circulating iron is bound to transferrin (transferrin-bound iron, 
TBI), which can be filtered by the glomerulus of the kidney into the renal tubular lumen.1 
Subsequently, filtered TBI is thought to be almost completely reabsorbed by renal tubular 
epithelial cells, since hardly any transferrin or iron is found in urine of healthy volunteers.1-
3 In addition, micropuncture studies in rats demonstrated the presence of transferrin in 
primary urine and showed iron can be reabsorbed by both the renal proximal tubule (PT) 
and distal tubule (DT).4  
Increased iron exposure can be harmful for tubular epithelial cells, because iron is 
known to catalyze reactive oxygen species formation in the Fenton reaction and cause 
tissue injury.5 In human and porcine PT epithelial cells, iron exposure decreased cellular 
viability and proliferation and caused oxidative cellular injury.6-8 Moreover, increased 
urinary iron levels have been found in patients with nephrotic syndrome and diabetic 
nephropathy,3,9-13 suggesting an association between enhanced urinary iron 
concentrations and renal injury. In animal models of renal diseases, such as minimal 
change nephrotic syndrome and nephrotoxic serum nephritis, increased urinary iron 
excretion coincided with renal tubular injury.14-16 Currently, it is not clear whether 
increased urinary iron concentrations are the result of increased glomerular iron filtration 
and/or insufficient tubular iron reabsorption and if these processes directly contribute to 
the renal tubular injury.  
During systemic iron overload, unrestricted iron intake from the intestine in HFE-
hereditary hemochromatosis (HFE-HH) or additional frequent red blood cell transfusions 
??? ?-thalassemia major increase circulating TBI and also result in the presence of non-
transferrin-bound iron (NTBI), when the iron binding capacity of transferrin is 
exceeded.17,18 Moreover, these patients also present with high plasma ferritin 
concentrations, reflecting iron deposition in parenchymal tissues, like the liver and heart.17 
????-thalassemia major, elevated plasma ferritin levels were also associated with renal iron 
deposition.19 Increased urinary iron concentrations have been observed in patients with 
systemic iron overload,20-22 suggesting that glomerular filtration of increased circulating 
iron exceeds the tubular iron reabsorption capacity in these patients. Alternatively, 
urinary iron excretion can result from insufficient iron reabsorption in either PTs or DTs. 
Filtered proteins, including TBI,23,24 are predominantly reabsorbed by PTs,25 but also DTs 
express transporters involved in iron handling and are reported to take up TBI.26,27 
Increased urinary transferrin levels in patients with Fanconi syndrome, characterized by 
compromised proximal tubular reabsorption,1 suggest the tubular reabsorption capacity 
affects urinary transferrin levels, and similarly, possibly also urinary iron levels.  
To better understand the contribution of increased glomerular iron filtration 
and/or insufficient tubular iron reabsorption by PTs and DTs to urinary iron levels and 
related renal injury, we performed an explorative study and measured plasma iron 
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parameters, urinary iron parameters and renal tubular injury markers among healthy 
subjects, patients with systemic iron overload and patients with renal tubular dysfunction.  
 
MATERIALS AND METHODS 
 
Study design 
This explorative, observational study included subjects between November 2016 and 
October 2017. Healthy volunteers (n=20) were recruited at the Radboud university 
medical center (Radboudumc; Nijmegen, the Netherlands). Exclusion criteria included 
presence of renal disease, iron overload disorder or urinary tract infection, use of 
chelation medication or active menstruation. Patients with systemic iron overload 
disorders (n=20; Table 2.1) were included based on the diagnosis made by their treating 
physician and with most recent determined transferrin saturation (TSAT)>70% at 
Radboudumc and Amsterdam university medical center (Amsterdam, the Netherlands). 
Patients with renal tubular dysfunction disorders (n=18; Table 2.1) were included based on 
the diagnosis made by their treating physician in Radboudumc, Erasmus Medical Center 
(Rotterdam, the Netherlands), and UCL Centre for Nephrology, Royal Free Hospital 
(London, United Kingdom). This study was approved by the local ethics committee and 
performed according to national legislation and the declaration of Helsinki. All subjects 
signed informed consent forms. 
Patients with HFE-HH were undergoing maintenance phlebotomies. Patients with 
?-thalassemia major on iron chelation medication withdrew the use of this medication for 
at least 4 days, to prevent bias in urinary iron. Plasma levels of deferasirox (DFX), used by 
???????????????????-thalassemia major, were determined as described in De Francia et al.28 
Urinary iron levels were corrected for minimal residual iron bound to DFX in three 
patients. Since deferoxamine and ??????????????????????????????????-thalassemia major 
patients, respectively) have a shorter half life than DFX, we anticipate that suspending 
these chelators for four days eliminated plasma concentrations and subsequent urinary 
excretion of potential iron-chelator complexes. 
 
Sample collection 
Heparin plasma and urine were collected, aliquoted and stored at -80°C. For analysis of 
glutathione s-transferase-pi-1-1 (GSTP1-1), urine samples were mixed with a 10% (v/v) 
storage buffer (1M HEPES pH 7.5, 5% bovine serum albumin, 1% sodium azide, 1% Tween-
20, 10% glycerol) within 30 minutes of collection. 
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????????????????????
Iron, total iron binding capacity (TIBC; calculated as transferrin (g/l)*25.0), creatinine, C-
reactive protein (CRP), ferritin, creatinine, transferrin, and albumin analyses were 
performed according to routine diagnostic protocols at the Radboud Laboratory for 
Diagnostics at Radboudumc. Measurements of NTBI and labile plasma iron (LPI), the 
pathologically most relevant fraction of NTBI,5 were performed according Zhang ??? ???
(1995)29 and Esposito ??? ?? (2003),30? respectively. TSAT (the percentage of circulating 
transferrin that is saturated with iron (calculated as iron/TIBC*100), NTBI and LPI were 
used as indicators of circulating iron species.17,18 Estimated glomerular filtration rate 
(eGFR) was determined using the modifications of diet in renal disease (MDRD) formula. 
Urinary iron analysis was performed by inductively coupled plasma mass spectrometry 
(ICP-MS) at Maastricht University Medical Center (the Netherlands). For analysis of urinary 
oxidative stress, thiobarbituric acid (TBA) reactive substances (TBARs) were measured 
based on a previously described method.31 In short, samples were mixed with 75 mM TBA 
in 75 mM KH2PO4 and heated to 96°C for 1h. After cooling, samples were mixed with 
butanol and centrifuged at low speed. Fluorescence of the supernatant was compared to a 
standard curve made of tetramethoxypropane. Kidney injury marker 1 (KIM-1; R&D 
Systems, DKM100) and GSTP1-132 were measured by ELISA. Plasma and urinary hepcidin 
concentrations were determined by a combination of weak cation exchange 
chromatography and time-of-flight mass spectrometry as previously described.33 All urine 
parameters were corrected for urinary creatinine concentration. 
 
 
?
????????????????????????????????????
 
????????
?????????
???????????????
????????????
??????????
??????????????
Subjects (n) 20 18 20 
Age (years) 37.4 ± 3.4 41.9 ± 4.2 50.1 ± 4.2* 
Gender (M/F) 12/8 17/1 14/6 
Type of 
disorder 
- 
Cystinosis, n=2 
??????????????????? 
Fanconi syndrome, n=3 
Nephronophthisis, n=1 
Tubulo-interstitial nephritis, n=1 
????????????????????? 
Secondary to chemotherapy, n=5 
Lithium-induced nephrogenic 
diabetes insipidus, n=1 
Unknown cause, n=1 
?-thalassemia major, n=9 
Diamond Blackfan anemia, n=1 
HFE-related hereditary 
hemochromatosis, n=10 
 
Age presented as mean ± standard error of the mean (SEM). *, p<0.05, compared to healthy controls by Mann 
Whitney U test. 
??????????? ?? ??????
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Statistical analysis 
Data were statistically analyzed using SPSS 22 (IBM) and presented as median and 
interquartile range (IQR). One patient with tubular dysfunction was excluded from urinary 
analysis due to low creatinine concentration and plasma analysis could not be performed 
in four patients with tubular dysfunction as plasma samples were absent. Data were 
analyzed by Mann Whitney U test and non-parametric Spearman correlation coefficients. 
A p-value <0.05 was considered statistically significant. 
 
RESULTS 
 
Clinical and laboratory characteristics 
Clinical characteristics of all study participants are listed in Table 2.1 and results of 
laboratory analyses in Table 2.2. Plasma CRP was within reference range (<10 mg/ml) for 
all groups, indicating plasma iron parameters were not biased by the presence of 
inflammation. Subjects with systemic iron overload were older than healthy controls (50.1 
± 4.2 years vs. 37.4 ± 3.4 years, p<0.05), but this was not the case for patients with renal 
tubular dysfunction (41.9 ± 4.2 years, ns). All three groups comprised predominantly male 
subjects (Table 2.1). 
 
Increased urinary excretion of iron, transferrin and NTBI in patients 
with systemic iron overload 
Plasma iron, TSAT, NTBI, LPI and ferritin were increased in patients with systemic iron 
overload compared to healthy controls, whereas TIBC, hepcidin and thehepcidin/ferritin 
ratio were decreased (ferritin p<0.05, hepcidin and hepcidin/ferritin ratio p<0.01, others 
p<0.001; Table 2.2), confirming low hepcidin-induced iron overload. Urinary iron and NTBI 
levels were significantly increased in patients with systemic iron overload compared to 
healthy controls (p<0.01 and p<0.05, respectively; Table 2.2). Urinary iron levels 
correlated moderately with plasma TSAT (r=0.47, p<0.05; Figure 2.1a), but not with 
plasma iron or TIBC alone (Figure 2.1b, c). These findings indicate that urinary iron 
excretion could be caused by glomerular filtration of increased circulating iron levels. 
Moreover, both urinary iron and NTBI concentrations correlated strongly with plasma 
ferritin levels (r=0.75, p<0.001, and r=0.71, p<0.001; Figure 3.1d, e), suggesting that the 
increased urinary iron excretion could also be associated with high iron levels deposited in 
renal tubuli.  
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Table 2.2: Results of laboratory analyses in the 3 study groups  
 
Healthy  
controls 
Renal tubular  
dysfunction 
Systemic  
iron overload 
Plasma 
Iron 
(μmol/l) 
16.0 (12.7 – 18.7) 15.0 (12.5 – 21.5) 30.5 (27.5 – 39.5)*** 
TIBC 
(μmol/l) 
64.0 (57.2 – 73.0) 60.0 (53.7 – 74.7) 44.5 (41.2 – 48.0)*** 
TSAT 
(%) 
24.5 (20.1 – 30.8) 24.4 (17.2 – 33.6) 74.9 (62.5 – 89.7)*** 
Ferritin 
(μg/l) 
121.0 (68.0 – 178.5) 179.5 (38.5 – 269.8) 371.0 (111.0 – 906.8)* 
NTBI 
(μmol/l) 
0.23 (0.23 – 0.23) 0.23 (0.23 – 0.23) 1.22 (0.72 – 2.32)*** 
LPI 
(μmol/l) 
0.11 (0.10 – 0.14) 0.15 (0.11 – 0.22) 0.24 (0.22 – 0.31)*** 
CRP 
(mg/ml) 
0.5 (0.5 – 0.5) 1.5 (0.5 -2.2) 1.0 (0.5 – 2.0) 
Hepcidin 
(nM) 5.1 (1.3 – 7.1) 7.3 (1.1 – 10.3) 0.8 (0.3 – 2.0)** 
Hepcidin/ferritin ratio 
(nmol/μg) 36.9 ( 20.7 – 50.4) 37.9 (15.4 – 43.6) 2.3 (1.4 – 6.1)** 
Urine 
Iron 
(μmol/g creatinine) 
0.03 (0.02 – 0.07) 0.09 (0.03 – 0.20)* 0.21 (0.05 – 2.39)** 
Transferrin 
(mg/g creatinine) 
1.0 (0.6 – 2.7) 3.0 (0.9 – 11.8)* 1.1 (0.6 – 10.8) 
NTBI 
(μmol/g creatinine) 
0.4 (0.2 – 0.7) 0.6 (0.4 – 1.6) 0.5 (0.2 – 1.7)* 
Hepcidin 
(nM/g creatinine) 20.5 (6.9 – 49.7) 16.5 (8.7 – 56.0) 2.9 (1.3 – 11.1)** 
Albumin 
(mg/g creatinine) 
3.8 (2.8 – 5.7) 27.5 (9.2 – 168.5)*** 13.1 (7.1 – 283.8)*** 
KIM-1 
(ng/mmol creatinine) 
0.3 (0.1 – 0.5) 0.7 (0.4 – 0.8)** 0.9 (0.6 – 2.2)*** 
GSTP1-1 
(ng/mmol creatinine) 
3.1 (1.8 – 6.2) 7.6 (2.1 – 65.6)* 2.6 (0.9 – 9.3) 
TBARs 
(μM/g creatinine) 1.4 (1.1 – 1.7) 1.4 (1.0 – 1.8) 2.5 (1.8 – 3.0)*** 
eGFR 
(ml/min/1.73m2) 
90.0 (67.8 – 100.8) 52.4 (34.6 – 80.1)*** 76.8 (64.0 – 109.5) 
Results presented as median (interquartile range (IQR)). *, p<0.05; **, p<0.01; ***, p<0.001 compared to healthy 
controls by Mann Whitney U test. eGFR calculated by MDRD formula. One healthy control and one patient with 
systemic iron overload were excluded from NTBI analysis and one patient with tubular dysfunction was excluded 
from urinary KIM-1 analysis. 
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GSTP1-1, glutathione s-transferase-pi-1-1; 
KIM-1, kidney injury marker 1; LPI, labile plasma iron; NTBI, non-transferrin-bound iron; TBARs, thiobarbituric acid 
(TBA) reactive substances; TIBC, total iron binding capacity; TSAT, transferrin saturation. 
 
We subsequently stratified patients with HFE-HH and ?-thalassemia major to 
examine urinary iron excretion specifically in these two distinct iron overload disorders 
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Figure 2.1: Urinary iron and non-transferrin-bound iron (NTBI) correlate with plasma iron parameters in 
systemic iron overload  
Correlation between urinary iron excretion and plasma transferrin saturation (TSAT) (a), iron (b), total iron 
binding capacity (TIBC) (c) and ferritin (all n=20) (d); urinary NTBI and plasma ferritin in patients with systemic 
iron overload (n=19) (e; all filled circles??????????????????????????????????????????????????????-thalassemia major 
(n=8; urinary NTBI value missing for one patient) (f; open circles). Each dot represents one patient. Presented 
with Spearman’s correlation coefficient (r) and significance (p-value or not significant (ns)).  
 
(Table 3.3). Patients with HFE-???? ???? ???? ????? ?-thalassemia major, were significantly 
older than healthy controls (p<0.001) and predominantly consisted of males, whereas 
both ???????? ????? ???????? ???????? ??? ?-thalassemia major. Plasma iron levels were 
increased in both HFE-????????-thalassemia major compared to healthy controls (both 
p<0.001) and both patient groups showed low hepcidin/ferritin ratios in line with their 
HFE-genotype and ineffective erythropoiesis, respectively.34,35 ????????? ?-thalassemia 
major patients showed a more severe increase in plasma TSAT and NTBI and decrease in 
TIBC (all p<0.05 compared to HFE-??????????????????????????????????????????-thalassemia 
major only (p<0.001 compared to both control and HFE-HH). These findings suggest that 
both circulating and tissue iron ????????? ???? ????? ??????????? ??? ????????? ????? ?-
thalassemia major than in HFE-HH patients in our study cohort, confirming previous 
findings.18 We found that urinary iron, transferrin and NTBI concentrations were only 
????????? ??? ?-thalassemia major (p<0.001, p<0.05 and p<0.01, respectively), whereas 
urinary NTBI strongly correlated with plasma TSAT in these patients (r=0.75, p<0.05, Figure 
2.1f). This demonstrates that only severely elevated iron parameters, as seen in ?-
thalassemia major, are associated with elevated urinary iron parameters. 
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Table 2.3: Laboratory results in subjects with HFE-???????? ??????????? ???????????????? ???? ?-thalassemia 
major 
 HFE-related hereditary hemochromatosis ?-thalassemia major 
Subjects (n) 10 9 
Age (y) 63.8 ± 3.7*** 37.4 ± 4.5 
Gender (M/F) 9/1 5/4 
Plasma 
Iron 
(μmol/l) 
30.0 (26.5 – 34.7)*** 31.0 (27.5 – 42.5)*** 
TIBC 
(μmol/l) 
46.0 (43.0 – 48.2)*** 42.0 (35.0 – 46.5)***, # 
TSAT 
(%) 
66.9 (58.7 – 77.6)*** 90.2 (71.9 – 92.6)***, # 
Ferritin 
(μg/l) 
113.0 (85.0 – 185.3) 958.0 (383.0 – 1504.0)***, ### 
NTBI 
(μmol/l) 
0.94 (0.43 – 1.25)*** 2.31 (1.20 – 2.54)***, # 
LPI 
(μmol/l) 
0.23 (0.19 – 0.24)*** 0.31 (0.24 – 0.46)***, # 
Hepcidin 
(nM) 0.3 (0.3 – 0.7)*** 1.7 (0.8 – 2.4)
## 
Hepcidin/ferritin ratio 
(nmol/μg) 2.3 (1.5 – 8.8)*** 2.3 (0.7 – 4.2)*** 
Urine 
Iron 
(μmol/g creatinine) 
0.1 (0.02 – 0.09) 2.4 (1.0 – 3.8)***, ### 
Transferrin 
(mg/g creatinine) 
0.8 (0.6 – 1.3) 2.8 (1.1 – 26.4)*, # 
NTBI 
(μmol/g creatinine) 
0.2 (0.1 – 0.4) 1.5 (0.7 – 2.5)**, ### 
Hepcidin  
(nM/g creatinine) 1.5 (0.7 – 2.8)*** 8.1 (3.1 – 17.3)
## 
Albumin 
(mg/g creatinine) 
8.4 (5.2 – 13.5)** 23.9 (11.6 – 705.6)***, # 
KIM-1 
(ng/mmol creatinine) 
0.9 (0.5 – 1.0)** 2.2 (0.9 – 3.4)***, # 
GSTP1-1 
(ng/mmol creatinine) 
1.6 (0.7 – 8.8) 5.9 (1.7 – 10.1) 
TBARs 
(μM/g creatinine) 2.3 (1.8 – 2.6)*** 3.1 (1.9 – 4.2)*** 
eGFR 
(ml/min/1.73m2) 
76.8 (62.8 – 99.3) 76.3 (62.1 – 129.0) 
Results as median (interquartile range (IQR)). *, p<0.05; **, p<0.01; ***, p<0.001 compared to healthy controls 
(Table 3.2); #, p<0.05; ##, p<0.01; ###, p<0.001 compared to hereditary hemochromatosis by Mann Whitney U test. 
eGFR calculated by MDRD formula. One patient with ?-thalassemia major was excluded from NTBI analysis. 
eGFR, estimated glomerular filtration rate; GSTP1-1, glutathione s-transferase-pi-1-1; KIM-1, kidney injury marker 
1; LPI, labile plasma iron; NTBI, non-transferrin-bound iron; TBARs, thiobarbituric acid (TBA) reactive substances; 
TIBC, total iron binding capacity; TSAT, transferrin saturation. 
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 Figure 2.2: Urinary iron and transferrin correlate with urinary kidney parameters in tubular dysfunction 
Correlation between urinary transferrin and iron with urinary albumin (n=17) (a, b); urinary albumin, transferrin 
and iron with estimated glomerular filtration rate (eGFR) (n=13) (c, d, e); urinary transferrin and iron with 
proximal tubular injury marker kidney injury marker 1 (KIM-1) (n=16; urinary KIM-1 value missing for one patient) 
(f, g) and distal tubular injury marker glutathione s-transferase-pi-1-1 (GSTP1-1) (n=17) (h, i) in patients with 
tubular dysfunction. Each dot represents one patient. Presented with Spearman’s correlation coefficient (r) and 
significance (p-value or not significant (ns)). 
 
Increased urinary iron and transferrin excretion in patients with 
tubular dysfunction 
Tubular dysfunction was shown by increased levels of PT injury marker KIM-1 and DT 
injury marker GSTP1-1 (p<0.01 and p<0.05 respectively, compared to healthy controls; 
Table 2.2). In these patients, urinary iron and transferrin, but not NTBI, were increased 
(both p<0.05) despite the fact that circulating iron homeostasis parameters were within 
reference range (iron, TSAT, NTBI, LPI, ferritin and hepcidin), suggesting that urinary iron 
loss did not result in decreased circulating and stored iron levels. These patients showed 
increased urinary albumin levels (p<0.05). Moreover, urinary transferrin and albumin 
levels strongly correlated (r=0.89, p<0.001; Figure 2.2a), thus indicating similar glomerular 
filtration and tubular handling of both proteins, as demonstrated before.9 Interestingly, 
urinary iron levels also related to albuminuria (r=0.61, p<0.01; Figure 2.2b), whereas  
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??????????????????????????????????????????? ????????????????? ??????????????????????-thalassemia major 
Correlation between urinary transferrin and proximal tubular injury marker kidney injury marker 1 (KIM-1) in 
patien??? ????? ?-thalassemia major (n=9). Each dot represents one patient. Presented with Spearman’s 
correlation coefficient (r) and significance (p-value). 
 
albumin, transferrin nor iron levels in urine correlated with eGFR in these patients (Figure 
2.2c, d, e), suggesting that insufficient tubular protein reabsorption, rather than increased 
glomerular filtration,36,37 may cause elevated iron and transferrin excretion. 
Moreover, we examined the relation between iron excretion and renal injury. 
Therefore, we assessed urinary TBAR concentrations, as a measure for urinary oxidative 
stress. We found that urinary TBARs were not increased compared to healthy controls 
(Table 2.2), suggesting that iron excretion did not readily result in oxidative stress in these 
patients. Subsequently, we studied the correlation between urinary iron and transferrin 
concentrations and KIM-1 and GSTP1-1 to investigate the relation between iron excretion 
and PT and DT injury, respectively.38,39 Whereas we found no correlation between KIM-1 
and urinary transferrin or iron levels (Figure 2.2f, g), GSTP1-1 was positively associated 
with both transferrin and iron (r=0.86, p<0.001, and r=0.56, p<0.05, respectively; Figure 
2.2h, i), indicating DT injury as potential cause of elevated urinary iron and transferrin 
excretion in patients with tubular dysfunction. 
 
Urinary iron excretion correlated with tubular injury in patients 
with systemic iron overload 
Finally, we examined if urinary iron excretion in systemic iron overload was associated 
with tubular injury. Patients with systemic iron overload showed increased urinary TBARs 
(p<0.001, Table 2.2). Whereas GSTP1-1 levels were not affected, urinary KIM-1 
concentrations were increased in patients with systemic iron overload (p<0.001; Table 
2.?????????????????????????????????-thalassemia major (p<0.001 compared to control, p<0.05 
compared to HFE-HH; Table 2.????????????????????????????????????????????????-thalassemia 
major correlated strongly with urinary KIM-1 levels (r=0.71, p<0.05; Figure 2.3), which 
might indicate reduced transferrin reabsorption as a consequence of PT injury.  
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Figure 2.4: Urinary hepcidin correlates with plasma hepcidin concentrations in systemic iron overload 
Correlation between urinary hepcidin and plasma hepcidin in patients with systemic iron overload (n=20). Each 
dot represents one patient. Presented with Spearman’s correlation coefficient (r) and significance (p-value). 
 
Urinary hepcidin excretion does not substantiate urinary iron 
excretion 
In addition to plasma hepcidin levels, we also analyzed hepcidin excretion in urine, since 
urinary hepcidin was recently reported to protect against acute kidney injury.40-42 We did 
not find an increase in urinary hepcidin levels in patients with tubular dysfunction (Table 
2.2), and, therefore, we could not underline a role of hepcidin in these patients. In 
patients with systemic iron overload, urinary hepcidin concentrations were significantly 
reduced, especially in HFE-HH patients (Table 2.2, 2.3). Urinary hepcidin levels strongly 
correlated with plasma hepcidin concentrations (r=0.85, p<0.001; Figure 2.4), 
corroborating our previous findings.43 
 
DISCUSSION 
Increased urinary iron concentrations have been associated with renal injury. Here, we 
investigated the contribution of glomerular filtration of increased circulating iron and 
insufficient tubular iron reabsorption to urinary iron excretion in patients with either  
systemic iron overload or renal tubular dysfunction. Our results demonstrate that both 
increased circulating iron levels and subsequent filtration as well as insufficient tubular 
reabsorption are associated with increased urinary iron concentrations and, importantly, 
renal injury.  
Patients with tubular dysfunction were included in this study to investigate the 
contribution of diminished PT TBI reabsorption to urinary iron concentrations. Although 
we cannot fully exclude the presence of glomerular injury in these patients, the high 
prevalence of proximal tubular dysfunction pathologies in our patient cohort together 
with our finding that increased urinary albumin excretion did not relate to eGFR, implicate 
that glomerular dysfunction are not likely to contribute to urinary iron and transferrin 
excretion in these patients. Recently, we reported iron deposition in PTs and DTs in 
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various CKD disorders.44 These patients predominantly showed glomerular diseases, which 
would result in increased filtration of circulating iron levels into the tubular lumen and, 
subsequently, urinary iron excretion. In our cohort of patients with tubular dysfunction, 
we presume that iron filtration by the glomerulus and consequent iron levels reaching the 
tubular lumen is not affected. Although both the PT injury marker KIM-1 and the DT injury 
marker GSTP1-1 showed increased concentrations in urine, only GSTP1-1 correlated with 
urinary iron and transferrin concentrations. We propose that increased TBI levels reach 
the DT because of hampered PT reabsorption. Increased DT iron exposure could result in 
DT iron accumulation and subsequent DT injury.5 In addition, our data suggest that DT iron 
reabsorption capacity is not sufficient to compensate for the increased iron delivery and, 
therefore, iron and transferrin are lost in urine in patients with tubular dysfunction. 
Therefore, both the PT and DT may contribute to urinary iron wasting during tubular 
dysfunction (Figure 2.5).  
Mild systemic iron overload observed in our HFE-HH subjects did not result in 
urinary iron or NTBI excretion. Despite mild PT injury as indicated by the increased KIM-1 
levels and oxidative stress as indicated by increased urinary TBARs, tubular iron 
reabsorption capacity was sufficient to prevent urinary iron excretion in patients with mild  
 
 
Figure 2.5: Proposed mechanism of iron reabsorption in the kidney in health, tubular dysfunction and systemic 
iron overload. 
In health (left panel), circulating transferrin-bound iron (TBI) is filtered into the renal tubular lumen by the 
glomerulus, and subsequently is completely reabsorbed. This is predominantly done by proximal tubules (PTs) 
and only to a minor extent in distal tubules (DTs). During tubular dysfunction (second left panel), similar TBI 
levels are filtered into the tubular lumen, but these are reabsorbed to a lower extent by PTs as a result of PT 
injury (indicated by lightning sign). Consequently, DTs reabsorb larger amounts of TBI, but, as a result of DT 
injury, iron (in red) and transferrin (in blue) are excreted in urine. In mild systemic iron overload (second right 
panel), increased circulating TBI and non-transferrin-bound iron (NTBI) are filtered into the tubular lumen. 
Despite oxidative stress and mild PT injury, reabsorption in PTs and DTs prevents iron and transferrin excretion. 
In severe systemic iron overload (right panel), TBI and NTBI are filtered into the tubular lumen in even larger 
concentrations, but limitedly reabsorbed by PTs as a result of increased intracellular iron levels, oxidative stress 
and PT injury. Iron reabsorption capacity in DTs is not sufficient to prevent iron and transferrin excretion in urine.  
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iron overload (Figure 2.5???????????????????????????????-thalassemia major with severe iron 
overload, demonstrated increased urinary iron, transferrin and NTBI excretion, 
demonstrating urinary iron reabsorption capacity falls short in these patients. The 
difference in clinical presentation between these patients groups can be explained by the 
regular maintenance phlebotomy in HFE-HH patients, resulting in only mildly elevated 
TSAT, whereas ferritin levels were within the normal range. Nevertheless, severe iron 
overload has also been observed in patients with newly diagnosed HFE-HH patients.18 
Therefore, the extent of systemic iron overload, rather than the disease pathology, 
determines urinary iron excretion. 
Besides glomerular filtration of increased circulating iron levels, disturbed tubular 
iron handling or tubular injury may also have contributed to the high urinary iron 
??????????????????? ????????-thalassemia major subjects. Increased plasma ferritin levels 
are indicative of high tissue iron stores, including the kidney.19 Moreover, mouse PT cells  
have been described to actively secrete ferritin proteins and ferritin is detectable in urine 
of healthy volunteers.20,45 However, iron levels in secreted ferritin are low45 and are, 
therefore, unlikely to largely contribute to urinary iron excretion. Alternatively, we cannot 
exclude that increased exfoliation of iron-loaded tubular epithelial cells contributed to 
urinary iron concentrations. Finally, PT injury observed in the ?-thalassemia major patients 
may have influenced urinary iron and transferrin excretion. Presumably, PT injury limits 
PTTBI reabsorption leading to more TBI excretion that cannot be compensated for by DT 
reabsorption. The increased urinary TBAR concentrations suggest that PT injury in patients 
??????-thalassemia major may result from oxidative stress, potentially caused by increased 
urinary iron levels. However, we cannot rule out other causes of the observed renal injury. 
???????????????????????????????????????????????????????-thalassemia major may be resulting 
from filtration of increased circulating iron, enhanced iron levels in renal tubuli and/or 
(oxidative) PT injury (Figure 2.5).   
Our finding of increased urinary KIM-1 ???????????-thalassemia major patients adds 
??? ???? ????????????????? ?????????????? ??????? ????-thalassemia,46-49 and confirms previous 
suggestions that persistent severe systemic iron overload can lead to renal injury.50 
Tubular epithelial cells can be exposed to harmful levels of iron both apically from the 
tubular lumen and basolaterally from the systemic circulation. Furthermore, tubular injury 
may also be related to use of chelation mediation.51-53 Future studies examining the 
etiology of renal injury during systemic iron overload are warranted, in order to prevent 
progressive kidney disease. 
Our results showed a correlation between urinary hepcidin and circulating 
hepcidin levels, confirming our previous observations.43 Although hepcidin has been 
reported to protect from acute kidney injury,54,55 our results cannot confirm this. 
Limitations of this study include the explorative and observational design with 
small subject groups. Although we aimed at including subjects in age- and gender-
matched groups, patients with HFE-??? ???????????????????????? ?????-thalassemia major, 
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reflecting the average age of these patient groups in the population.56,57 Furthermore, all 
study groups predominantly consisted of male subjects, except for ???? ?-thalassemia 
major patients. Although age above 40 years and male gender have been reported to 
increase levels of urinary KIM-1 and albumin in healthy individuals,58,59 this is unlikely to 
have largely influenced KIM-1 ???? ???????? ??????? ??? ?????? ??? ?-thalassemia. In addition, 
partly because the specific disorders are rare, the renal tubular dysfunction patient group 
consisted of a heterogeneous collection of disorders. 
The knowledge that both filtration of systemic iron levels and tubular iron 
reabsorption influence urinary iron excretion has several implications. In patients with 
iron overload disorders prevention or reduction of tubular iron reabsorption could be 
used to enhance urinary iron excretion and, thus, lower the systemic iron burden and 
potential renal injury. The latter is also important for patients with chronic kidney disease. 
Glomerular injury leads to increased protein filtration, including TBI, resulting in increased 
urinary iron excretion and renal iron loading.3,9-13 In CKD animal models, tubular injury was 
associated with urinary iron excretion and reduction of circulating iron levels by using a 
low-iron diet or treatment with an iron chelator reduced renal tubular injury.60,61 In CKD, 
preventing renal iron accumulation by reducing tubular reabsorption could be an 
interesting therapeutic option. 
In conclusion, our results suggest that both glomerular filtration of increased 
circulating iron levels and insufficient tubular iron reabsorption could increase urinary iron 
excretion and cause renal injury. 
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ABSTRACT 
In patients with iron overload disorders, increasing number of reports of renal dysfunction 
and renal iron deposition support an association between increased iron exposure and 
renal injury. In systemic iron overload, elevated circulating levels of transferrin-bound 
(TBI) and non-transferrin-bound iron (NTBI) are filtered to the renal proximal tubules, 
where they may cause injury. However, the mechanisms of tubular iron handling remain 
elusive. To unravel molecular renal proximal tubular NTBI and TBI handling, human 
conditionally immortalized proximal tubular epithelial cells (ciPTECs) were incubated with 
55Fe as NTBI and fluorescently labeled holo-transferrin as TBI. Ferrous iron importers ZIP8 
and ZIP14 were localized in the ciPTEC plasma membrane. Whereas silencing of either 
ZIP8 or ZIP14 alone did not affect 55Fe uptake, combined silencing significantly reduced 
55Fe uptake compared to control (p<0.05). Furthermore, transferrin receptor 1 (TfR1) and 
ZIP14, but not ZIP8, colocalized with early endosome antigen 1 (EEA1). TfR1 and ZIP14 also 
colocalized with uptake of fluorescently labeled transferrin. Furthermore, ZIP14 silencing 
decreased 55Fe uptake after 55Fe-Transferrin exposure (p<0.05), suggesting ZIP14 could be 
involved in early endosomal transport of TBI-derived iron into the cytosol. Our data 
suggest that human proximal tubular epithelial cells take up TBI and NTBI, where ZIP8 and 
ZIP14 are both involved in NTBI uptake, but ZIP14, not ZIP8, mediates TBI-derived iron 
uptake. This knowledge provides more insights in the mechanisms of renal iron handling 
and suggests that ZIP8 and ZIP14 could be potential targets for limiting renal iron 
reabsorption and enhancing urinary iron excretion in systemic iron overload disorders.  
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INTRODUCTION 
Iron is an essential element for life, but it can also be harmful by catalyzing the formation 
of reactive oxygen species in the Fenton reaction.1 The human body is able to regulate 
iron uptake and storage, but has limited abilities to regulate iron excretion.2 Therefore, 
disturbed intestinal iron uptake in hereditary hemochromatosis, and frequent red blood 
cell transfusions in ?-thalassemia major, can result in systemic iron overload and organ 
damage.2 In these disorders, patients present with increased levels of iron bound to the 
circulating transport protein transferrin (transferrin-bound iron; TBI).2 Once transferrin is 
largely saturated, non-transferrin-bound iron (NTBI) can be detected.3,4 In contrast to iron 
bound to transferrin, iron in NTBI is only loosely bound to molecules such as citrate, 
available for redox cycling and, therefore, considered a toxic iron species.3,5 Nowadays, 
iron-removal therapies decrease hepatic and cardiac iron loading mortality and extend 
patient’s lives.6-9 However, in recent years, kidney function abnormalities have been 
arising in ???????????????-thalassemia major,10 including increased urinary excretion of N-
acetyl-D-???????????????? ?????? ???? ?-2-microglobulin, indicators of renal proximal 
tubular damage.11-16 Also, renal iron deposition has been observed in adult patients with 
hereditary hemochromatosis17-21 or ?-thalassemia syndromes.14,22,23 In vitro studies have 
shown that iron exposure can result in decreased cellular viability in murine and human 
renal tubular epithelial cells.24-26 Altogether, these findings support an association 
between increased renal tubular iron exposure and renal tubular injury in systemic iron 
overload. 
Tubular epithelial cells in the kidney share many iron handling proteins with other 
organ systems, such as transferrin receptor 1 (TfR1), divalent metal transporters ZIP8 
(SLC39A8), ZIP14 (SLC39A14) and divalent metal transporter 1 (DMT1, SLC11A2), and iron 
exporter ferroportin, but their precise cellular localization and function in renal iron 
handling remain uncertain.27-29 Circulating TBI is suggested to be filtered into the tubular 
lumen by the glomerulus.30,31 Subsequently, iron in the tubular lumen has been reported 
to be completely reabsorbed by endocytic transport in renal tubular cells.28 In agreement, 
hardly any iron is found in urine of healthy volunteers.32,33 TBI reabsorption has been 
reported to mainly take place in proximal tubular epithelial cells (PTs), facilitated by TfR1 
and the megalin-cubilin receptor complex.30,31,34,35 After dissociation from transferrin, iron 
transport from the endosome into the cytosol is suggested to involve a divalent metal 
transporter. Although not yet clarified in PTs, studies in other cells suggest a role for ZIP8, 
ZIP14 and/or DMT1 in this process.36-38 In the cytosol, iron is oxidized by H-ferritin and 
stored in L-ferritin, may be utilized by iron requiring processes or exported into the blood 
stream by the cellular exporter ferroportin.28 Tubular NTBI could be directly derived from 
the circulation by glomerular filtration or dissociated from filtered TBI as a result of 
acidification of the filtrate passing along the nephron.27,28,39 In vitro studies have reported 
that ZIP8 and ZIP14 are involved in direct NTBI uptake from the plasma membrane,37,40-43 
but evidence for PTs is lacking.  
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In this study, we first characterized TBI and NTBI handling in human conditionally 
immortalized proximal tubular epithelial cells (ciPTECs). Human ciPTECs, originating from 
renal tissue, have previously been shown to express functional influx and efflux 
transporters for solute reabsorption and drug excretion.44,45 Next, we examined the 
localization of divalent metal transporters ZIP8, ZIP14 and DMT1 in these cells, i.e. at the 
plasma membrane and/or in endosomes, and studied the role of ZIP8 and ZIP14 in 
mediating iron uptake from NTBI and TBI.  
 
MATERIALS AND METHODS 
 
Cell culture 
ciPTECs (clone T1), kindly provided by the department of Pharmacology and Toxicology, 
Radboud Institute for Molecular Life Sciences, Radboud university medical center, 
Nijmegen,44 were cultured using DMEM HAM's F-12 phenol red-free medium (Thermo 
Fisher Scientific) containing 5 ?g/ml insulin, 5 ?g/ml transferrin, 5 ng/ml selenium, 36 
ng/ml hydrocortisone, 10 ng/ml epithelial growth factor 40 pg/ml tri-iodothyronine (all 
Sigma Aldrich), 10% (v/v) fetal calf serum (FCS; Greiner Bio-one), and 1% (v/v) penicillin-
streptomycin (Thermo Fisher Scientific). Cells were cultured at 33°C and 5% CO2 and 
maturated for 24h at 33°C and 5% CO2 and 7 days at 37°C and 5% CO2 prior to 
experiments. Cells were cultured on transwell permeable supports to obtain polarization 
(Corning® Transwell®, coated with 50 μg/ml collagen VI (both Sigma Aldrich)) for ZIP8, 
ZIP14, DMT1 and ferroportin immunostaining, 55Fe transport and Alexa Fluor 546-
conjugated human holotransferrin (Alexa546-Transferrin, Thermo Fisher Scientific) uptake 
studies. Transepithelial electrical resistance (TEER) measurements and FITC-inulin 
permeability analysis were performed as previously described.44 
 
Iron exposure 
To simulate NTBI exposure, cells were exposed to 0-500 μM ferric citrate (FeC, Sigma 
Aldrich). FeC was dissolved overnight in MQ water at 37°C and added to medium devoid of 
FCS. Cell pellets were collected and stored at -80°C prior to iron assessment or 
immunoblotting. For TBI uptake studies, cells were depleted of transferrin by incubation in 
DMEM HAM's F-12 medium without supplements for 2h and exposed to 25 μg/ml 
Alexa546-Transferrin for 30 min. In iron loading conditions, cells were instead exposed to 
100 μM FeC and 100 μg/ml holo-transferrin (Sigma Aldrich) for 2h and subsequently 
exposed to Alexa546-Transferrin. Afterwards, cells were used for immunostaining as 
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described below. To simulate iron overload exposure, cells were exposed to 100 μM FeC in 
medium supplemented with FCS for 48h and used for immunostaining of ZIP8 and ZIP14. 
Small interfering RNAs (siRNAs) 
Cells were seeded at 20% confluency and transfected on two consecutive days with a 50 
pmol (ZIP8, ZIP14) or 100 pmol (ferroportin) small interfering RNAs (siRNAs) (ON-
TARGETplus SMARTpool siRNAs for SLC39A8, SLC39A14, SLC40A1 and Non-targeting pool 
as scrambled control, Dharmacon) and 5 μl oligofectamine in Opti-MEM (both Thermo 
Fisher Scientific). After 4h, fresh medium was added. Cells were analyzed 48h after the 
second transfection. 
 
Protein isolation and immunoblotting 
Proteins were isolated using RIPA buffer (0.15 M NaCl, 0.012 M Sodium Deoxycholate, 1% 
NP40, 0.1% SDS, 0.05 M Tris, pH 7.5, freshly supplemented with protease inhibitors (Roche 
Complete Mini, Roche)). Protein concentration was determined using the Pierce BCA assay 
kit according to the manufacturer’s instructions (Thermo Fisher Scientific). Protein 
samples were prepared in loading buffer, separated on SDS-PAGE gels, transferred to a 
nitrocellulose or PVDF membrane and incubated with primary antibody overnight at 4°C. 
After 1h incubation at RT with secondary antibody, proteins were visualized on an Odyssey 
????????????????????? ??????? ???????????-actin) or LAS-3000 scanner for chemiluminescence 
(all other primary antibodies). Antibodies and dilutions are summarized in Supplementary 
Table 3.1.  
 
Cell surface biotinylation 
Cells were biotinylated with 0.5 mg/ml Sulfo-NHS-LC-LC-biotin (Thermo Fisher Scientific) 
for 30 min at 4°C with gentle shaking. Protein lysates were collected by scraping and 
incubated overnight with Neutravidin beads (Thermo Fisher Scientific) to isolate cell 
surface biotinylated proteins. After eluting cell surface proteins from the beads in Laemmli 
buffer (Biorad) supplemented with 50 mM DTT for 30 min at 37°C, proteins were directly 
used for immunoblotting since the Pierce BCA assay could not be applied in this buffer 
solution. Therefore, both membrane protein and total lysate protein fraction were loaded 
on SDS-PAGE gels to obtain comparable Na K ATPase bands and allow comparison of 
proteins of interest between the two fractions. 
 
RNA isolation and quantitative PCR 
RNA isolation was performed using TRIzol (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. A reverse transcription reaction was performed with 1 ?g 
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RNA, 4 ?l first strand buffer, 1 ?l dNTPs (12.5 mM), 2.04 ?l random primers, 2 ?l DDT, 1 ?l 
M-MLV (all Thermo Scientific) and 0.5 ?l RNAsin (Promega Corporation). The PCR cycle 
consisted of 10 min at 20 °C, 45 min at 42°C and 10 min at 95°C. Quantitative PCR was 
performed on a CFX96 (Bio-rad) using 4 μl cDNA (10 ng/ml), 10 μl SYBR Green Power 
master mix (Applied Biosystems) and 6 μl primer mix (containing 1 μM forward primer and 
reverse primer). The PCR protocol was as follows: 7 min at 95°C, 40 cycles of 15 sec at 
95°C and 1 min at 60°C, and 10 min at 95°C, with a measurement at the end of each cycle. 
????? ??????? ???????????? ??????????? ?????? ????????? ????????? ??? ???? ???? ??????????? ???
Supplementary Table 3.2.  
 
Immunofluorescent staining 
Cells seeded on coverslips or transwell supports were fixed with 4% paraformaldehyde or 
2% paraformaldehyde supplemented with 4% sucrose, permeabilized with 0.5% Triton X-
100, 0.2% Tween-20 or 1% SDS and incubated with primary antibody overnight at 4°C. 
Subsequently, cells were stained with fluorescent secondary antibody for 1h at RT and 
counterstained with DAPI (4',6-diamidino-2-phenylindole, 300 μM, Thermo Fisher 
Scientific). Images were taken using the Zeiss S/N 3834004266 or confocal Olympus 
FV1000. Co-stainings were performed for TfR1, ZIP8, ZIP14 and DMT1 with early 
endosome antigen 1 (EEA1). Antibodies are summarized in Supplementary Table 3.1.  
 
Iron assessment 
Intracellular iron level were determined using the chromogen bathophenanthroline as 
described.46 Iron concentrations were calculated by comparison to a standard curve of 
ferrous sulphate and corrected for protein concentration.  
 
55Fe transport 
Cells were incubated with 0.2 μM 55FeCl3 (Perkin Elmer) in a mixture with 100 μM FeC and 
1 mM ascorbic acid (Sigma Aldrich) in Krebs-Henseleit-HEPES (KH-H) buffer supplemented 
with 2.5 mM CaCl2·2H2O, 25 mM NaHCO3 and 10 mM HEPES pH 7.4 (Sigma Aldrich). For 
cells grown in transwell supports, cells were depleted of iron in DMEM HAM's F-12 
medium without supplements for 2h and incubated with 55Fe in KH-H in the apical 
compartment or in medium in the basolateral compartment for 8h at 37°C. For ZIP8 and 
ZIP14 siRNA experiments, cells were depleted of iron in KH-H buffer for 2h and incubated 
with 55Fe for 30 min afterwards. For ferroportin siRNAs, cells were exposed to 55Fe for 2h. 
Subsequently, cells were washed with ice-cold KH-H and harvested using RIPA buffer. 
Afterwards, radioactivity was measured using liquid scintillation counting. Radioactivity in 
protein pellets was corrected for protein concentration.  
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55Fe-TBI was prepared by incubating apo-transferrin (Sigma Aldrich) with 7.5 nmol 
55FeCl3 and 75 nmol Sodium Citrate in KH-H for 1h at RT. Unbound iron was removed by 
repeated washing in 30K Amicon filter units. After iron depletion in KH-H buffer for 2h, 
cells were exposed to 2 uM 55Fe-TBI for 4h and analyzed as described above.  
 
Statistical analysis 
Data were statistically analyzed using GraphPad Prism and presented as mean ± SEM. 
Results were analyzed by one-way ANOVA with Dunnett’s post test or Student’s t-test 
where appropriate. Differences were considered statistically significant when p<0.05.  
 
RESULTS 
 
Characterization ciPTEC model for studying iron handling 
We first characterized the presence and abundance of known iron handling proteins in 
ciPTECs in unstimulated conditions and after iron exposure. Upon exposure to NTBI (FeC), 
ciPTECs showed a time-dependent increase in intracellular iron levels, which was 
statistically significant for 100 and 200 μM FeC after exposure for 16 and 24h (Figure 3.1a). 
This was complemented by increased total ferritin and decreased TfR1 protein levels 
compared to control (Figure 3.1b), confirming genomic iron responsive element – iron 
responsive protein (IRE-IRP) regulation of these proteins in ciPTECs.47 Next, we examined 
iron uptake in polarized ciPTECs, grown on transwell supports. Monolater integrity was 
confirmed by minimal paracellular permeability of the diffusion marker FITC-inulin (7.6 ± 
0.8 pmol/min/cm2??? ???????????? ????? ?????? ????2) and clear expression of the tight 
junction protein zona occludens 1 (ZO-1; Figure 3.1c).44 In ciPTECs cultured on transwell 
supports, apical 55Fe exposure resulted in intracellular iron loading while basolateral 55Fe 
exposure showed only limited cellular uptake (Figure 3.1d). This indicates that ciPTECs 
take up iron mainly from the apical cellular side. Additionally, we characterized the 
direction of iron export in ciPTECs. Polarized ciPTECs showed basolateral iron export after 
apical 55Fe exposure, while basolateral 55Fe exposure showed negligible apical iron export 
(Figure 3.1d). CiPTECs also demonstrated uptake of Alexa546-Transferrin (holo-
transferrin), which was diminished in combination with unlabelled holo-transferrin, 
indicating ligand-specific competition, or at 4°C, suggesting active uptake (Figure 3.1e). 
Alexa546-Transferrin uptake was mostly observed after apical exposure, and little uptake 
was seen after basolateral exposure, whereas both apical and basolateral uptake was 
reduced in iron-loaded cells (Figure 3.1f). The latter suggests that ciPTECs regulate TBI 
uptake based on intracellular iron levels through IRE-IRP regulation. 
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??????????????????????????????????????????????????????????????????????????????????????
Intracellular iron concentration (a), total ferritin and transferrin receptor 1 (TfR1) protein levels (b) in ciPTECs 
after incubation with different concentrations of ferric citrate (NTBI). Zona occludens 1 (ZO-1) immunostaining 
(in green) confirming monolayer integrity in polarized ciPTECs. ZO-1 tight junctions indicated by arrows (c). 55Fe 
content in apical compartment, basolateral compartment and cell lysate after 55Fe exposure from the apical (A to 
BL) or basolateral (BL to A) cellular side (d). Alexa546-Transferrin (546Tf, in red) internalization alone, combined 
with holo-transferrin (Holo-Tf) or at 4°C (e). 546Tf internalization in iron deplete or iron replete conditions, from 
apical or basolateral cellular side (f). Nuclei counterstained with DAPI (in blue). Representative images and 
graphs showing mean of three independent experiments for each time point or FeC concentration except n=6 for 
panel c. Scale bar 5 μM. One-way ANOVA with Dunnett’s post test compared to control at each time point was 
used in a; * p<0.05; ** p<0.01; *** p<0.001. 
  
We further investigated the role of ferroportin in iron export observed in ciPTECs. 
Ferroportin immunostaining showed localization near the basolateral cellular side (Figure 
3.2a), in agreement with its presumed role in iron export in PTs to the plasma.48 To study 
the functional contribution of ferroportin to iron export, we used siRNA technology. 
Successful ferroportin knockdown was confirmed on mRNA level (p<0.001, Figure 3.2b). 
Ferroportin knockdown increased cellular 55Fe content compared to scrambled control, 
while 55Fe in the exposure solution was decreased (p<0.05 and p<0.01, respectively, Figure 
3.2c). This was complemented by increased total ferritin protein levels and a trend of 
decreased ???? mRNA levels in ferroportin knockdown compared to control (Figure 3.2d).  
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???????????????????????????????????????????????????????
Ferroportin immunostaining (in green) in polarized ciPTECs (a). Nuclei counterstained with DAPI (in blue). 
Confocal images taken in x-y and y-z axis showing apical (A) and basolateral (BL) cellular side. CiPTEC ??????????? 
mRNA expression (b), pmol 55Fe in cell lysate or solution (c), total ferritin protein expression and ????????????
??????????????????mRNA expression (d) after transfection with scrambled control (Scr) or ferroportin (FPN1) small 
interfering RNAs (siRNA). Representative images and graphs showing mean of at least three independent 
experiments (a, n=3; b, n=9; c, n=4; d, both n=3). Scale bar 5 μM?? ?????????? ?-test was used in b, c and d; * 
p<0.05; ** p<0.01. 
 
These data confirm that ferroportin functions as an iron exporter in ciPTECs at the 
basolateral membrane. 
 
????????????????????????????????????
To investigate whether ZIP8 and ZIP14 could mediate apical NTBI uptake, we examined 
their localization in ciPTECs. We found ZIP8 and ZIP14 immunostaining near the apical 
cellular side in ciPTECs cultured on transwell supports (Figure 3.3a). We applied cell 
surface biotinylation and subsequent immunoblotting to investigate the localisation of 
these transporters at the plasma membrane and/or in intracellular endosomes. Succesful 
membrane isolation was confirmed by the presence of plasma membrane marker Na K 
ATPase in the cell surface fractions, whereas the endosomal marker EEA1 and cytosolic 
???????? ?-actin were absent compared to the total cell fractions (Figure 3.3b). We 
detected both ZIP8 and ZIP14 in the ciPTEC plasma membrane and total cell lysate 
fraction. In contrast, DMT1 immunostaining was detected near the apical membrane, but 
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we did not detect this protein in cell surface fractions (Figure 3.3a, b). This indicates ZIP8 
and ZIP14 are potential candidates for NTBI uptake at the plasma membrane and 
subsequent experiments have, therefore, focused on ZIP8 and ZIP14.  
We applied ZIP8 and ZIP14 siRNA technology to knockdown each transporter on 
mRNA level (60% ZIP8 and 60% ZIP14 mRNA remaining compared to scrambled control; 
p<0.001), without affecting mRNA expression of the other ZIP transporter (ZIP14 and ZIP8, 
respectively) (Figure 3.4a, b). Protein expression was decreased to 50% of scrambled 
control for ZIP8 and 60% for ZIP14 (Figure 4a, b). However, silencing of either ZIP8 or 
ZIP14 did not significantly reduce 55Fe uptake (85% and 95% of scrambled control,  
 
 
Figure 3.3 Presence of ZIP8, ZIP14 and DMT1 in ciPTECs 
ZIP8, ZIP14 and divalent metal transporter 1 (DMT1) immunostaining (in green) in polarized ciPTECs. Nuclei 
counterstained with DAPI (in blue). Confocal images taken in x-y and y-z axis showing apical (A) and basolateral 
(BL) cellular side (a). Cell surface biotinylation and immunoblotting of ZIP8, ZIP14 and DMT1 in both membrane 
fraction and total lysate fraction. In addition, Na K ATPase was used as positive control for cellular membrane 
proteins, early endosome antigen 1 (EEA1) as negative control for end?????????????????????-actin as negative 
control for cytosolic proteins. Similar Na K ATPase protein levels were loaded in both membrane fraction and 
total lysate fraction. Prolonged chemiluminescence confirmed depicted findings (data not shown) (b). 
Representative images showing three independent experiments. Scale bar 5 μM. 
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?????????????????????????? ??????????????????????????????
???? and ????? mRNA and protein expression after transfection with scrambled control (Scr) and either ZIP8 (a) 
or ZIP14 small interfering RNA (siRNA) (b). Pmol 55Fe uptake in cell lysate after either ZIP8 (c) or ZIP14 siRNA 
transfection (d). ???? and ????? mRNA and protein expression (e) and pmol 55Fe uptake in cell lysate (f) after 
transfection with scrambled control or combined ZIP8 + ZIP14 siRNAs. Representative graphs. Number of 
experiments depicted in each panel?????????????-test was used in a-e; * p<0.05; *** p<0.001.  
 
respectively, Figure 3.4c, d). Since both transporters are described to have similar iron 
transport capacities,49 we also applied combined siRNA knockdown. Both transporters 
were successfully downregulated on mRNA and protein level (50% ???? and 40% ??????
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Figure 3.5 Transferrin receptor 1 mediates Alexa546-Transferrin uptake in ciPTECs  
Transferrin receptor 1 (TfR1) immunostaining (in green) in polarized ciPTECs (a). TfR1 immunostaining (in green) 
colocalization with Alexa546-Transferrin (546Tf) internalization (in red) (b) or early endosome antigen 1 (EEA1) 
immunostaining (in red) (c).  Nuclei counterstained with DAPI (in blue). Confocal images taken in x-y and y-z axis 
showing apical (A) and basolateral (BL) cellular side. Representative images of three experiments. Scale bar 5 μM.  
 
mRNA, and 50% ZIP8 and 50% ZIP14 protein remaining, respectively; Figure 3.4e). 
Knockdown of both transporters significantly reduced 55Fe uptake (70% of control, p<0.05, 
Figure 3.4f). This indicates that both ZIP8 and ZIP14 play a role in NTBI uptake and indeed 
show redundancy in ciPTECs. 
TBI-derived iron uptake involves ZIP14 
We detected TfR1 near the ciPTEC apical membrane using fluorescent immunostaining 
(Figure 3.5a) and found TfR1 to colocalize with both EEA1 and Alexa546-Transferrin 
(Figure 3.5b, c), indicating TBI uptake involves TfR1 via endocytosis. Subsequently, we 
examined whether ZIP8 and ZIP14 may play a role in iron uptake resulting from TBI 
endocytosis. We found only ZIP14,but not ZIP8, to colocalize with EEA1 (Figure 3.6a), 
suggesting a possible involvement of ZIP14 in transport of iron out of the endosome 
towards the cytosol. This staining pattern was not affected by iron exposure (Figure 3.6b), 
indicating ZIP8 is absent from ciPTEC endosomes independent of cellular iron status. ZIP14 
immunostaining colocalized with Alexa546-Transferrin uptake (Figure 3.6c), but ZIP14 
knockdown did not affect Alexa546-Transferrin uptake (Figure 3.6d). Cellular 55Fe content, 
however, was decreased in ZIP14 knockdown cells compared to control after 55Fe-TBI 
exposure (p<0.05, Figure 3.6e). This indicates ZIP14 could be involved in TBI-derived iron 
uptake. DMT1 was also found to colocalize with EEA1 immunostaining (Figure 3.6f) and,  
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Figure 3.6 ZIP14 
mediates Alexa546-
Transferrin uptake in 
ciPTECs 
Double immunostaining 
of ZIP8 or ZIP14 (in green) 
and early endosome 
antigen 1 (EEA1, in red) in 
unstimulated conditions 
(a) or after 48h iron 
overload exposure (b). 
ZIP14 immunostaining (in 
green) colocalization with 
Alexa546-Transferrin 
(546Tf) internalization (in 
red) (c). 546Tf 
internalization (d) or 
pmol 55Fe in cell lysate 
after 55Fe-TBI exposure 
(e) after transfection with 
scrambled control or 
ZIP14 small interfering 
RNA (siRNA). Double 
immunostaining of 
divalent metal 
transporter 1 (DMT1, in 
green) and EEA1 (in red) 
(f). ???? mRNA 
expression (g) after 
transfection with ZIP14 or 
scrambled control 
siRNAs. Nuclei 
counterstained with DAPI 
(in blue). Confocal images 
show x-y and y-z axis. 
Representative images 
and graphs of three 
experiments. Scale bar 5 
???? ?????????? ?-test was 
used in e, g; * p<0.05. 
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Figure 3.7 Proposed NTBI and TBI handling in proximal tubular epithelial cells  
Non-transferrin-bound iron (NTBI) and transferrin-bound iron (TBI) present in the systemic circulation are filtered 
by the glomerulus into the tubular lumen and are subsequently reabsorbed by proximal tubular cells. NTBI 
uptake at the plasma membrane involves both ZIP8 and ZIP14 that show redundancy. TBI uptake involves TfR1-
mediated endocytosis. Subsequently, iron is transported from the endosome towards the cytosol via ZIP14 and 
potentially also divalent metal transporter 1 (DMT1). Once in the cytosol, in the labile iron pool, iron is utilized, 
stored in ferritin or exported back into the circulation by ferroportin at the basolateral membrane.   
 
even though DMT1 mRNA expression did not change with ZIP14 knockdown (Figure 3.6g), 
ZIP14 and DMT1 could be redundant in TBI-derived iron uptake. 
DISCUSSION 
Evidence of renal complications in patients with systemic iron overload is accumulating, 
while the molecular mechanisms of renal NTBI and TBI handling in systemic iron overload 
remain unclear. We have shown that human PTs take up both NTBI and TBI. NTBI uptake 
involves both ZIP8 and ZIP14, which demonstrate redundancy. In contrast, TBI uptake is 
mediated by TfR1 endocytosis, where ZIP14, but not ZIP8, may be involved in iron release 
from the endosome into the cytosol (Figure 3.7).  
In addition to studies that report the suitability of ciPTECs to study renal 
physiology,44,45 we have demonstrated that this model is also qualified to study renal PT 
iron handling as it contains mechanisms for iron uptake, intracellular handling and export. 
Using this model, we newly demonstrated the subcellular distribution of endogenous ZIP8 
and ZIP14 in human PTs using cell surface biotinylation, immunoblotting and 
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immunofluorescent colocalization stainings, which extends previous studies that mostly 
relied on overexpression models.28 Our results show variability in divalent iron transporter 
localization in PT cells in terms of their localization at the plasma membrane or at the 
endosomal membrane. NTBI exposure was experimentally approached by addition of FeC 
to serum-free medium, preventing TBI formation, but allowing formation of citrate- bound 
NTBI. Interestingly, we observed a difference in involvement of ZIP8 and ZIP14 in NTBI and 
TBI uptake by ciPTECs. Although siRNA silencing in ciPTECs was limited, i.e. silencing of 
~50% was achieved for all examined proteins, including ZIP8, ZIP14, ferroportin and ZIP8 
and ZIP14 combined, it nevertheless demonstrated that both ZIP8and ZIP14 were involved 
in NTBI uptake, whereas only ZIP14 may play a role in TBI-derived iron uptake. These 
observations support the notion that we studied uptake of two distinct iron species. ZIP8 
and ZIP14 were both present at the ciPTEC plasma membrane and showed redundancy in 
tubular NTBI import. This redundancy for plasma membrane NTBI uptake is likely since 
both ZIP8 and ZIP14 are reported to transport iron together with HCO3
- at pH 6.5-
7.5.36,41,42,50 Also in hereditary hemochromatosis mouse models lacking ZIP14, NTBI uptake 
in the kidney was still detected, further corroborating redundancy of iron transporters.51 
Besides ZIP8 and ZIP14, other mechanisms for NTBI uptake have been described in various 
organs, which could explain why even the combined silencing of ZIP8 and ZIP14 did not 
abolish NTBI uptake in our model. In human hepatocytes, DMT1 was detected at the 
plasma membrane and was found to mediate NTBI uptake in these cells.38 Although we 
previously detected DMT1 in human PTs,52 it was not present at the plasma membrane in 
ciPTECs. As a result, we believed that a role for DMT1 in direct NTBI uptake at the plasma 
membrane was unlikely and focussed our studies on ZIP8 and ZIP14. Furthermore, in the 
circulation, NTBI can be bound to albumin53 and, as such, bereabsorbed in the PT by the 
multiligand megalin-cubilin receptor complex.54 Alternatively, L-type voltage-dependent 
calcium channels have been reported to facilitate NTBI uptake in cardiomyocytes,55,56 
which may also be the case in the human kidney, as these channels have been 
demonstrated in rat kidney.57 
We showed that TBI is internalized predominantly from the apical cellular side 
and this is mediated by the endocytic transporter TfR1. In addition, also the megalin-
cubilin receptor complex is reported to take up TBI in PTs.35 The fact that TBI uptake was 
reduced during iron loading implies IRE-IRP-regulated restriction of TBI uptake, hence 
suggesting that TBI uptake in PTs is predominantly mediated through TfR1. Moreover, 
TfR1 reduction in iron excess conditions suggests that TBI uptake is not the major cause of 
PT iron accumulation during iron overload. Since ZIP8 and ZIP14 abundance is not 
controlled by IRE-IRP regulation,49 it is plausible that especially unrestricted tubular NTBI 
uptake by these proteins results in renal iron loading and potentially subsequent iron-
mediated kidney injury during systemic iron overload.  
In ciPTECs, ZIP14 may play a role in transport of iron from the endosome towards 
the cytosol. In the endosome, ferric iron is released from transferrin, and, subsequently, 
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reduced to ferrous iron, possibly by a STEAP protein or Prion protein, which have been 
found in human and mouse kidney, respectively.58-60 Iron is found to dissociate from 
transferrin at pH 6.5,61 and ZIP14 is shown to transport iron at a similar pH.36,41 
Furthermore, ZIP14 is shown to mediate iron uptake from TBI in hepatocytes,36 while both 
ZIP8 and ZIP14 are found to mediate iron uptake from TBI uptake in neurons.37 Our results 
support the novel conclusion that ZIP14, but not ZIP8, may be involved in TBI-derived iron 
uptake in PT early endosomes. Our data do not substantiate the presence of ZIP8 in 
endosomes, which was shown for overexpressed rat ZIP8 in HEK293 cells.42 However, TBI-
derived iron uptake was not abolished with ZIP14 knockdown. Indeed, renal iron loading 
was observed in several hereditary hemochromatosis mouse models with TBI exposure 
despite ZIP14 knockout.51 Besides ZIP14, we detected DMT1 in endosomes in ciPTECs and, 
therefore, DMT1 is a potential candidate for endocytic iron transport in PTs, like is 
reported in hepatocytes.62-64 DMT1 is shown to transport iron at pH 5.5.62 Therefore, it is 
possible that DMT1 transports iron into the cytosol from late endosomes, which are 
characterized by a pH between 4.5 and 5.541 in PTs, and this is an interesting topic for 
future studies (in ciPTECs). Moreover, also TRPML1 (mucolipin1) is reported to transport 
iron in late endosomes or early lysosomes.65 The importance of this transporter in 
endosomal iron uptake is illustrated by findings of decreased cytosolic iron levels in 
TRPML1 knockout fibroblasts, and iron-deficiency and anaemia in patients with TRPML1 
mutations.65,66 TRPML1 has also been found in the kidney and could, thus, mediate 
endosomal iron transport into the cytosol.67 
 Although ZIP8 and ZIP14 demonstrated redundancy in ciPTEC NTBI transport, 
differential functions for both transporters have been reported. Despite similar iron 
transport capacities,49 ZIP8 and ZIP14 show a different localization pattern at the organ 
level, suggesting that these transporters have different roles in NTBI uptake from the 
circulation. While ZIP14 has been reported as the main NTBI uptake transporter in the 
liver and pancreas,51 ZIP8 is implicated to be the major NTBI transporter in hippocampal 
neurons.37 As such, mutations in ZIP8 and ZIP14 in patients both lead to changes in metal 
transport, but show distinct phenotypes.68-71 In addition to PTs, ZIP8 and ZIP14 are also 
present in human distal tubular epithelial cells,52,72 but it remains to be investigated to 
what extent both transporters are involved in NTBI handling in the distal nephron.  
In our current study in human ciPTECs, we observed ferroportin expression at the 
basolateral side of the cell, whereas expression at the apical and basolateral membrane 
was reported previously in murine PT.39,73-76 We recently showed ferroportin expression in 
human kidney biopsies also at the basolateral cellular side.52 Moreover, our findings in 
ciPTECs show that ferroportin functioned solely as iron exporter, and not as iron importer 
as has previously been suggested.76 Our results are in line with the general belief of a 
ferroportin cellular iron export function.77 Since to date no other iron cellular iron 
exporters have been identified, ferroportin is essential for physiological renal iron 
handling. Moreover, reabsorption of filtered iron and export back into the systemic 
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circulation is crucial for maintaining adequate body iron levels as well as preventing 
intracellular renal iron loading and potential iron-induced renal toxicity.  
In summary, our findings in human ciPTECs show that ZIP8 and ZIP14 are involved 
in TBI and NTBI uptake. Nevertheless, the results also demonstrate high redundancy in 
divalent metal transport in ciPTECs, suggesting a complex mechanisms of iron uptake. 
Future studies should be aimed at elucidating the apparent complex process of proximal 
tubular iron reabsorption to further assess the contribution of individual transporters to 
iron uptake in physiological conditions and during systemic iron overload.  
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SUPPLEMENTARY INFORMATION 
 
Supplementary Table 3.1: Overview used primary antibodies  
Protein Primary antibody 
TfR1 Thermo Fisher Scientific 136800, 1:500 
ZIP8 ProteinTech 20459-1-AP, 1:500 
ZIP14 Atlas Antibodies HPA016508, 1:500 
DMT1 Abcam ab55735, 1:350 
ZO-1 Invitrogen 402200, 1:100 
EEA1 
Abcam ab2900, 1:1000 (immunoblot and immunostaining with DMT1) 
Abcam ab70521, 1:200 (immunostaining with TfR1, ZIP8, ZIP14) 
Na K ATPase Koenderink lab, 1:25001 
Total ferritin Sigma Aldrich F5012, 1:250 
Ferroportin  Abcam ab85370, 1:100 
?-actin Sigma Aldrich A5441, 1:100,000 
DMT1, divalent metal transporter 1; EEA1, early endosome antigen 1; TfR1, transferrin receptor 1; ZO-1, Zona 
occludens 1. 
 
Supplementary Table 3.2: Overview used quantitative PCR primers 
Protein Forward primer ???- ??? ??????????? ??????- ??? 
TfR1 CCCAGTTGCTGTCCTGATATAGA TTGAGAAAACAATGCAAAATGTG 
ZIP8 TTATCTCTGTCCCCCTTTGTCCTC CGCCTTCGAAAGAACAGCAG 
ZIP14 CTGGACCACATGATTCCTCAG GAGTAGCGGACACCTTCCAG 
DMT1 ATGGCCCTCACATTTGGATA CGAACATGCCCTTGAGTACC 
Ferroportin GGGGTCGCCTAGTGTCAT CAGGTAGTCGGCCAAGGAT 
HPRT GCTATAAATTCTTTGCTGACCTGCTG AATTACTTTTATGTCCCCTGTTGACTGG 
DMT1, divalent metal transporter 1; HPRT, Hypoxanthine-guanine phorphoribosyltransferase; TfR1, transferrin 
receptor 1. 
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ABSTRACT 
Iron can catalyze reactive oxygen species (ROS) formation, causing cellular injury. In 
systemic iron overload, renal tubular epithelial cells are luminally exposed to high iron 
levels due to glomerular filtration of increased circulating iron. Reports of tubular 
???????????????? ???????????????? ????-thalassemia major support an association between 
increased chronic iron exposure and renal tubular injury. In acute iron exposure, Nuclear 
factor-erythroid 2-related factor 2 (Nrf2) may protect from iron-induced injury, whereas 
chronic renal stress may lead to Nrf2 exhaustion. We studied the cytotoxic mechanisms of 
chronic iron exposure using human conditionally immortalized proximal tubular epithelial 
cells (ciPTECs). Long-term iron exposure resulted in iron accumulation, cytosolic ROS 
formation and increased heme oxygenase 1 (HMOX-1) mRNA expression (all p<0.001). This 
was accompanied by nuclear translocation of Nrf2 and induction of its target protein 
NQO1, which both could be blocked by the Nrf2 inhibitor trigonelline. Interestingly, iron 
and trigonelline incubation reduced ROS production, but did not affect HMOX-1 mRNA 
levels. Moreover, ferritin protein and CHOP mRNA expression were induced in combined 
iron and trigonelline incubated cells (p<0.05). Together, these findings suggest that 
chronic iron exposure induces oxidative stress and that exhaustion of the antioxidant Nrf2 
pathway may lead to renal injury.  
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INTRODUCTION  
Iron is indispensable for life, but it can also be harmful by catalyzing reactive oxygen 
species (ROS) formation in the Fenton reaction.1 The human body carefully regulates iron 
uptake and storage, but has limited abilities to regulate iron excretion.2 As a result, 
increased intestinal iron uptake in hereditary hemochromatosis and increased body iron 
acquisition through f????????????????????????????????????????-thalassemia syndromes have 
been shown to result in chronic systemic iron overload and subsequent organ damage.2 
Patients with systemic iron overload suffer from elevated circulating iron levels, which are 
bound to the transport protein transferrin (transferrin-bound iron, TBI).2 Once transferrin 
becomes largely saturated with iron, non-transferrin-bound iron (NTBI) can be detected.3,4 
Although iron is tightly bound to transferrin in TBI, iron is only loosely bound to small 
molecules such as  citrate, in NTBI.3 As such, iron in NTBI is available for redox cycling and 
is, therefore, considered a toxic iron species.3,5 Circulating TBI and NTBI are filtered into 
the renal tubular lumen by the glomerulus.6-8 Subsequently, iron in the tubular lumen is 
suggested to be completely reabsorbed by renal tubular cells, since hardly any iron is 
present in urine of healthy volunteers.9,10 As a result, in patients with elevated circulating 
iron levels, proximal tubular epithelial cells (PTECs) are chronically exposed to high and 
potentially harmful iron levels.  
In patients with hereditary hemochromatosis11-15 or ?-thalassemia major,16,17 
renal iron deposition has been observed. Moreover, renal dysfunction in patients with ?-
thalassemia major has been reported with increased urinary excretion of N-acetyl-?-D-
???????????????? ???????????-2-microglobulin, both markers for renal PTEC damage.16-21 
Combined, these observations suggest that chronic iron overload may cause increased 
iron accumulation in the kidney, and, as such, may lead to clinically relevant 
nephrotoxicity over time.  
The question remains, however, which exact molecular mechanisms are involved 
in renal tubular injury during chronic TBI and NTBI exposure. Previous animal and human 
studies suggest that chronically increased renal tubular iron exposure and injury in 
systemic iron overload depend on the balance between oxidative stress and antioxidative 
systems.22-28 The major cellular pathway that protects against oxidative injury has been 
shown to be coordinated by Nuclear factor-erythroid 2-related factor 2 (Nrf2),29 which is 
reported to protect from short term iron-induced injury in PTECs. Nrf2 knockout mice 
showed increased PTEC injury and urinary excretion of NAG 24h after a single ferric 
nitrilotriacetate (Fe-NTA) injection.30 In animal models of chronic kidney disease, Nrf2 
activity exhausted over time despite continuous presence of oxidative stress.31-33 
Therefore, we tested the hypothesis that Nrf2 exhaustion as a result of persistent 
oxidative stress underlies renal injury observed in chronic iron overload conditions.  
To this end, we examined the intracellular effects of long-term iron overload 
exposure in human conditionally immortalized PTECs (ciPTECs) and the role of the Nrf2 
pathway herein. 
77
Inhibition of Nrf2 alters cell stress induced by chronic iron exposure
4
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 78
METHODS 
 
Cell culture 
ciPTECs (clone T1, kindly provided by dr. M. Wilmer, Radboud university medical center)34 
were cultured using DMEM HAM's F-12 phenol red-free medium (Thermo Fisher Scientific) 
containing 5 ?g/ml insulin, 5 ?g/ml transferrin, 5 ng/ml selenium, 36 ng/ml 
hydrocortisone, 10 ng/ml epithelial growth factor and 40 pg/ml triiodothyronine (all Sigma 
Aldrich), 10% (v/v) fetal calf serum (Greiner Bio-one), and 1% (v/v) penicillin-streptomycin 
(Thermo Fisher Scientific). Cells were cultured at 33°C and 5% CO2, and grown for 24h at 
33°C and 5% CO2 and 7 days at 37°C and 5% CO2 prior to experiments.  
 
Iron exposure 
Cells were exposed to 0-500 μM ferric citrate (FeC, Sigma Aldrich) for 72h (toxicity array) 
or 48h (all other experiments) with or without 1 μM trigonelline hydrochloride (Sigma 
Aldrich). We calculated that already 100 μM FeC could saturate transferrin levels in fetal 
calf serum35 with iron and, as such, this would result in ciPTEC iron exposure containing 
both saturated TBI and NTBI. Cell pellets were collected and stored at -80°C until analysis. 
 
Protein isolation and immunoblotting 
Cell pellets were lysed using RIPA buffer (0.15 M NaCl, 0.012 M Sodium Deoxycholate, 
0.1% NP40, 0.1% SDS, 0.05 M Tris, pH 7.5, freshly supplemented with protease inhibitors 
(Complete mini, Roche)). Protein concentration was determined using the Pierce BCA 
assay kit according to the manufacturer’s instructions (Thermo Fisher Scientific). Protein 
samples were separated on SDS-PAGE gels, transferred to nitrocellulose membrane and 
incubated with primary antibody overnight at 4°C. After 1h incubation at RT with 
secondary antibody, proteins were visualized on a LAS-3000 scanner for 
chemiluminescence (Transferrin receptor 1 (TfR1)) or Odyssey fluorescence scanner (all 
other proteins). Primary antibodies and dilutions are summarized in Supplementary Table 
4.1.  
 
Nucleus enrichment 
Cells were resuspended in mild lysis buffer (10 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 
270 mM sucrose, 0.1% NP-40, 20 mM Tris-HCl, pH 7.5, freshly supplemented with 1 mM 
DTT and protease inhibitors) and disrupted using a Douncer homogenizer. After 
centrifugation, pellets were incubated with RIPA lysis buffer and supernatant was 
collected as nuclear fraction.  
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RNA isolation and quantitative PCR 
RNA isolation was performed using TRIzol™ (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. A reverse transcription reaction was performed with 1 ?g 
RNA, 4 ?l first strand buffer, 1 ?l dNTPs (12.5 mM), 2.04 ?l random primers, 2 ?l DDT, 1 ?l 
M-MLV (all Thermo Fisher Scientific) and 0.5 ?l RNAsin (Promega Corporation). The PCR 
cycle existed of 20 °C for 10 min, 42 °C for 45 min and 95 °C for 10 min. Quantitative PCR 
was performed on a CFX96 (Bio-rad) using 4 μl cDNA (10 ng/ml), 10 μl SYBR Green Power 
master mix (Applied Biosystems) and 6 μl primer mix  (containing 1 μM forward primer 
and reverse primer). The PCR protocol was as follows: 7 min at 95°C, 40 cycles of 15 sec at 
95°C and 1 min at 60°C, and 10 min at 95°C, with a measurement at the end of each cycle. 
Fold change values were calculated relative to the housekeeping gene hypoxanthine-
guanine phosphoribosyltransferase ??????? ?????? ???? ????? ????????? ??? ???? ????
summarized in Supplementary Table 4.2. 
 
Toxicity array 
The RT2 Profiler PCR Array Human Stress & Toxicity Pathway Finder (Qiagen), containing 
84 different genes and 5 housekeeping genes was used together with RT2 SYBR Green 
????? ??????????????????????????????????? ???????????????????????????? 
 
Iron assessment 
Intracellular iron level were determined using the chromogen bathophenanthroline as 
described.36 Iron concentrations were calculated by comparison to a standard curve of 
ferrous sulfate and corrected for protein concentration.  
 
Oxidative stress measurement 
?????? ????? ?????????? ????? ??? ??? ???? ??-dichlorodihydrofluorescein di-acetate (CM-
H2DCFDA, Thermo Fisher Scientific) and FeC for 1h at 37°C. Fluorescence was measured 
using a Victor X Multilabel Plate Reader (Perkin Elmer).  
For oxidative stress staining, cells were incubated with 50 μM CellROX™ Green for 
30 min at 37°C, fixed with 4% paraformaldehyde, stained with DAPI (????-diamidino-2-
phenylindole, 300 μM, Thermo Fisher Scientific) and mounted. Images were taken using a 
Zeiss Apotome FL microscope and AxioVision software. 
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Statistical analysis 
Data were statistically analyzed using GraphPad Prism 5.03 and presented as mean ± SEM. 
Results were analyzed by One-Way ANOVA with Dunnett’s post test or Student’s t-test, 
where appropriate. Differences were considered statistically significant when p<0.05.  
 
RESULTS 
 
Long term iron overload results in Nrf2 pathway activation  
In ciPTECs, 48h iron overload exposure significantly and concentration-dependently 
increased intracellular iron levels (p<0.05 for 100 μM and 200 μM, p<0.001 for 500 μM 
FeC compared to control) (Figure 4.1a). High intracellular iron levels are known to 
decrease TfR1 and induce ferritin protein expression as a result of posttranslational 
genomic iron responsive element – iron responsive protein (IRE-IRP) regulation37, which 
was confirmed in our model in a concentration-dependent manner (Figure 4.1b). Although 
morphological cell death was not observed (data not shown), chronic iron exposure 
significantly induced ROS production (p<0.05 for 200 μM, p<0.001 for 500 μM; Figure 4.1c) 
and heme oxygenase 1 (HMOX-1) mRNA expression (p<0.05 for 100 μM, p<0.01 for 200 
μM and 500 μM), which is a marker for cellular oxidative stress38 (Figure 4.1d).  
Next, we applied an explorative gene expression array to identify pathways 
involved in long-term iron-induced stress in ciPTECs. Indeed, 72h iron exposure 
predominantly induced genes regulated by Nrf2 (Figure 2), including NAD(P)H quinone 
dehydrogenase 1 (NQO1), glutamate-cysteine ligase modifier subunit (GCLM) and 
thioredoxin reductase 1 (TXNRD1). Induction of these genes was confirmed by additional 
quantitative PCR, which showed increased mRNA expression of these genes in a 
concentration-dependent manner upon 48h of iron exposure, which was statistically 
significant at 200 μM and 500 μM FeC (Figure 4.3a). Chronic iron exposure induced Nrf2 
protein levels in enriched nuclear lysates of ciPTECs, without affecting Nrf2 protein levels 
in total cell lysates (Figure 4.3b), and moderately increased NQO1 protein levels (Figure 
4.3c). Together, these data support activation of the Nrf2 pathway by long-term iron 
exposure.   
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Figure 4.1: Long-term iron uptake and resulting cellular stress in ciPTECs 
Intracellular iron concentration (a), total ferritin and transferrin receptor 1 (TfR1) protein levels (b), cytosolic 
reactive oxygen species (ROS) production (c) and heme oxygenase 1 (HMOX-1) mRNA expression after incubation 
????? ?????????? ??????????????? ??? ??????? ????????? ???????? ???????? ????????? ??? ?-actin. Representative images and 
graphs showing mean of at least three independent experiments. * p<0.05; ** p<0.01; *** p<0.001.  
 
Nrf2 downregulation activates other cellular stress mechanisms 
To investigate the effects of iron overload exposure upon Nrf2 exhaustion, we used the 
Nrf2 inhibitor trigonelline to reduce ciPTEC Nrf2 expression.39,40 Addition of trigonelline to 
iron exposure diminished Nrf2 nuclear translocation, as indicated by significantly reduced 
Nrf2 protein levels in enriched nuclear lysates whereas Nrf2 protein levels in total cell 
lysates remained unaffected (Figure 4.4a). Moreover, trigonelline also diminished the 
induction of NQO1 protein levels and decreased mRNA levels of Kelch like ECH associated 
protein 1 (KEAP1), the Nrf2 binding protein29 (p<0.05 at 500 μM FeC with trigonelline, 
compared to 500 μM FeC alone) (Figure 4.4b and c, respectively).  
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Figure 4.2: Explorative qPCR array results after long-term iron overload exposure in ciPTECs 
Results Stress and Toxicity Pathway finder PCR array (Qiagen) after 72h of exposure to 200 μM ferric citrate 
compared to control. Genes categorized according to manufacturer’s protocol. mRNA expression presented 
relative to housekeeping gene HPRT. Results indicated as increased (green), similar (grey) or decreased 
compared to control (red). Description of all genes can be found in Supplementary Table 4.3.  
 
Surprisingly, trigonelline co-administration decreased oxidative stress production 
compared to iron exposure alone (Figure 4.5a), whereas HMOX-1 mRNA levels were not 
altered (Figure 4.5b), indicating that cellular stress was still present. To confirm iron 
uptake by cells co-incubated with trigonelline, protein levels of TfR1 and ferritin were 
measured. We again observed a concentration-dependent reduction in TfR1 protein levels 
(Figure 4.5c), similar to previous incubation with iron alone (Figure 4.1b), which suggests a 
comparable intracellular iron content. However, we observed a striking increase in ferritin 
protein levels in cell exposed to iron and trigonelline compared to iron alone (Figure 4.5c).  
Induction of both ferritin subunits, H-ferritin (FTH) and L-ferritin (FTL), was 
confirmed on mRNA level (p<0.05 for 200 μM and 500 μM iron + trigonelline compared to 
iron alone for FTH1; p<0.01 for 200 μM and 500 μM iron for FTL; Figure 4.5d). To explore 
potential iron-mediated cell stress mechanisms in Nrf2-downregulated cells, we measured 
CCAAT-enhancer-binding protein homologous protein (CHOP), an indicator of endoplasmic 
reticulum (ER) stress. We observed a significant induction of CHOP mRNA levels with 
trigonelline co-administration compared to iron alone (p<0.05 for 200 μM iron + 
trigonelline, p<0.01 for 500 μM iron + trigonelline compared to iron alone, Figure 4.5e). 
This suggests that in case of Nrf2 exhaustion, mechanisms other than oxidative stress may 
lead to renal injury. 
DISCUSSION 
Chronically increased luminal iron exposure has been associated with renal tubular injury 
in patients with systemic iron overload. However, the molecular mechanisms involved in  
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Figure 4.3: Nrf2 pathway activation by long-term iron overload in ciPTECs 
NAD(P)H quinone dehydrogenase 1 (NQO1), Thioredoxin reductase 1 (TXNRD1) and Glutamate-Cysteine Ligase 
Modifier Subunit (GCLM) mRNA expression (a), and Nuclear factor erythroid 2-related factor 2 (Nrf2) protein 
expression in total cell lysate or enriched nuclear fraction, and NQO1 protein expression in total cell lysate (b) 
after incubation with different concentrations of ferric citrate. Protein content ????????? ??? ?-actin (total cell 
lysate) or Histone H3 (nuclear fraction). Representative images and graphs showing mean of at least three 
independent experiments. * p<0.05; ** p<0.01. 
 
injury during chronic iron overload exposure remained unclear. In this study, we showed  
that long-term iron exposure resulted in iron loading, oxidative cellular stress and 
activation of the antioxidative protective Nrf2 pathway in ciPTECs. Moreover, Nrf2 
downregulation attenuated ROS production, but simultaneously induced CHOP and 
ferritin. This suggests that other stress-related pathways may be activated during 
persistent iron exposure once the protective Nrf2 pathway is exhausted (Figure 4.6). 
We showed that long-term iron exposure results in PTEC iron loading, which is in 
agreement with reports of PT iron deposition in systemic iron overload animal models.41,42 
This resulted in IRE-IRP-mediated downregulation of TfR1,37 suggesting this transporter 
may not play a major role in PTEC iron uptake. PTECs have other, presumably IRE-IRP-
independent, mechanisms that take up iron during increased luminal iron exposure. 
Potentially, TBI could be taken up by the endocytic megalin:cubilin transporter complex or 
divalent metal transporters at the plasma membrane mediate NTBI uptake.6 Long-term 
iron exposure activated the antioxidative Nrf2 pathway in ciPTECs. The Nrf2 system is 
known to protect cells from a large variety of electrophilic and oxidative stressors by 
coordinating the cellular antioxidant response.43 Indeed, Nrf2 knockout mice are more 
susceptible to acute Fe-NTA nephrotoxicity than control mice, as shown by enhanced 
renal tubular necrosis and depletion of glutathione levels in the kidney after Fe-NTA 
injection.44 We now show in vitro that also chronic iron overload activates the  
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Figure 4.4: Nrf2 downregulation using trigonelline in ciPTECs 
Nuclear factor erythroid 2-related factor 2 (Nrf2) protein expression in total cell lysate (a) or enriched nuclear 
fraction (b), NAD(P)H quinone dehydrogenase 1 (NQO1) protein expression in total cell lysate (c) and Kelch like 
ECH associated protein 1 (KEAP1) mRNA expression after incubation with different concentrations of ferric citrate 
????????????????????????????????????????????????????????????????????????????????????????????????????????????????-actin 
(total cell lysate) or Histone H3 (nuclear fraction). Representative images and graphs showing mean of at least 
three independent experiments. Iron + trigonelline treated cells compared to control, * p<0.05; ** p<0.01; *** 
p<0.001. Iron + trigonelline treated cells compared to iron only treated cells, # p<0.05. 
 
antioxidative Nrf2 pathway. Although we observed increased ROS and cellular stress in 
ciPTECs after long-term iron exposure, these cells did not show signs of cell death, possibly 
as a result of Nrf2 activation. Previous studies showed Nrf2 exhaustion in murine models 
of chronic kidney disease.31-33 Rats subjected to 5/6 nephrectomy developed oxidative 
stress and lipid peroxidation over time, whereas Nrf2 protein levels in the remnant kidney 
tissue were decreased rather than increased compared to control animals.32 Also in Imai 
rats, a model of spontaneous focal glomerulosclerosis, persistent oxidative stress and 
impaired Nrf2 activation were observed.33 During systemic iron overload, failure of Nrf2 
activation could potentiate cytotoxicity of persistent iron overload exposure.  
Interestingly, we observed decreased ROS levels, induction of ferritin protein 
levels and enhanced CHOP mRNA levels with Nrf2 downregulation by trigonelline and 
long-term iron exposure. The iron storage molecule ferritin is mainly regulated by iron 
availability via IRE-IRP regulation and is increased with intracellular iron loading.37 
Increased iron storage in ferritin could prevent intracellular iron from being redox active 
and could explain our findings of decreased ROS formation.45 In contrast, Nrf2 KO mice 
showed increased oxidative stress 6h after Fe-NTA injection.30,44 This discrepancy could be 
caused by the iron exposure time, as long-term iron exposure of 48h in our model could 
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????????????????????????????????????????????????????????????????
Oxidative stress production (a), heme oxygenase 1 (HMOX-1) mRNA expression (b), total ferritin and transferrin 
receptor 1 (TfR1) protein expression (c), H-ferritin (FTH1) and L-ferritin (FTL) (d) and CCAAT-enhancer-binding 
protein homologous protein (CHOP) mRNA expression after incubation with different concentrations of ferric 
citrate with (striped bars) or without (open bars) the Nrf2 inhibitor trigonelline (Trig). Protein content relative to 
?-actin. Representative images and graphs showing mean of at least three independent experiments. Iron + 
trigonneline treated cells compared to control, * p<0.05; ** p<0.01; *** p<0.001. Iron + trigonelline treated cells 
compared to iron only treated cells, # p<0.05; ## p<0.01.  
 
model could initiate chronic survival mechanisms that differ from acute cellular stress 
signalling after iron exposure for only 6h. Potentially, ferritin is not yet increased after 6h 
of iron incubation, whereas it is after 48h, which could explain differential signalling after 
acute or chronic iron exposure. Ferritin is also induced by inflammatory cytokines and 
Nuclear Factor kappa-light-chain-enhancer of activated B cell (NF-????signalling, the latter 
being repressed by Nrf2.29,46 Therefore, ferritin induction during Nrf2 exhaustion might 
involve multiple mechanisms, that require further studies. During Nrf2 inhibition, we 
observed a shift from oxidative stress to potential ER stress signalling as confirmed by 
induction of CHOP mRNA expression. During long-term ER stress, the physiological 
unfolded protein response (UPR) becomes overruled by apoptotic UPR signalling, which 
includes the activation of CHOP and other apoptotic UPR genes.47 In hepatocytes, ER 
stress activation was reported to induce H-ferritin mRNA expression.48 This suggests that 
ER stress could also be related to the ferritin induction in ciPTECs during Nrf2 exhaustion. 
Although ferritin is known to initially safely store iron inside its core, long-term iron 
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Figure 4.6: Schematic overview of stress pathways 
during long-term iron overload exposure in proximal 
tubular epithelial cells 
In systemic iron overload, renal tubular epithelial cells are 
exposed to increased levels of transferrin-bound iron 
(TBI) and non-transferrin-bound iron (NTBI). Cellular 
uptake into the labile iron pool results in induction of 
intracellular iron storage protein ferritin and heme 
oxygenase 1 (HMOX-1), a marker for cellular stress. 
Moreover, reactive oxygen species (ROS) are produced, 
resulting in an anti-oxidative response mediated by 
Nuclear factor erythroid 2-related factor 2 (Nrf2), 
balancing oxidative and anti-oxidative conditions (a). 
When Nrf2 is downregulated by using trigonelline (Trig), 
ROS production is decreased, whereas HMOX-1 is not 
affected. Simultaneously, ferritin and CHOP, a marker for 
endoplasmic reticulum (ER) stress, are induced. This 
suggests that other stress pathways can be activated 
during Nrf2 exhaustion, which could potentially mediate 
chronic iron-induced renal injury (b). 
 
accumulation in ferritin shells may be pro-oxidative.45 ER stress in tubular epithelial cells is 
suggested to be involved in the development or progression of chronic kidney disease.47 
Cells subjected to chronic ER stress are cleared via apoptosis, which is frequently seen in 
chronic kidney disease.49 Our explorative qPCR array showed that iron overload exposure 
in ciPTECs induced pro-apoptotic caspase 1 (CASP1) but decreased anti-apoptotic tumor 
necrosis factor receptor superfamily member 10b (TNFRSF10B) mRNA expression, 
suggesting long-term iron exposure may initiate apoptotic cellular signalling. As such, long-
term iron overload exposure in patients with systemic iron overload could induce renal 
PTEC injury through induced ER stress-mediated apoptosis upon intracellular iron 
accumulation.   
In systemic iron overload, PTECs are likely to be a target of iron-mediated injury. 
Filtered proteins are predominantly reabsorbed by PTECs,6,50 suggesting these cells are 
exposed to high iron levels in systemic iron overload. Moreover, PTECs are sensitive to 
injury due to their high level of energy consumption and mitochondrial content.51 
Nevertheless, in severe iron overload exposure, PTEC injury hampers PTEC iron 
reabsorption, and increased iron levels pass down the nephron and reach distal tubules. 
As this could result in iron accumulation and subsequent injury in these epithelial cells, 
examination of the mechanisms of iron-induced injury in distal tubular epithelial cells is a 
relevant aspect for future studies.    
In conclusion, our findings show that long-term iron exposure activates the Nrf2 
pathway in PTECs. Nrf2 exhaustion may result in activation of ER stress and could attribute 
to chronic iron overload-induced PTEC injury, which may differ from known mechanisms in 
acute iron-induced kidney injury. Further studies in chronic iron overload models 
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examining the mechanisms of iron-mediated renal injury could be used to identify 
treatment strategies to decrease iron-mediated renal injury in patients with systemic iron 
overload.   
 
ACKNOWLEDGEMENTS 
The authors thank Merel Platenburg and Alex Geerlings for technical assistance.  
 
  
87
Inhibition of Nrf2 alters cell stress induced by chronic iron exposure
4
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 88
REFERENCES 
1. Koppenol WH. The centennial of the Fenton reaction. Free radical biology & medicine 1993;15:645-51. 
2. Brissot P, Loreal O. Iron metabolism and related genetic diseases: A cleared land, keeping mysteries. 
Journal of hepatology 2016;64:505-15. 
3. Brissot P, Ropert M, Le Lan C, Loreal O. Non-transferrin bound iron: a key role in iron overload and iron 
toxicity. Biochimica et biophysica acta 2012;1820:403-10. 
4. de Swart L, Hendriks JC, van der Vorm LN, et al. Second international round robin for the quantification 
of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. 
Haematologica 2016;101:38-45. 
5. Cabantchik ZI. Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Frontiers 
in pharmacology 2014;5:45. 
6. Thevenod F, Wolff NA. Iron transport in the kidney: implications for physiology and cadmium 
nephrotoxicity. Metallomics : integrated biometal science 2016;8:17-42. 
7. Zhang D, Meyron-Holtz E, Rouault TA. Renal iron metabolism: transferrin iron delivery and the role of 
iron regulatory proteins. Journal of the American Society of Nephrology : JASN 2007;18:401-6. 
8. Norden AG, Lapsley M, Lee PJ, et al. Glomerular protein sieving and implications for renal failure in 
Fanconi syndrome. Kidney international 2001;60:1885-92. 
9. Rodriguez E, Diaz C. Iron, copper and zinc levels in urine: relationship to various individual factors. 
Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements 
1995;9:200-9. 
10. Green R, Charlton R, Seftel H, et al. Body iron excretion in man: a collaborative study. The American 
journal of medicine 1968;45:336-53. 
11. Ozkurt S, Acikalin MF, Temiz G, Akay OM, Soydan M. Renal hemosiderosis and rapidly progressive 
glomerulonephritis associated with primary hemochromatosis. Renal failure 2014;36:814-6. 
12. Marble A, Bailey CC. Hemochromatosis. The American journal of medicine 1951;11:590-9. 
13. Rous P. Urinary Siderosis : Hemosiderin Granules in the Urine as an Aid in the Diagnosis of Pernicious 
Anemia, Hemochromatosis, and Other Diseases Causing Siderosis of the Kidney. The Journal of experimental 
medicine 1918;28:645-58. 
14. Okumura A, Kondo K, Hirai C, et al. Nephrogenic diabetes insipidus associated with hemochromatosis. 
American journal of kidney diseases : the official journal of the National Kidney Foundation 2002;40:403-6. 
15. Chmieliauskas S, Banionis D, Laima S, et al. Autopsy relevance determining hemochromatosis: Case 
report. Medicine (Baltimore) 2017;96:e8788. 
16. ElAlfy MS, Khalil Elsherif NH, Ebeid FSE, et al. Renal iron deposition by magnetic resonance imaging in 
pediatric beta-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy . 
Eur J Radiol 2018;103:65-70. 
17. Hashemieh M, Radfar M, Azarkeivan A, et al. Renal Hemosiderosis among Iranian Transfusion 
Dependent beta-Thalassemia Major Patients. Int J Hematol Oncol Stem Cell Res 2017;11:133-8. 
18. Annayev A, Karakas Z, Karaman S, Yalciner A, Yilmaz A, Emre S. Glomerular and Tubular Functions in 
Children and Adults with Transfusion-Dependent Thalassemia. Turk J Haematol 2018;35:66-70. 
19. Quinn CT, Johnson VL, Kim HY, et al. Renal dysfunction in patients with thalassaemia. British journal of 
haematology 2011;153:111-7. 
20. Ahmadzadeh A, Jalali A, Assar S, Khalilian H, Zandian K, Pedram M. Renal tubular dysfunction in 
pediatric patients with beta-thalassemia major. Saudi journal of kidney diseases and transplantation : an official 
publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2011;22:497-500. 
21. Deveci B, Kurtoglu A, Kurtoglu E, Salim O, Toptas T. Documentation of renal glomerular and tubular 
impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia. Ann Hematol 
2016;95:375-81. 
22. Budak H, Kocpinar EF, Gonul N, Ceylan H, Erol HS, Erdogan O. Stimulation of gene expression and 
activity of antioxidant related enzyme in Sprague Dawley rat kidney induced by long-term iron toxicity. 
Comparative biochemistry and physiology Toxicology & pharmacology : CBP 2014;166:44-50. 
23. Sponsel HT, Alfrey AC, Hammond WS, Durr JA, Ray C, Anderson RJ. Effect of iron on renal tubular 
epithelial cells. Kidney international 1996;50:436-44. 
24. Sheerin NS, Sacks SH, Fogazzi GB. In vitro erythrophagocytosis by renal tubular cells and tubular 
toxicity by haemoglobin and iron. Nephrology, dialysis, transplantation : official publication of the European 
Dialysis and Transplant Association - European Renal Association 1999;14:1391-7. 
25. Ansar S, Iqbal M, AlJameil N. Diallyl sulphide, a component of garlic, abrogates ferric nitrilotriacetate-
induced oxidative stress and renal damage in rats. Hum Exp Toxicol 2014;33:1209-16. 
88
Chapter 4
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 89
26. Gholampour F, Behzadi Ghiasabadi F, Owji SM, Vatanparast J. The protective effect of hydroalcoholic 
extract of Ginger (Zingiber officinale Rosc.) against iron-induced functional and histological damages in rat liver 
and kidney. Avicenna J Phytomed 2017;7:542-53. 
27. von Herbay A, de Groot H, Hegi U, Stremmel W, Strohmeyer G, Sies H. Low vitamin E content in 
plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. Journal of hepatology 
1994;20:41-6. 
28. Ghone RA, Kumbar KM, Suryakar AN, Katkam RV, Joshi NG. Oxidative stress and disturbance in 
antioxidant balance in beta thalassemia major. Indian journal of clinical biochemistry : IJCB 2008;23:337-40. 
29. Kerins MJ, Ooi A. The Roles of NRF2 in Modulating Cellular Iron Homeostasis. Antioxidants & redox 
signaling 2017. 
30. Tanaka Y, Aleksunes LM, Goedken MJ, et al. Coordinated induction of Nrf2 target genes protects 
against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. Toxicology and applied pharmacology 
2008;231:364-73. 
31. Aminzadeh MA, Sato T, Vaziri ND. Participation of endoplasmic reticulum stress in the pathogenesis of 
spontaneous glomerulosclerosis--role of intra-renal angiotensin system. Translational research : the journal of 
laboratory and clinical medicine 2012;160:309-18. 
32. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation 
in chronic renal failure. American journal of physiology Renal physiology 2010;298:F662-71. 
33. Kim HJ, Sato T, Rodriguez-Iturbe B, Vaziri ND. Role of intrarenal angiotensin system activation, 
oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression 
of focal glomerulosclerosis. The Journal of pharmacology and experimental therapeutics 2011;337:583-90. 
34. Jansen J, Schophuizen CM, Wilmer MJ, et al. A morphological and functional comparison of proximal 
tubule cell lines established from human urine and kidney tissue. Experimental cell research 2014;323:87-99. 
35. Young SP, Garner C. Delivery of iron to human cells by bovine transferrin. Implications for the growth 
of human cells in vitro. The Biochemical journal 1990;265:587-91. 
36. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in 
formalinised liver samples. S Afr J Med Sci 1968;33:9-11. 
37. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell 
2017;168:344-61. 
38. Lever JM, Boddu R, George JF, Agarwal A. Heme Oxygenase-1 in Kidney Health and Disease. 
Antioxidants & redox signaling 2016;25:165-83. 
39. Boettler U, Sommerfeld K, Volz N, et al. Coffee constituents as modulators of Nrf2 nuclear 
translocation and ARE (EpRE)-dependent gene expression. J Nutr Biochem 2011;22:426-40. 
40. Arlt A, Sebens S, Krebs S, et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline 
renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression 
and proteasome activity. Oncogene 2013;32:4825-35. 
41. Yatmark P, Morales NP, Chaisri U, et al. Iron distribution and histopathological study of the effects of 
deferoxamine and deferiprone in the kidneys of iron overloaded beta-thalassemic mice. Exp Toxicol Pathol 
2016;68:427-34. 
42. Zhou XJ, Laszik Z, Wang XQ, Silva FG, Vaziri ND. Association of renal injury with increased oxygen free 
radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Laboratory 
investigation; a journal of technical methods and pathology 2000;80:1905-14. 
43. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and 
intermediary metabolism. Trends Biochem Sci 2014;39:199-218. 
44. Kanki K, Umemura T, Kitamura Y, et al. A possible role of nrf2 in prevention of renal oxidative damage 
by ferric nitrilotriacetate. Toxicol Pathol 2008;36:353-61. 
45. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and 
more. Biochimica et biophysica acta 2009;1790:589-99. 
46. Pham CG, Bubici C, Zazzeroni F, et al. Ferritin heavy chain upregulation by NF-kappaB inhibits 
TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004;119:529-42. 
47. Inagi R, Ishimoto Y, Nangaku M. Proteostasis in endoplasmic reticulum--new mechanisms in kidney 
disease. Nature reviews Nephrology 2014;10:369-78. 
48. Oliveira SJ, Pinto JP, Picarote G, et al. ER stress-inducible factor CHOP affects the expression of hepcidin 
by modulating C/EBPalpha activity. PloS one 2009;4:e6618. 
49. Sanz AB, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A. Mechanisms of renal apoptosis in health and 
disease. Journal of the American Society of Nephrology : JASN 2008;19:1634-42. 
89
Inhibition of Nrf2 alters cell stress induced by chronic iron exposure
4
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 90
50. Abouhamed M, Gburek J, Liu W, et al. Divalent metal transporter 1 in the kidney proximal tubule is 
expressed in late endosomes/lysosomal membranes: implications for renal handling of protein-metal complexes. 
American journal of physiology Renal physiology 2006;290:F1525-33. 
51. Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role 
of the glomerulotubular junction. American journal of physiology Renal physiology 2016;311:F145-61. 
 
  
90
Chapter 4
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 91
SUPPLEMENTARY INFORMATION  
 
Supplementary Table 4.1: Overview used primary antibodies  
Protein Primary antibody 
TfR1 Thermo Scientific 136800, 1:500 
Total ferritin Sigma Aldrich F5012, 1:250 
Nrf2 Abcam ab31163, 1:1000 
NQO1 Abcam ab34173, 1:1000 
Histone H3 Abcam ab24834, 1:1000 
?-actin Sigma A5441, 1:100,000 
NQO1, NAD(P)H quinone dehydrogenase 1; Nrf2, nuclear factor erythroid 2-related factor 2; TfR1, Transferrin 
receptor 1. 
 
Supplementary Table 4.2: Overview used quantitative PCR primers 
Gene ??????????? ??????- ??? ??????????? ??????- ??? 
HMOX-1 AGACACCCTAATGTGGCAGC CTGAGCCAGGAACAGAGTGG 
NQO1 TGAAGAAGAAAGGATGGGAGGT GGCCTTCTTTATAAGCCAGAACA 
TXNRD1 TGTCATGTGAGGACGGTCGG TTCACAAACACAACGGGCAG 
GCLM ACTGACTTAGGAGCATAACTTACC AAGAATATCTGCCTCAATGACACC 
KEAP1 CATCCACCCTAAGGTCATGGA GACAGGTTGAAGAACTCCTCC 
FTH1 GAAGCTGCAGAACCAACGA CACACTCCATTGCATTCAGC 
FTL CACCTGACCAACCTCCACAG CGTGCTTGAGAGTGAGCCTT 
CHOP CTTCTCTGGCTTGGCTGACT TCCCTTGGTCTTCCTCCTCT 
HPRT GCTATAAATTCTTTGCTGACCTGCTG AATTACTTTTATGTCCCCTGTTGACTGG 
CHOP, CCAAT-enhancer-binding protein homologous protein; FTH1, Ferritin heavy chain; FTL, Ferritin light chain; 
GCLM, Glutamate-cysteine ligase modifier subunit; HMOX-1, Heme oxygenase 1; HPRT, Hypoxanthine-guanine 
phosphoribosyltransferase; KEAP1, Kelch like ECH associated protein 1; NQO1, NAD(P)H quinone dehydrogenase 
1; TXNRD1, Thioredoxin reductase 1. 
 
Supplementary Table 4.3: Overview target genes in gene expression array 
Gene Description  
ADM Adrenomedullin 
AKR1B1 Aldose reductase 
AQP1 Aquaporin 1 
AQP2 Aquaporin 2 
AQP4 Aquaporin 4 
ARNT Aryl hydrocarbon receptor nuclear translocator 
ATF4 Activating transcription factor 4 (tax-responsive enhancer element B67 
ATF6 Activating transcription factor 6 
ATF6B Activating transcription factor 6 beta 
ATG12 Autophagy protein 12 
ATG5 Autophagy protein 5 
ATG7 Autophagy protein 7 
ATM Ataxia telangiectasia mutated kinase 
ATR Ataxia telangiectasia and Rad3 related kinase 
BBC3 BCL2 binding component 3 
BECN1 Beclin 1 
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BID BH3 interacting domain death agonist 
BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 
CA9 Carbonic anhydrase IX 
CALR Calreticulin 
CASP1 Caspase 1 
CCL2 Chemokine (C-C motif) ligand 2 
CD40LG CD40 ligand 
CDKN1A P21 
CFTR Cystic fibrosis transmembrane conductance regulator 
CHEK1 Checkpoint kinase 1 
CHEK2 Checkpoint kinase 2 
CRP C-reactive protein 
DDB2 DNA damage-binding protein 2 
DDIT3 DNA damage-inducible transcript 3 
DNAJC3 DnaJ homolog, subfamily C, member 3 
EDN1 Endothelin 1 
EPO Erythropoietin  
FAS Fas 
FTH1 H-Ferritin 
GADD45A Growth arrest and DNA-damage-inducible alpha 
GADD45G Growth arrest and DNA-damage-inducible gamma 
GCLC Glutamate-cysteine ligase, catalytic subunit 
GCLM Glutamate-cysteine ligase, modifier subunit 
GRB2 Growth factor receptor-bound protein 2 
GSR Glutathione reductase 
GSTP1 Glutathione S-transferase pi 1 
HMOX1 Heme oxygenase-1 
HSP90AA1 Heat shock protein 90kDa alpha, class A member 1 
HSP90B1 Heat shock protein 90kDa beta, member 1 
HSPA4 Heat shock 70kDa protein 4 
HSPA4L Heat shock 70kDa protein 4-like 
HSPA5 Heat shock 70kDa protein 5 
HUS1 HUS1 checkpoint clamp component 
IFNG Interferon gamma 
IL1A Interleukin 1 alpha 
IL1B Interleukin 1  beta 
IL6 Interleukin 6 
IL8 Interleukin 8 
LDHA Lactate dehydrogenase A 
MCL1 Induced myeloid leukemia cell differentiation protein 
MMP9 Matrix metallopeptidase 9 
MRE11A Double-strand break repait protein 
NBN Nibrin 
NFAT5 Nuclear factor of activated T-cells 5 
NQO1 NAD(P)H quinone dehydrogenase 1 
PARP1 Poly (ADP-ribose) polymerase 1 
PRDX1 Peroxiredoxin 1 
92
Chapter 4
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 93
PVR Poliovirus receptor 
RAD17 Cell cycle checkpoint protein RAD17 
RAD51 DNA repear protein RAD51 
RAD9A RAD9 Checkpoint Clamp Component A 
RIPK1 Receptor-interacting serine-threonine kinase 1 
SERPINE1 Serpin E1 
SLC2A1 Glucose transporter 1 
SLC5A3 Sodium/myo-inositol cotransporter 
SQSTM1 Sequestosome 1 
TLR4 Toll-like receptor 4 
TNF Tumor necrosis factor 
TNFRSF10A Tumor necrosis factor receptor superfamily, member 10a 
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b 
TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A 
TP53 Tumor protein p53 
TXN Thioredoxin 
TXNL4B Thioredoxin-like 4B 
TXNRD1 Thioredoxin reductase 1 
ULK1 Serin/threonine-protein kinase ULK1 
VEGFA Vascular endothelial growth factor A 
XPC DNA repair protein complementating XP-C cells 
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ABSTRACT 
Iron is suggested to play a detrimental role in the progression of chronic kidney disease 
(CKD). The kidney recycles iron back into the circulation. However, the localization of 
proteins relevant for physiological tubular iron handling and their potential role in CKD 
remain unclear. We examined associations between iron deposition, expression of iron 
handling proteins and tubular injury in kidney biopsies from CKD patients and healthy 
controls using immunohistochemistry. Iron was deposited in proximal (PT) and distal 
tubules (DT) in 33% of CKD biopsies, predominantly in pathologies with glomerular 
dysfunction, but absent in controls. In healthy kidney, PT contained proteins required for 
iron recycling including putative iron importers ZIP8, ZIP14, DMT1, iron storage proteins L- 
and H-ferritin and iron exporter ferroportin, while DT only contained ZIP8, ZIP14, and 
DMT1. In CKD, iron deposition associated with increased intensity of iron importers 
(ZIP14, ZIP8), storage proteins (L-, H-ferritin), and/or decreased ferroportin abundance. 
This demonstrates that tubular iron accumulation may result from increased iron uptake 
and/or inadequate iron export. Iron deposition associated with oxidative injury as 
indicated by heme oxygenase-1 abundance. In conclusion, iron deposition is relatively 
common in CKD, and may result from altered molecular iron handling and may contribute 
to renal injury.  
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INTRODUCTION 
Chronic kidney disease (CKD) affects 13% of the population worldwide.1 Current treatment 
for CKD patients is mainly aimed at ameliorating renal symptoms, including proteinuria,2 a 
major risk factor for disease progression.3 However, in many patients, this does not 
prevent progression to end-stage renal disease.4 The absence of targeted treatment 
modalities can, at least partly, be attributed to the lack of detailed molecular knowledge 
on the pathophysiological mechanisms of CKD. 
 Preclinical studies have suggested a detrimental role for (reactive) iron in the 
progression of CKD.5 Increased exposure of renal tubular epithelial cells to iron leads to 
cellular damage,6-9 since iron catalyzes highly reactive radical formation in the Fenton 
reaction.10 In addition, in patients with various forms of CKD, increased urinary iron levels 
and renal iron deposition were found,8,11-19 supporting an association between iron 
deposition and renal tubular injury. However, it has not been elucidated in which tubular 
segment iron is deposited.  
Human-based studies examining renal iron handling are scarce.5 It has been 
suggested that human renal tubular epithelial cells are able to handle iron in physiological 
conditions, but the localization of proteins involved in cellular iron handling is debated.20 
Transferrin-bound iron (TBI) in the systemic circulation is suggested to be filtered by the 
glomerulus into the tubular lumen21,22 and is subsequently completely reabsorbed by 
endocytic transport.20 This can be facilitated by transferrin receptor 1 (TfR1) and the 
megalin-cubilin receptor complex in proximal tubular epithelial cells (PT), and the NGAL 
receptor (NGALR) in distal tubular epithelial cells (DT).22-25 Based on in vitro and in vivo 
studies,  iron transport into the cytosol is reported to involve the putative divalent metal 
transporters ZIP8 (SLC39A8), ZIP14 (SLC39A14) or divalent metal transporter 1 (DMT1, 
SLC11A2).26-28 Subsequently, iron is oxidized by the ferroxidase H-ferritin and stored in L-
ferritin, utilized by iron requiring processes, or exported into the blood stream by iron 
exporter ferroportin (SLC40A1).20 
Proteinuria as a result of glomerular damage in CKD is linked to tubulointerstitial 
injury,29 which is associated with increased filtration of TBI.5,9,30 Increased exposure of TBI 
can lead to tubular accumulation of reactive iron as a result of inadequate or disturbed 
iron handling. In diabetic nephropathy, the kidney can also be exposed to non-transferrin-
bound iron (NTBI) derived from filtered TBI as a result of acidification of the filtrate as it 
passes along the nephron,5,31 or directly filtered from the circulation.32 NTBI uptake from 
the tubular lumen is thought to be mediated by ZIP8, ZIP14 and/or DMT1.20 
For the first time in human kidney, we characterized associations between the 
presence and localization of iron deposition, proteins involved in cellular iron handling and 
tubular injury in kidney biopsies of patients with CKD and healthy controls.  
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METHODS 
 
Design 
Biopsies from patients with CKD and controls were used to examine the presence and 
localization of iron deposition. Subsequently, a selection of prevalent kidney diseases33 
and controls was made to examine proteins involved in cellular iron handling and tubular 
injury.  
 
Patients 
Renal biopsy material was collected from patients with CKD and potential kidney donors 
(healthy controls). Biopsies were classified based on clinical presentation of the patient 
and histological assessment by a trained renal pathologist. Biopsies were collected in 
University Medical Centre Groningen (the Netherlands (NL)) and Royal Free Hospital (RFH; 
London, United Kingdom (UK)), during the period of 1996-2014 and 2011-2016, 
respectively. Biopsies from both hospitals were used to assess iron deposition. For 
assessment of iron handling proteins and tubular injury, CKD biopsies and healthy kidneys 
from RFH only were selected, based on tissue availability aiming at age- and gender-
matching. Biopsies with excessive tissue damage (>70% of tissue) were excluded.  
 Procedures and use of anonymized material left over from diagnostic care were 
performed according to Dutch ethical guidelines. Accordingly, this study did not require 
approval from an ethical committee and material from patients from UMCG could be used 
without informed consent. All patients from RFH signed informed consent. All material 
was collected according to the Declaration of Helsinki.  
 
Histological stainings 
Biopsy tissue was embedded in paraffin and cut into 5 μm sections. Renal histology was 
assessed by Periodic acid-Schiff (PAS) staining and iron deposition by Perls’ staining, 
according to routine staining protocols.  
 
Immunohistochemistry 
Stainings were performed using the Bond Polymer Refine Detection system (Leica 
Biosystems, Newcastle-Upon-Tyne, UK) and provided materials on a Leica Bond Max and 
Autostainer XL apparatus for DMT1 (Novus Biologicals, Abingdon, UK, H00004891-M01, 
1:2000), ZIP8 (Protein Tech, Manchester, UK, 20459-1-AP, 1:500), ZIP14 (Atlas Antibodies, 
Bromma, Sweden, HPA016508, 1:1000), L-ferritin (Abcam, Cambridge, UK, ab69090, 
1:2000), H-ferritin (Abcam ab65080, 1:4000), ferroportin (Abcam ab85370, 1:300) and HO-
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1 (Abcam ab13243, 1:100). After antigen retrieval (Bond ER1 or ER2) , sections were 
incubated with primary antibody for 15 min diluted in Bond Primary Antibody diluent or 
Antibody diluent with Background Reducing Components (Dako Agilent, Stockport, UK) 
and secondary antibody  for 8 min. Signal visualization was performed with Polymer 
Refine for 8 min, DAB for 10 min and DAB enhancer (Leica Biosystems). Afterwards, nuclei 
were counterstained with haematoxylin and images were taken with a Leica DM 2000 
microscope connected to a Leica Microsystem Ltd camera, NanoZoomer whole slide 
imager (Hamamatsu Photonics, Welwyn Garden City, UK) or a VisionTek digital microscope 
(Sakura Finetek, Alphen aan den Rijn, NL). Appropriate negative control stainings were 
included for all primary and secondary antibodies (Supplementary Figure 5.1 and 5.2, 
respectively ).  
 
Image analysis 
Stainings were evaluated by an expert in renal pathology. Staining intensity was assessed 
in 5 images per biopsy using the H DAB plugin of ImageJ after correction for background 
staining. Tubular injury was scored as percentage of the kidney section.  
 
Statistical analysis 
Data were analyzed by one-way ANOVA with Dunnett’s post test using GraphPad Prism, to 
evaluate staining intensity and tubular injury in CKD compared to control. Differences 
were considered statistically significant when p<0.05.  
 
RESULTS 
 
Iron deposition in CKD 
We found iron deposition in 33% of biopsies from various forms of CKD (n=126), but not in 
controls (n=8; Figure 5.1, Table 5.1). Iron was deposited in a granular pattern in tubular 
epithelial cells and in the majority of CKD in both PT and DT. In minimal change disease, 
iron deposition was found in PT only. We detected iron deposition in kidney disorders 
characterized by nephrotic glomerulopathy (membranous glomerulopathy, focal 
segmental glomerular sclerosis (FSGS), minimal change disease), glomerulonephritis 
(Wegener’s disease, anti-glomerular basement membrane (GBM) disease), mesangial 
glomerular expansion (diabetic nephropathy), and potentially mixed nephrotic and 
nephritic glomerular injury (lupus nephritis (LN), IgA nephropathy (IgAN), hypertensive 
glomerulopathy) (Figure 5.1b-k). These findings suggest that renal tubular iron deposition 
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Figure 5.1: Iron deposition in chronic kidney disease 
Representative images of Perls’ staining in healthy control (a), diabetic nephropathy (b), membranous 
glomerulopathy (MG; c), IgA nephropathy (d), focal segmental glomerulosclerosis (FSGS; e), minimal change 
disease (f), lupus nephritis (g), Wegener’s disease (h), hypertension nephropathy (i), anti-glomerular basement 
membrane (GBM) disease (j), and thin basement membrane disease (TBMD; k). Renal structures indicated as 
glomerulus (G), proximal tubule (PT), distal tubule (DT). Iron indicated with arrows. Scale bar 20 μM. 
 
is a relatively common phenomenon in kidney disorders with glomerular dysfunction of 
different natures. 
 
Tubular iron handling proteins in healthy kidney 
In controls, ZIP8, ZIP14 and DMT1 were detected in both PT and DT (Figure 5.2a-c, Table 
5.2). ZIP8 was detected at the apical side of the tubules, whereas ZIP14 was localized 
intracellularly. DMT1 was observed both apically and intracellularly. Interestingly, L- 
ferritin, H-ferritin and ferroportin were observed only in PT (Figure 5.2d-f, Table 5.2). Both 
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Table 5.1: Prevalence of tubular iron deposition in renal biopsies in chronic kidney disease 
Kidney disease 
 
Abbreviation 
 
Patients 
with tubular iron 
deposition / Total 
patients 
(n/n) (%) 
Localization of iron 
deposition 
 
Diabetic nephropathy DN 6/27 (22) PT + DT 
Membranous glomerulopathy  7/21 (33) PT + DT 
IgA nephropathy IgAN 7/19 (37) PT + DT 
Focal segmental glomerular sclerosis FSGS 6/19 (32) PT + DT 
Minimal change disease  3/13 (23) PT 
Lupus nephritis LN 3/11 (27) PT + DT 
Wegener’s disease  5/7 (71) PT + DT 
Hypertension nephropathy  3/4 (75) PT + DT 
Anti-glomerular basement membrane disease  1/1 (100) PT + DT 
Thin basement membrane disease  0/1 (0) 
Total  41/123 (33) 
Healthy control  0/8 (0) 
DT, distal tubule; PT, proximal tubule. 
 
Table 5.2: Tubular localization of iron handling proteins in the healthy kidney  
Protein 
Proximal 
tubule 
Distal 
tubule 
Tubular localization 
Apical Basolateral Intracellular 
ZIP8 + + + - - 
ZIP14 + + - - + 
DMT1 + + + - + 
L-ferritin + - - - + 
H-ferritin + - - - + 
Ferroportin + - - + + 
DMT1, divalent metal transporter 1; +, present; -, not detected.  
 
ferritins showed intracellular orientation while ferroportin was expressed intracellularly 
and at the basolateral membrane. These findings indicate that PT express proteins for iron 
import, storage and export, while DT only express proteins involved in iron import in 
physiological conditions. 
Tubular iron handling proteins in CKD 
To characterize tubular iron handling during proteinuric CKD, a subset of kidney diseases 
was selected, including diabetic nephropathy, classified as early and advanced (DNE and 
DNA, respectively), FSGS, LN and IgAN (Table 5.3). Tubular localization of iron handling 
proteins in CKD was similar to controls (Figure 5.3-6). Staining intensity, however, differed 
between CKD and controls. ZIP14 showed comparable intensity in PT and DT, and, 
therefore, both segments were analyzed together. ZIP14 intensity was significantly 
increased in FSGS and IgAN compared to control (both p<0.001; Figure 5.3g-l, s). In FSGS, 
ZIP14 intensity was increased in two patients only, while all IgAN biopsies showed 
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Figure 5.2: Immunohistochemistry of iron handling proteins in healthy kidney  
Representatives images of ZIP8 (a), ZIP14 (b), divalent metal transporter 1 (DMT1; c), L-ferritin (d), H-ferritin (e), 
and ferroportin (f) staining in healthy kidney. Renal structures indicated as glomerulus (g), proximal tubule (PT), 
distal tubule (DT). Scale bar 20 μM. 
 
Table 5.3: Characteristics of patients included for immunohistochemical staining of cellular iron handling 
proteins 
 
 
DNE, established diabetic nephropathy; DNA, advanced diabetic nephropathy; F, female; FSGS, focal segmental 
glomerulosclerosis; IgAN, IgA nephropathy; LN, lupus nephritis; M, male.  
Biopsies selected based on tissue availability aiming at age- and gender-matched groups.  
 
enhanced ZIP14 staining. ZIP8 and DMT1 showed differential staining between PT and DT, 
and were, therefore, analyzed separately. ZIP8 intensity was increased in DT in DNE and 
FSGS compared to control (both p<0.01; Figure 5.3a-f, s), while ZIP8 intensity in PT (Figure 
Kidney disease 
Patients 
(n) 
Age 
(years, mean ± SD) 
Gender 
(M/F) 
Control 6 44.8 ± 16.1 3/3 
DNE 8 46.6 ± 13.3 4/4 
DNA 5 58.4 ± 12.4 4/1 
FSGS 5 49.0 ± 18.3 3/2 
LN 5 35.2 ± 14.2 1/4 
IgAN 5 26.6 ± 9.2 3/2 
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Figure 5.3: Immunohistochemistry of putative iron importers in chronic kidney disease 
Representative images of ZIP8 (a-f), ZIP14 (g-l), and divalent metal transporter 1 (DMT1; m-r) staining in control 
(a, g, m), early diabetic nephropathy (DNE; b, h, n), advanced diabetic nephropathy (DNA; c, i, o), focal segmental 
glomerulosclerosis (FSGS; d, j, p), lupus nephritis (LN; e, k, q) and IgA nephropathy (IgAN; f, l, r). Intensity in 
proximal and distal tubules quantified (s). Dots represent all quantified images (5 images per biopsy). Renal 
structures indicated as glomerulus (G), proximal tubule (PT), distal tubule (DT). Scale bar 40 μM. ** p<0.01; *** 
p<0.001. 
 
5.3a-f, s) was unchanged. DMT1 intensity in either PT or DT was not different from control 
(Figure 5.3m-r, s). L-ferritin staining was increased in FSGS (p<0.001; Figure 5.4a, d, m), 
mainly caused by 2 biopsies, while H-ferritin was overall increased in DNE (p<0.05) and 
DNA (p<0.001; Figure 5.4g-i, m). Moreover, ferroportin showed decreased intensity in DNE 
(p<0.01) and DNA (p<0.001) in PT (Figure 5.5). Interestingly, for some CKD biopsies, the 
observed changes in iron handling protein intensity coincided with iron deposition. In 
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Figure 5.4: Immunohistochemistry of intracellular iron handling proteins in chronic kidney disease 
Representative images of L-ferritin (a-f) and H-ferritin (g-l) staining in control (a, g), early diabetic nephropathy 
(DNE; b, h), advanced diabetic nephropathy (DNA; c, i), focal segmental glomerulosclerosis (FSGS; d, j), lupus 
nephritis (LN; e, k), and IgA nephropathy (IgAN; f, l). Intensity quantified (m) in proximal tubules. Dots represent 
all quantified images (5 images per biopsy). Renal structures indicated as glomerulus (G), proximal tubule (PT), 
distal tubule (DT). Scale bar 40 μM. * p<0.05; *** p<0.001 
 
FSGS and IgAN biopsies with PT iron deposition, ZIP14 intensity was increased, which was 
accompanied by increased L-ferritin intensity in FSGS. In DNE and DNA with PT iron 
deposition, H-ferritin abundance was increased along with decreased ferroportin 
intensity. In DT, ZIP8 and/or ZIP14 were increased concurrent with iron deposition in 
DNE,FSGS and IgAN, but neither were observed in DNA. In contrast, no changes in protein 
abundance of both tubules were seen in any of the LN biopsies despite iron deposition in 
2 of the biopsies. These findings are summarized in Figure 5.6. 
104
Chapter 5
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 105
?
Figure 5.5: Immunohistochemistry of cellular iron export protein in chronic kidney disease 
Representative images of ferroportin staining in control (a), early diabetic nephropathy (DNE; b), advanced 
diabetic nephropathy (DNA; c), focal segmental glomerulosclerosis (FSGS; d), lupus nephritis (LN; e), and IgA 
nephropathy (IgAN; f). Intensity quantified (g) in proximal tubules. Dots represent all quantified images (5 images 
per biopsy). Renal structures indicated as glomerulus (G), proximal tubule (PT), distal tubule (DT). Scale bar 40 
μM. ** p<0.01; *** p<0.001. 
 
In conclusion, our findings show associations between tubular iron deposition 
and abundance of iron handling proteins in most types of CKD, which differ between 
specific pathologies. Overall, tubular iron deposition was related to increased iron import  
(ZIP8, ZIP14) in PT and DT, in some CKD biopsies accompanied by increased storage 
(ferritin) or decreased export (ferroportin) in PT. 
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Figure 5.6: Overview of observations on iron deposition and intensity of iron handling proteins in chronic 
kidney disease 
Overview of iron deposition (in blue) and iron handling protein intensity in healthy control (a), early diabetic 
nephropathy (DNE; b), advanced diabetic nephropathy (DNA; c), focal segmental glomerulosclerosis (FSGS; d), 
lupus nephritis (LN; e), and IgA nephropathy (IgAN; f). Increased protein intensity compared to healthy controls 
(in grey) visualized in green, decreased protein intensity in red. DMT1, divalent metal transporter 1. 
 
???????????????????????
Tubular injury was assessed with PAS and heme oxygenase-1 (HO-1) staining. We used PAS 
staining to assess gross histology and scored renal injury based on tubular atrophy, 
blebbed tubular structures and irregular tubular cytoplasm (Figure 5.7a-d). Renal damage 
was increased in DNE and DNA compared to control and moderately elevated in FSGS 
(Figure 5.7e). HO-1, a marker for oxidative cellular stress,34 showed comparable intensity 
in both PT and DT, which was increased in CKD (control < DNE = DNA < IgAN < FSGS = LN; 
Figure 5.8). Increased HO-1 staining coincided with iron deposition in DNE, FSGS, LN and 
IgAN, but was also induced in DT of DNA without iron deposition.  
In conclusion, we found oxidative cellular stress, but not histological damage, to 
associate with iron deposition.  
 
DISCUSSION  
Increased iron accumulation may be a detrimental factor in progression of CKD, but the 
mechanisms of iron handling in the human kidney are not fully elucidated. In this study we 
found iron deposition in one third of biopsies from various CKD disorders, predominantly 
in pathologies with glomerular dysfunction. We observed that in the healthy kidney, PT 
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Figure 5.7: PAS staining for tubular injury in chronic kidney disease  
Representative images of PAS staining in control (a) or chronic kidney disease showing atrophic tubules with loss 
of brush border and enlarged basement membrane (b), blebbed tubules (c) and interstitial fibrosis (d). 
Percentage of tissue with tubular injury scored (E) per patient. Renal structures indicated as glomerulus (G), 
proximal tubule (PT), and distal tubule (DT). Symbols indicate proximal tubular brush border with asterisk, 
blebbed tubules with double asterisk, basement membrane with arrow, and fibrosis with hashtag. Scale bar 20 
μM. 
 
contain proteins involved in iron import, storage and export, while DT only showed 
proteins involved in iron import. Associations between iron deposition, intensity of iron 
handling proteins and tubular injury in CKD were seen, which differed between the 
pathologies. Nevertheless, in the majority of CKD, tubular iron deposition was 
accompanied by an increase in iron import proteins ZIP8 and/or ZIP14 in both PT and DT. 
This coincided with an increase in iron storage proteins or decrease in iron exporter in PT 
and increased oxidative cellular injury in both PT and DT. 
Our data show that iron deposition is a relatively common phenomenon in CKD 
with glomerular dysfunction. In physiological conditions, TBI filtered by the glomerulus is  
believed to be almost completely reabsorbed by the tubular epithelium. In this process, PT 
reabsorb the bulk of filtered proteins and DT play only a minor role.20 We hypothesize that 
in nephropathic glomerulopathy or pathologies with mesangial glomerular damage, PT 
iron reabsorption is increased by large amounts of TBI leaking from the injured 
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Figure 5.8: Immunohistochemistry of injury marker HO-1 in chronic kidney disease 
Representative images of heme oxygenase-1 (HO-1) staining in control (a), early diabetic nephropathy (DNE; b), 
advanced diabetic nephropathy (DNA; c), focal segmental glomerulosclerosis (FSGS; d), lupus nephritis (LN; e), 
and IgA nephropathy (IgAN; f). Renal structures indicated as glomerulus (G), proximal tubule (PT), and distal 
tubule (DT). Scale bar 40 μM. 
 
glomerulus, resulting in local iron deposition. Moreover, when the reabsorption capacity 
of PT is overwhelmed, DT might also be exposed to increased iron levels, leading to DT 
iron deposition. In addition, we found iron deposition in pathologies with nephritic 
glomerular damage, which present with both hematuria and proteinuria.35 Our results 
complement previous studies of renal iron deposition in CKD biopsies,11,12 which was 
localized to PT lysosomes.18,19 In our study, we demonstrated iron deposition also in DT in 
CKD. In addition, we show that iron deposition relates to oxidative cellular injury, as 
assessed by HO-1 staining. This strengthens the supposition that iron accumulation 
facilitates highly reactive radical formation that damage membranes, proteins and DNA, 
and, subsequently, causes tissue injury, which has been reported in renal tubular cells and 
animal models of CKD,6-9,36-38 Interestingly, iron reduction via a low-iron diet or treatment 
with an iron chelator has been reported to reduce renal iron accumulation and 
tubulointerstitial injury in various CKD animal models.36-38 Together with findings of 
increased urinary iron levels and renal iron deposition in patients with CKD,11-19 this 
suggests that renal iron loading could contribute to disease progression in patients with 
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CKD. Biopsies used in this study were taken for diagnostic purposes and are usually at a 
relatively early stage in disease progression, which is reflected by their tubular injury 
score. However, renal injury was already more established at the time of biopsy for 
diabetic nephropathy, especially for DNA. Nevertheless, our findings of iron deposition 
and associated oxidative cellular injury in FSGS, LN and IgAN biopsies suggest that iron 
may already be involved in the onset of renal disease and contribute to CKD progression.  
We are the first to show ZIP14 and DMT1 in human kidney, whereas ZIP8 was 
previously described in human kidney.39 Until now, DMT1 and ZIP14 were only 
demonstrated in murine PT, and DMT1 and ZIP8 in only mouse and rat DT.40-46 Luminal TBI 
reabsorption is suggested to involve TfR1, but TfR1 localization, on the apical or 
basolateral membrane of tubular epithelial cells, is debated.31,42,47-49 Since we did not 
obtain reliable TfR1 stainings, our study is not able to add to the understanding of TfR1 
localization. Following entry in the cytosol, iron is known to be oxidized by H-ferritin and 
stored in L-ferritin. Our results of intracellular expression of both ferritins in PT agree with 
other studies.49,50 Cytosolic iron is suggested to be transported back to the systemic 
circulation via the exporter ferroportin.20 Although both apical and basolateral localization 
of ferroportin are shown in murine PT,31,42,47-49 our human kidney results clearly 
demonstrate basolateral localization only. This discrepancy might be related to species 
difference 51. In our studies, ferroportin was absent in DT, as is shown in rats.47 The 
absence of ferritin and ferroportin in DT support that DT only play a minor role in 
physiological TBI reabsorption. Lack of effective iron storage and export could make these 
cells vulnerable to iron accumulation and related injury in case of high iron exposure.  
For the majority of CKD disorders, we could distinguish an overall increased 
intensity of ZIP8 or ZIP14 that might have contributed to iron deposition. TfR1 and DMT1 
are known to protect cells by limiting iron uptake via iron responsive element-iron 
responsive protein (IRE-IRP) regulation,52 but this is not described for ZIP8 and ZIP14.53 
Interestingly, ZIP8 and ZIP14 increase with iron loading in hepatocytes.28,54 Therefore, ZIP8 
and ZIP14 are plausible candidates for unrestricted iron import and subsequent iron 
loading in kidney tubular epithelium from either endocytosis TBI or direct NTBI transport 
over the apical membrane.5,31,32 Future assessment of the intracellular localization and 
function of ZIP8 and ZIP14 would be valuable to dissect potential iron transport routes in 
CKD. 
We observed decreased ferroportin and concomitant increased H-ferritin 
intensity in diabetic nephropathy, which may explain PT iron deposition in these patients. 
Based on IRE-IRP regulation, however, we would expect ferroportin to increase with 
cellular iron loading.52 At the systemic level, ferroportin is regulated by hepcidin, which 
causes ferroportin degradation.55 Also renal ferroportin protein abundance is shown to 
decrease with high circulating hepcidin levels.56 Interestingly, elevated hepcidin levels 
have been reported in patients with type 2 diabetes in the presence of chronic renal 
disease, obesity or inflammation,57,58 which could explain the observed reduction in 
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ferroportin intensity. Unfortunately, serum hepcidin levels were not available in our study. 
Moreover, renal biopsies in our study were obtained from patients with either type 1 or 
type 2 diabetes and the former patients do not have increased hepcidin levels.59 Our 
findings of an association between decreased ferroportin and increased H-ferritin are 
corroborated by studies in human macrophages in which ferroportin silencing led to 
increased H-ferritin protein levels,60 suggesting that H-ferritin upregulation could result 
from decreased ferroportin. Conversely, others showed a reciprocal relationship between 
H- ferritin and ferroportin by reporting reduced ferroportin mRNA and protein levels in 
conditional PT H-ferritin knockout mice.49 Ferroportin is regulated by several multilayered 
signals, where hepcidin is reported to have a dominant effect.55 This makes it difficult to 
determine whether renal iron deposition is due to ferroportin decreases or merely results 
from other mechanisms. Moreover, because of its multilayered regulation, the 
contribution of ferroportin to tubular iron loading may be different for various kidney 
diseases as observed in our study. 
Besides ferroportin, also other cellular proteins involved in renal iron handling are 
regulated by processes beyond iron metabolism, including inflammation and oxidative 
stress.55,61,62 These processes are also believed to contribute to the pathophysiology of 
CKD.63 Therefore, changes in abundance of proteins we studied cannot solely be 
attributed to changes in iron handling. Vice versa, iron loading was observed in LN without 
changes in protein abundance. In these patients, iron accumulation could be mediated by 
other potential iron transporters that we were not able to include in this study, such as 
TfR1, the megalin-cubilin receptor complex or NGALR.22-25 This underlines the complex 
mechanisms involved in the various CKD pathologies, which may (to various extents) all 
contribute to changes in renal iron handling proteins.  
In summary, our findings in human renal biopsies form the basis for further 
elucidating renal iron handling in health and disease. Future studies should focus on 
unraveling the molecular mechanisms of renal iron loading in individual CKD disorders. 
This will determine whether and how reduction of renal iron accumulation in CKD is a 
feasible target to halt disease progression.  
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SUPPLEMENTARY INFORMATION 
 
 
Supplementary Figure 5.1: Primary antibody control stainings  
Representative images of primary antibody control (primary antibody replaced by IgG control) for staining 
procedure of ZIP8 (a), ZIP14 (b), divalent metal transporter 1 (DMT1; c), L-ferritin (d), H-ferritin (e), ferroportin (f) 
and heme oxygenase-1 (HO-1; g). Renal structures indicated as glomerulus (G), proximal tubule (PT), and distal 
tubule (DT). Scale bar 20 μM. 
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Supplementary Figure 5.2: Secondary antibody control stainings  
Representative images of secondary antibody control (omission of primary antibody) for staining procedure of 
ZIP8 (a), ZIP14 (b), divalent metal transporter 1 (DMT1; c), L-ferritin (d), H-ferritin (e), ferroportin (f) and heme 
oxygenase-1 (HO-1; g). Renal structures indicated as glomerulus (G), proximal tubule (PT), and distal tubule (DT). 
Scale bar 20 μM. 
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INTRODUCTION  
 
Historically, iron handling and transport have mainly been studied in organs including the 
liver and gut. However, iron handling in the kidney has increasingly gained attention over 
the past few years due to findings of increased urinary and renal iron levels associated 
with renal injury.1 In this thesis, we studied the molecular mechanisms of renal iron 
handling and its potential toxicity in human health and in patients with systemic iron 
overload and chronic kidney disease (CKD). We showed that glomerular filtration and 
tubular reabsorption both can contribute to excretion of iron in human urine and 
characterized uptake mechanisms for transferrin-bound iron (TBI) and non-transferrin-
bound iron (NTBI) in human proximal tubular (PT) epithelial cells (PTECs). Moreover, we 
demonstrated that long term iron exposure can result in renal cytotoxicity in human 
PTECs. In addition, we demonstrated tubular iron accumulation and altered renal iron 
handling protein expression in human CKD. In this chapter, our findings and their 
implications will be discussed and placed into the perspective of future research.  
 
REDUNDANCY 
 
Renal tubular iron uptake reaches beyond single transporters and is a complex interplay of 
multiple proteins. Iron transporters transport either TBI or NTBI with different affinities. 
The abundance and localization, both intracellular and tubular, differs for the various   iron 
transporters. Combined, all transporters ensure that tubular iron is reabsorbed, 
independent of the iron species and competition of other ligands.2,3 This underlines the 
assumption ????? ???? ??????? ??? ???????? ???????????? ??????????? ????? ??????? to ensure that 
excretion of this scarce metal in urine is limited in physiological conditions.4 Iron transport 
redundancy complicates  assessment of the role of individual transporters in renal iron 
handling in health and disease. Redundancy of iron transport may differ between PTECs 
and distal tubular (DT) epithelial cells (DTECs), and may also be different in pathological 
conditions. Insights in renal iron transport and redundancy will increase our understanding 
of renal iron handling and could also be relevant in clinical settings to inhibit renal iron 
uptake. It has to be determined how strong iron transport redundancy is in disease 
conditions and whether one transporter potentially dominates, in order to establish if 
inhibition of iron uptake is feasible as a therapeutic target to prevent renal iron 
accumulation.  
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Redundancy in TBI transport 
TBI filtered into the tubular lumen can be reabsorbed by endocytic transporters 
transferrin receptor 1 (TfR1) and the megalin:cubilin:amnionless receptor complex at the 
apical membrane in proximal tubules (PTs).5 We confirmed previous findings from rat 
studies that TBI uptake in PTs predominantly takes place from the apical cellular side and 
is mediated by TfR1 in human conditionally immortalized PTECs (ciPTECs) (Chapter 3).6-8 
Moreover, in ciPTECs, our observations  suggest that TfR1 is likely to play a larger role in 
TBI uptake than the megalin:cubilin:amnionless receptor complex in physiological 
conditions. Also in mouse renal progenitors, TfR1 was of vital importance for iron 
acquisition. TfR1 KO renal progenitors explanted at E11 (embryonic day 11) were not able 
to grow in medium containing holo-transferrin,9 suggesting TfR1-mediated iron uptake is 
vital for renal tubular cells. Therefore, we postulate that TfR1 is the main transporter for 
TBI uptake in physiological conditions. However, in pathological conditions of iron 
overload, the megalin:cubilin:amnionless receptor complex is likely to play a larger role 
than TfR1, since in these conditions TfR1 abundance is decreased by iron responsive 
element ? iron responsive protein (IRE-IRP)-mediated regulation.10  
After TBI endocytosis, iron is released from transferrin and transported into the 
cytosol. Although divalent metal transporter 1 (DMT1), ZIP8 and ZIP14 are shown to 
mediate this process in hepatocytes, macrophages and neurons,11-16 we showed that 
ZIP14, but not ZIP8, is involved in TBI-derived iron transport towards the cytosol in ciPTECs 
(Chapter 3). ZIP14 silencing did not largely inhibit TBI-derived iron uptake in our cells. 
Moreover, ZIP14 was found to be dispensable in renal iron loading after TBI exposure in 
HFE or HFE2 KO mice, models for HFE-related hereditary hemochromatosis (HFE-HH),17 
which suggests  that additional transporters are involved in PTEC endocytic iron uptake. 
DMT1 is a potential candidate for PTEC endosomal iron transport, which we detected in 
human kidney and localized to ciPTECs endosomes (Chapter 3, Chapter 5). Four splice 
variants of DMT1 have been described, based on alternative splicing of both the N- and C-
terminus, which all have been detected in mouse and rat kidney,7,18 but not yet in human 
kidney. Interestingly, only two DMT1 isoforms contain an IRE element,18 and differential 
expression of these isoforms, i.e. expression at plasma membrane, endosomes and/or 
lysosomes, has been described in hepatocytes, epithelial cells and Madin-Darby Canine 
Kidney (MDCK) cells,19-21 suggesting that the different DMT1 variants may display distinct 
iron-handling functions within tubular cells. Using an antibody targeting all four isoforms, 
DMT1 was detected in late endosomes/lysosomes in rat PTECs where it colocalized with 
fluorescently labelled transferrin, suggesting DMT1 may be involved in endosomal iron 
transport in kidney tubular cells.7 Another potential candidate for endosomal iron 
transport is mucolipin-1 (transient receptor potential cation channel, mucolipin 
membrane 1, TRPML1). This ion channel is shown to export calcium or iron from late 
endosomes and early lysosomes in hepatocytes,22 but was also detected in the human 
kidney.23 
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Redundancy in NTBI transport 
Redundancy is also shown for NTBI uptake at the plasma membrane, which is filtered into 
the renal tubular lumen in conditions of systemic iron overload.5 ZIP8, ZIP14 and DMT1 
have all three been described to facilitate NTBI uptake in various non-renal cell types and 
experimental set ups,2,12,16,24-27 in addition to which we have now identified ZIP8 and ZIP14 
as NTBI uptake transporters in ciPTECs. The redundancy between ZIP14 and ZIP8 in 
Chapter 3 is supported by a study with whole body ZIP14 KO mice, in which loss of ZIP14 
did not abolish renal iron loading subsequent to NTBI exposure.17 Redundancy in iron 
transport by ZIP8 and ZIP14 is not surprising, considering that these transporters show 
similarities in metal transport characteristics.28 Both metal transporters transport a large 
variety of divalent metals, e.g. manganese, cadmium, zinc and iron, but not copper, and 
are metal/bicarbonate symporters.2,15 Using iron transport studies in Xenopus oocytes, 
mouse ZIP14 was shown to have a higher affinity for iron transport, i.e. K0.5 (iron 
concentration at which transport is half maximal) of 2.2 μM for ZIP14 vs 0.7 μM for 
ZIP8,2,15 but apparently the iron transport abilities of ZIP8 were sufficient to compensate 
for ZIP14 downregulation in our ZIP14 silencing experiments in ciPTECs. Potentially, this 
could be facilitated by increased ZIP8 abundance, since ZIP8 mRNA expression levels were 
higher than ZIP14 in mouse kidney.29 Furthermore, other transporters may also mediate 
NTBI uptake in tubular epithelial cells. We detected ZIP8, ZIP14 and DMT1 in DTs in human 
kidney biopsies (Chapter 5), which potentially also internalize NTBI. Moreover, DTECs also 
express Transient receptor potential cation channel subfamily V member 5 (TRPV5, or 
ECaC) and other calcium channels, which could mediate iron uptake. Transport studies 
with the TRPV5 isoform present in pufferfish, which is shown to display all structural 
features of mammalian TRPV5, reported that TRPV5 is also permeable for iron.30 The 
TRPV5 protein is detected in rat kidney,31 indicating that TRPV5 may also serve as a 
transporter involved in DTEC NTBI acquisition. Alternatively, both L-type and T-type 
voltage-dependent calcium channels (LTCC and TTCC, respectively) have been reported to 
facilitate NTBI uptake in cardiomyocytes during iron overload.32-34 Both LTCCs and TTCCs 
have been demonstrated on the apical membrane of rat DTECs,35,36 suggesting these 
channels may mediate NTBI uptake in the kidney. To our knowledge, no other candidates 
for NTBI transport have been described in PTs.  
 
Implications of iron transport redundancy  
Redundancy of metal transport by ZIP8 and ZIP14 can also be illustrated by findings in 
patients with rare congenital disorders of manganese metabolism resulting from ZIP8 or 
ZIP14 deficiency. Mutations in the gene for ZIP8 (SLC39A8) result in intellectual disability, 
cerebellar atrophy or features of Leigh-like mitochondrial disease.37 Moreover, these 
patients suffer from serum manganese deficiency and urinary manganese wasting.38 
However, serum iron levels were within normal range.39 In contrast, ZIP14 deficiency, 
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resulting from mutations in the SLC39A14 gene, is recently reported to result in 
hypermanganesemia and childhood-onset parkinsonism-dystonia,40 potentially as a result 
of reduced biliary manganese clearance.41,42 Interestingly, similar to findings in ZIP8 
deficient patients, serum iron indices are normal.41,42 The findings in these patients 
suggest that loss of ZIP8 or ZIP14 iron transport function was compensated for and 
physiological iron metabolism was not affected. 
 Inhibition of iron uptake transport by renal tubular epithelial cells could 
potentially be a new therapy to reduce renal tubular iron accumulation. Moreover, this 
could also be used to reduce systemic iron levels in patients with systemic iron overload, 
by enhancing excretion of iron in urine (as discussed in Chapter 2). However, such an 
approach is challenging considering iron transport redundancy. Moreover, transporters 
involved in renal iron handling are not specific for the metal iron. Although the 
megalin:cubilin:amnionless transporter complex is involved in TBI reabsorption in PTECs,6 
inhibition of this transporter complex may result in severe side effects since this 
transporter complex also reabsorbs a large variety of other proteins.43 Similarly, ZIP8 and 
ZIP14 transport various other divalent metals in addition to iron.28 
 
TUBULAR IRON HANDLING 
 
The presence of iron handling proteins has been described in PTs, DTs as well as other 
tubular segments such as the loop of Henle and collecting duct,5 but their functioning in 
human renal iron reabsorption have barely been described. In healthy conditions, PTs 
reabsorb the bulk of proteins (>80%) from the glomerular filtrate, limiting urinary protein 
excretion.5 Since PTs are adjacent to the glomerulus and play such a key role in protein 
reabsorption, it is suggested that predominantly PTs reabsorb filtered TBI in health. This 
explains the expression of TfR1 and divalent metal transporters DMT1 and ZIP14 on the 
luminal tubular side, as well as cellular expression of proteins involved in iron storage and 
export (Chapter 3, Chapter 5). The critical role of PT TBI reabsorption was underlined by 
our results of urinary iron and transferrin excretion in patients with a dysfunction of PT 
endocytic reabsorption, termed Fanconi syndrome (Chapter 2), in line with findings by 
others.44-46 We hypothesize that PTs are not able to take up all filtered TBI in case of PT 
dysfunction and/or injury, and, subsequently, TBI is passed down the nephron towards 
DTs. The  role of PTs in iron reabsorption is illustrated in patients with nephrotic chronic 
kidney disease (CKD), in whom injury to the glomerulus leads to  increased TBI levels in the 
tubular lumen, resulting in PTEC iron deposition (Chapter 5).47-49 PT iron reabsorption can 
become overwhelmed or saturated, as shown by increased transferrin and iron excretion 
in patients with nephrotic CKD.44,50-55  
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Due to the enormous PT reabsorption capacity, DTs seem to play only a minor 
role in physiological iron reabsorption from the glomerular filtrate.5 However, it is not 
completely clear how DTs meet their physiological iron demand, necessary for intracellular 
processes. It is most plausible that DTECs attain the iron required for cell functioning from 
the circulating TBI, i.e. via basolateral uptake. Rat and human DTECs are reported to 
express TfR1,56,57 which was detected at the basolateral membrane in MDCK cells, a cell 
line believed to originate from a DT nephron segment,58,59 suggesting that TfR1 mediates 
TBI uptake in DTECs at the basolateral membrane. Basolateral DTEC iron acquisition could 
be distinct from a basolateral iron uptake mechanism in PTECs. Luminal iron reabsorption 
in PTECs is likely to provide sufficient iron levels for normal PTEC physiology, such that an 
additional basolateral iron acquisition mechanism may be designed for low amounts of 
iron. Indeed, TfR1 was recently detected at the basal membrane of PTECs and DTECs in 
human kidney biopsies, but its abundance in DTECs was more intense than in PTECs.57 In 
contrast, in pathological conditions when iron travels down the nephron resulting from PT 
iron reabsorption insufficiency, DTs may be luminally exposed to high iron levels. Our 
immunohistochemistry stainings in healthy human kidney biopsies (Chapter 5) and 
previous findings of others60-64 show that DTECs contain iron uptake transporters, such as 
NGAL receptor (NGALR), DMT1, ZIP8 and ZIP14, allowing TBI to be taken up by these 
tubular cells. In our biopsy study, we could not detect ferritin orferroportin in DTECs 
(Chapter 5). However, since every cell type in the human body is dependent on iron, iron 
storage in ferritin is also essential for every cell,65 and thus, it is very unlikely that DT do 
not possess ferritin. Indeed, mRNA expression of L- and H-ferritin mRNA was recently 
reported in a mouse cortical collecting duct cell line (mCCDcl1).
66 Likely, the abundance of 
ferritin in the DTECs is much lower compared to the PTECs, which is in line with the 
presumed low iron fluxes in DTECs compared to PTECs. The absence of ferroportin in 
DTECs is supported by findings of others. Ferroportin could not be detected in DTECs of rat 
biopsies67 or mCCDcl1 cells (R. van Swelm, unpublished observations). Since ferroportin is 
the only known mammalian iron exporter, DTECs appear to lack an effective mechanism 
to export iron, which could render the DT vulnerable for iron accumulation and potential 
associated injury. 
 
Clinical implications of tubular iron handling  
We observed iron accumulation in PTECs and DTECs in human CKD (Chapter 5), suggesting 
that these tubules are at risk for iron-mediated renal injury. Also in animal models of CKD, 
iron deposition was localized to PTECs and DTECs.68 However, to date it remains unknown 
whether the onset of renal injury in CKD could be (partly) attributed to iron. The same 
knowledge gap can be identified in systemic iron overload. Persistent systemic iron 
overload has been observed to lead to PT and DT iron deposition in patients with HFE-HH 
??? ?-thalassemia syndromes,69-73 but it is not yet clear whether the presence of iron 
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deposition in these tubular segments also implies that iron plays an active role in renal 
disease or injury process.  
 Altogether, we show  in this thesis that PTECs and DTECs have differential iron 
transport mechanisms that may precede iron-mediated injury in these tubular segments. 
However, these findings also underline that differential iron reabsorption in PTECs and 
DTECs in pathology is complex and more evidence is needed to elucidate the role of these 
various transport mechanisms in the onset and/or progression of iron-mediated kidney 
injury.  
 
IRON CYTOTOXICITY 
 
By exposing ciPTECs to long term iron overload, we showed that iron can induce formation 
of cytosolic reactive oxygen species (ROS; Chapter 4). Oxidative stress is frequently 
mentioned as a mechanism of iron toxicity, based on the ability of iron to catalyze ROS 
formation in the Fenton and Haber Weiss reaction.74 However, oxidative stress is 
nowadays used as a generic concept encompassing numerous, yet diffuse and nonspecific, 
cellular processes, whereas this term was initially introduced to specifically indicate 
cellular redox biology.75 Cellular redox sources are numerous, ranging from byproducts of 
electron transport chain complexes up to intentional ROS production as cellular defense 
mechanisms, and comprise various labile oxygen and nitrogen species that can arise in 
different cellular organelles.76 As such, it is very difficult to identify changes in either 
oxidative stress or cellular redox biology and to pinpoint how exactly iron exposure affects 
these cellular processes at the biochemical level. Furthermore, the cellular redox balance 
is determined by production of oxidative species on the one hand and the protective 
antioxidative defense on the other hand. As soon as the oxidants dominate, these harmful 
molecules cause injury to cellular structures including DNA, proteins and lipids.77 The 
transcription factor Nuclear factor-erythroid 2-related factor 2 (Nrf2) is known to be 
induced by oxidants and coordinates the protective cellular antioxidative response.78 In 
our studies, iron overload in ciPTECs induced Nrf2 nuclear translocation as well as 
activation of its targets (Chapter 4). Nrf2 is reported to protect from short term iron-
induced renal injury in PTs,79,80 suggesting that the antioxidative Nrf2 response may also 
be involved in protection against renal cellular injury caused by iron in chronic exposure 
conditions. Oxidative stress is inseparably linked to inflammation, another detrimental 
process associated with  iron exposure,81 and both are common enhancers of renal 
injury.82 The Nrf2 pathway shows crosstalk with Nuclear Factor kappa-light-chain enhancer 
of activated B cell (NF-??) signaling, which is the main transcription factor regulating the 
cellular inflammatory response.83 Iron is also suggested to directly affect NF-????????????.84 
Furthermore, both Nrf2 and NF-?????????????????????th endoplasmic reticulum (ER) stress 
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signaling, which is a precursor of apoptotic cellular processes.85 ER stress can also be 
induced by ferroptosis, a pathway of regulated cell death which is specifically dependent 
on iron.86 Being distinct from apoptosis and necrosis, ferroptosis may result from 
inappropriate antioxidant mechanisms and consequent accumulation of lipid peroxides.87 
Altogether, this illustrates that iron-mediated renal injury may be a complex interplay of 
several interacting cellular signaling pathways and processes. As a result, it remains to be 
determined if there is a dominant mechanism that facilitates the deleterious effects of 
iron on the cellular level, or if oxidative stress, inflammation, ER stress and ferroptosis 
collaboratively contribute to this process. Moreover, future studies are required to 
investigate if the harmful effects of iron are caused by the same mechanisms in the 
various pathologies characterized by renal iron loading, such as CKD and systemic iron 
overload. Activation or modulation of related detrimental processes, such as oxidative 
stress and inflammation, by other causes may affect the magnitude and/or mechanisms of 
iron toxicity. For example, although we have identified intensified heme oxygenase 1 (HO-
1) protein abundance, a marker for cellular oxidative stress, in various CKD pathologies, its 
expression level varied among these pathologies (Chapter 5). As a result, the ability of iron 
to induce oxidative cellular damage may be different between the pathologies.  
 
Clinical evidence of renal iron toxicity 
Although iron has cytotoxic abilities and iron exposure is associated with renal injury in 
various pathologies,1 it remains to be determined to what extent iron is involved in the 
onset or progression of kidney injury. During systemic iron overload, it is plausible that 
increased iron levels in the kidney provoke tubular injury. The degree of iron loading in the 
circulation, represented by the degree and duration of blood transfusion in patients with 
?-thalassemia major, was found to correlate with urinary excretion of N-acetyl-?-D-
glucosaminidase (NAG), a marker for renal tubular damage.88,89 Moreover, iron levels in 
the human parenchymal tissues, represented by serum ferritin levels, correlated with 
urinary NAG concentrations and activity.90,91 Serum ferritin levels were also found to 
correlate with the degree of renal iron accumulation.92 Interestingly, it has been suggested 
that increased serum ferritin levels can be caused by renal tubular iron loading.93,94 
indicating that iron overload inside tubular cells may be involved in causing renal injury 
during systemic iron overload. Interestingly, the causal role of iron in kidney injury was 
highlighted by findings that tubular injury markers, such as NAG, were no longer increased 
??????-thalassemia major patients were treated with  iron chelator deferoxamine.91,95,96 
In CKD, iron is likely to play a role in progression of renal injury rather than the onset. The 
pathogenesis of CKD is multifactorial and complex, often including hypertension, diabetes, 
obesity or exposure to drugs or toxins.97 Increased iron levels in the kidney could be 
considered as a toxin and initiate renal injury, although this is highly unlikely based on the 
knowledge that systemic iron levels are within the normal range or rather indicative of 
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iron deficiency at the initial stages of CKD.98 Therefore, a role of iron in CKD is more likely 
to be-mediated by increased TBI filtration as a result of glomerular leakage and 
proteinuria, potentially aggravating tubulointerstitial injury. In experimental studies with 
human subjects with CKD, chelation therapy with EDTA was shown to reduce a decline in 
kidney function in patients with chronic renal insufficiency.99 Moreover, deferiprone 
treatment was successful in reducing proteinuria in patients with diabetic nephropathy or 
glomerulonephritis.100 These studies suggest that iron is involved in the progression of 
CKD. 
The assessment of the clinical relevance of iron in the initiation or progression of 
kidney injury requires studies of  these processes over time  for each of the relevant 
disorders. Prospective, longitudinal, observational human studies should clarify if the 
extent of renal injury associates with urinary iron concentrations and quantification of iron 
deposition in the kidney.  
?
TREATMENT MODALITIES  
 
In patients with HFE-HH ?????-thalassemia major, current iron removal therapies consist 
of phlebotomy and iron chelation therapy, respectively, but these therapies are not 
without burdens and complications.101,102 Phlebotomy is successful in removing large 
quantities of circulating iron and inducing a gradual decline in body iron stores,103 but 
requires weekly or biweekly visits to the hospital for a long period of time.101,104 Moreover, 
iron chelation therapy results in urinary and/or fecal excretion of iron-chelator complexes 
and reduces systemic iron levels,105 but adverse effects such as growth restriction, 
gastrointestinal symptoms and renal abnormalities have been recognized.106-109 A new 
treatment strategy aimed at enhancing urinary iron excretion could decrease systemic 
iron levels without these side effects. Reducing renal reabsorption of TBI and NTBI would 
be effective in reducing severe systemic iron levels since a decrease of circulating iron will 
induce iron release from tissue iron stores.110  However, due to the redundancy in renal 
TBI and NTBI uptake mechanisms this approach may not be feasible. Moreover, excretion 
of high iron concentrations in urine may favor development of urinary tract infections111 
or iron-induced cytotoxicity in lower nephron segments, causing potential unfavorable 
complications.  
 Alternatively, our obtained insights in renal iron handling and subsequent toxicity 
may provide leads for the development of novel compounds intended to reduce the onset 
and/or progression of iron-mediated renal injury. Prevention of iron-mediated renal injury 
could be aimed at reduction of iron reabsorption, affecting intracellular pathways and/or 
inhibition of cell death processes (Figure 6.1). Inhibition of tubular iron reabsorption could 
reduce the enhanced labile iron levels within the tubular epithelial cells and subsequent 
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toxicity. However, it is required that iron transport inhibition includes PTs as well as lower 
nephron segments, in order to prevent iron accumulation along the entire nephron. As 
described above, inhibition of TBI and/or NTBI uptake may have the potential to reduce 
iron reabsorption but also has its challenges, such as iron transport redundancy. 
Therefore, future studies will need to determine whether individual or combined TBI and 
NTBI reabsorption inhibition therapy may have the potential to reduce accumulation of 
this labile iron species and consequent cytotoxic effects in renal tubular epithelial cells 
without increasing urinary bladder infections. 
 The deleterious effects of iron on renal tubular epithelial cells could be reduced 
by targeting intracellular pathways. Although this is presumed to be a complex interplay of 
multiple signaling and effector players, enhancing the cellular antioxidative response, 
potentially via Nrf2, or inhibiting inflammatory or ER stress cascades may be effective in 
reducing injury to renal tubular cells. Previously, the Nrf2 activator bardoxolone methyl 
has been successful in improving kidney function, decreasing the induction of renal injury 
and preventing the onset of end stage renal disease in clinical trials in patients with 
diabetes type 2 and CKD.112-114 However, a phase 3 clinical trial including patients with 
diabetes type 2 and CKD stage 4 was terminated due to increased events of heart 
failure,115 suggesting the degree of CKD progression may alter the effectiveness of this 
therapy. This shows that antioxidant induction therapies should be studied with caution to 
see in which CKD populations they may be used without causing serious adverse effects. 
 
                
Figure 6.1: Treatment targets for prevention of iron-mediated renal tubular  injury. 
Prevention of iron-mediated renal injury in renal tubular epithelial cells could be aimed at 1) decreasing uptake 
of transferrin-bound iron (TBI) and/or non-transferrin-bound iron (NTBI); 2) affecting intracellular pathways such 
as oxidative stress, inflammation of endoplasmic reticulum (ER) stress; and 3) decreasing cell death processes 
(indicated with lightning sign) such as ferroptosis.  
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However, these strategies may have potential for reducing renal injury in CKD. Moreover, 
this therapy may also be effective in patients with systemic iron overload, where oxidative 
stress is also identified in the pathogenesis of iron-mediated renal injury (Chapter 4).116,117 
Furthermore, iron-mediated renal injury could be reduced by preventing the 
terminal cell death processes induced by iron exposure. Iron exposure is shown to induce 
tubular atrophy and tubular necrosis. 117-119 As described above, these could be due to cell 
death processes of iron-dependent ferroptosis.87 Evidence is growing that ferroptosis is 
involved in different AKI pathologies.120 Interestingly, ferroptosis inhibitors are shown to 
attenuate morphological tubular injury following renal ischemia-reperfusion injury in 
mice.121 It remains to be investigated whether ferroptosis is also involved in CKD and/or 
renal injury observed with systemic iron overload disorders.   
In a broader perspective, it is conceivable that the exact molecular mechanisms 
of iron handling and subsequent injury to renal tubular cells vary for diseases of different 
etiology. Therefore, it will be essential to study the applicability of novel treatment 
modalities in detail for each of the different pathologies.  
PERSPECTIVES FOR FUTURE RESEARCH 
 
In this thesis we have demonstrated the presence of excess iron in human kidney and 
urine in relation to  renal injury. Moreover, we have increased the insights into the 
mechanisms that are involved in renal iron handling processes and their potential 
subsequent toxicity. These results serve as the first steps towards future research into 
elucidating whether iron may initiate renal injury in systemic iron overload and aggravate 
the progression of renal injury in CKD.  
 In vitro and animal studies have examined associations between renal iron 
accumulation and injury in various disorders of CKD and systemic iron overload, but both 
are relatively unexplored in humans. Whereas animal studies have shown that iron 
accumulates in the kidney and urine in various CKD pathologies, longitudinal studies in 
patients with CKD are required to examine if disease progression results in a higher iron 
concentrations in the kidney or urine in humans. In addition, animal and subsequent 
human studies  are warranted to assess whether renal iron deposition may be the cause of 
renal injury progression. This includes  examination of  molecular injury mechanisms that 
are involved in this process and interventions for renal iron reduction, such as an iron-
restricted diet or administration of an iron chelator. In systemic iron overload, future 
studies should initially focus on increasing evidence on renal iron accumulation in these 
disease pathologies since the current evidence for iron accumulation in the kidney in 
animal models and patients with systemic iron overload is limited. Renal iron 
accumulation could be assessed by studying renal biopsies in systemic iron overload 
animal models and by making use of non-invasive T2* magnetic resonance imaging in 
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patients with systemic iron overload.92,96 Subsequently, animal and human studies are 
needed to assess whether renal iron accumulation precedes renal injury, and whether 
amelioration of iron accumulation reduces renal complications in systemic iron overload. 
Within both CKD and systemic iron overload disorders, specific research interests could be 
included, such as studying the role of PTs and DTs separately, i.e. by comparing iron 
accumulation in these tubules in renal biopsies, or examining the effect of filtration of 
increased systemic iron levels. Furthermore, observational study designs in humans would 
allow to identify renal iron handling among multiple disorders of systemic iron overload or 
CKD. As such, individual pathologies could be pointed out in which iron may play a large 
role in causing renal injury and where therapies for reducing iron-mediated renal injury 
may be specifically beneficial for future patient care. 
 
CONCLUSION  
 
The results described in this thesis have expanded our knowledge into the mechanisms of 
renal iron handling in health, systemic iron overload and CKD. As such, we obtained a 
better understanding of the potential of iron to induce renal injury. Our results may aid in 
future studies aimed at decreasing iron-mediated injury in the kidney.  
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SUMMARY 
 
The metal iron (Fe) is essential for a large number of processes in the human body. 
However, it can also be toxic by catalyzing the formation of reactive oxygen radicals. Our 
current understanding of systemic and cellular iron homeostasis is mainly derived from 
studies in hepatocytes, erythrocyte precursors, enterocytes and macrophages. Knowledge 
of iron homeostasis in the kidney is limited, despite the presence of many proteins 
involved in cellular iron handling. The kidney is thought to play a crucial role in 
??????????????????????????????????????????????????????????????????????????????????????????????
in the various renal tubular segments in physiological conditions is still unclear. Moreover, 
due to the potential differential expression of iron handling proteins in the nephron 
segments, and the expression of addition kidney-specific iron handling proteins, renal iron 
handling may be different from iron handling processes observed in other organs.  
The human body has limited physiological mechanisms to regulate iron excretion. 
As a consequence, disturbed iron acquisition, i.e. via the intestine in hereditary 
?????????????????????????????????? ????????? ??????????????? ????????????? ????-thalassemia 
syndromes, can result in systemic iron overload and, consequently, increase renal iron 
?????????? ????????? ??? ?????? ????? ??????????? ???? ?????? ???????????? ??? ????????? ????? ?-
thalassemia syndromes supports an association between increased iron exposure and 
renal injury in conditions of systemic iron overload. Furthermore, in disorders of chronic 
kidney disease (CKD), renal iron deposition and increased urinary iron levels are described. 
Moreover, reduction of systemic iron levels has been reported to reduce renal iron 
accumulation and tubular injury in various CKD animal models, suggesting a relation may 
exist between renal iron accumulation and renal injury in CKD. In this thesis, we examined 
renal tubular iron handling in human health, systemic iron overload disorders and CKD. As 
such, we aimed to gain insights into the molecular mechanisms of renal tubular iron 
handling and the detrimental role of iron in renal injury. 
Circulating iron can be filtered by the glomerulus, and is almost completely 
reabsorbed by the proximal and distal tubular epithelial cells (PTs and DTs, respectively), 
preventing excretion of this scarce metal in urine. Although increased urinary iron levels 
were found in various pathologies, in remains unclear whether urinary iron excretion may 
be caused by glomerular filtration of increased circulating iron levels and/or disturbed 
tubular iron reabsorption. In Chapter 2, we examined whether both processes could 
contribute to urinary iron excretion and renal injury. Therefore, we compared plasma and 
urine iron parameters and urinary tubular injury markers between patients with systemic 
iron overload, patients with renal tubular dysfunction and healthy controls. Expectedly, 
plasma iron parameters were increased only in patients with systemic iron overload, but 
urinary iron levels were enhanced in both patient groups compared to healthy controls. 
We demonstrated that glomerular filtration of increased circulating iron levels contributed 
to iron excretion in urine, since urinary iron levels associated with elevated plasma iron 
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parameters in systemic iron overload patients, as indicated by elevated transferrin 
saturation (TSAT), which is a marker for circulating iron loading. Moreover, in patients 
????? ?-thalassemia major, in which circulating iron parameters were severely elevated, 
iron levels in urine also associated with plasma ferritin levels, which are an indicator of 
renal tubular iron stores. Furthermore, disturbed tubular reabsorption contributed to 
urinary iron and transferrin excretion, since iron and transferrin levels in urine associated 
with urinary excretion of glutathione s-transferase-pi-1-1 (GSTP-1-1) in patients with 
tubular dysfunction, which is a marker for DT injury and, as such, confirms renal injury in 
these patients. Interestingly, filtration of high circulating iron levels also related to renal 
injury, since we found that levels of iron and transferrin in patients with systemic iron 
overload associated with urinary concentration of kidney injury marker 1 (KIM-1), a 
marker for injury for PTs. 
In disorders of systemic iron overload, iron largely saturates the circulating iron 
binding protein transferrin (transferrin-bound iron, TBI) and also binds to low-molecular 
weight ligands, termed non-transferrin-bound iron (NTBI). In Chapter 3, we studied the 
molecular mechanisms of TBI and NTBI uptake in human conditionally immortalized PT 
epithelial cells (ciPTECs), focusing on divalent metal transporters ZIP8 and ZIP14. We first 
characterized iron handling in ciPTECs, by showing that both fluorescently labeled 
transferrin (as TBI) and 55Fe (as NTBI) were internalized by ciPTECs. In addition, the iron 
export protein ferroportin was localized at the ciPTEC basolateral side and showed 
functional iron export characteristics, since small interfering RNA (siRNA) silencing 
increased cellular 55Fe content compared to scrambled control, while 55Fe in the exposure 
solution was decreased. When studying NTBI uptake, we found that both ZIP8 and ZIP14 
localized to the ciPTEC plasma membrane, but 55Fe uptake was not affected by siRNA 
silencing of either ZIP8 or ZIP14 alone. In contrast, simultaneous silencing of both 
transporters reduced 55Fe uptake compared to control, indicating that both transporters 
are involved in NTBI uptake and show redundancy. Furthermore, transferrin receptor 1 
(TfR1) and ZIP14, but not ZIP8, colocalized with early endosome antigen 1 (EEA1) staining. 
Both TfR1 and ZIP14 also colocalized with fluorescently labeled transferrin uptake. 
Moreover, ZIP14 silencing decreased 55Fe uptake after 55Fe-transferrin exposure, 
suggesting ZIP14 also mediates endosomal transport of TBI-derived iron towards the 
cytosol.  
Reports of renal iron accumulation and renal injury in patients with systemic iron 
overload suggest that chronic exposure to increased iron levels results in nephrotoxicity. 
In acute iron exposure conditions, activation of the major cellular antioxidative pathway 
coordinated by Nuclear factor erythroid 2-related factor 2 (Nrf2) is known to protect from 
oxidative cellular injury. However, Nrf2 is also described to become exhausted in chronic 
renal stress. Therefore, Chapter 4 examined the hypothesis that Nrf2 exhaustion as a 
result of iron-mediated oxidative stress underlies renal injury in chronic iron overload in 
ciPTECs. Chronic iron exposure induced iron accumulation, cytosolic reactive oxygen 
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species (ROS) formation and increased ????????????????????????? mRNA expression, a 
marker of cellular oxidative stress. Moreover, this was accompanied by nuclear 
translocation of Nrf2 and induction of its target NAD(P)H quinone dehydrogenase 1 
(NQO1) on protein level. To simulate ciPTEC Nrf2 exhaustion we applied the Nrf2 inhibitor 
trigonelline. Indeed, addition of trigonelline to iron exposure decreased Nrf2 nuclear 
translocation and NQO1 protein levels. Interestingly, although iron and trigonelline 
incubated cells showed reduced cytosolic ROS levels, ???????mRNA levels were still 
increased. Moreover, iron and trigonelline incubation induced ???? mRNA expression, 
which is an indicator of endoplasmic reticulum stress, and ferritin protein levels. Although 
ferritin functions as intracellular iron storage molecule, it is also induced by other stress-
related mechanisms such as inflammation. Altogether, although Nrf2 exhaustion did not 
enhance oxidative stress formation in ciPTECs, other stress-related mechanisms could 
induce PT cytotoxicity during high iron exposure.  
In Chapter 5, we described our immunohistochemical studies into the presence 
and localization of iron handling proteins in renal biopsies of healthy controls and patients 
with various CKD pathologies. In these biopsies, we studied the expression of iron 
handling proteins in relation to iron deposition and renal injury. Iron was deposited in 
both PTs and DTs in 33% of the CKD biopsies, predominantly in pathologies with 
glomerular dysfunction, but was absent in controls. In the healthy kidney, we detected the 
iron uptake transporters ZIP8, ZIP14 and divalent metal transporter 1 (DMT1), iron storage 
proteins L- and H-ferritin and iron exporter ferroportin in PTs, indicating PTs are equipped 
for iron recycling. In contrast, DTs only expressed iron uptake transporters ZIP8, ZIP14 and 
DMT1. In the various CKD pathologies, iron accumulation associated with increased 
intensity of iron importers ZIP8 and ZIP14, storage proteins L- and H-ferritin, and/or 
decreased expression of iron exporter ferroportin, suggesting that iron loading in CKD may 
be the result of increased iron acquisition and/or decreased iron export. Iron deposition 
also associated with oxidative cellular injury, as indicated by enhanced renal heme 
oxygenase 1 (HO-1) protein staining, indicating that iron deposition in CKD may contribute 
to renal injury through oxidative stress.  
Chapter 6 discusses the findings described in this thesis and gives implications 
and suggestions for future research into renal iron handling. The results of this thesis have 
expanded our knowledge into the mechanisms of renal iron handling in health, systemic 
iron overload and CKD. As such, we gained more insights in the potential of iron to induce 
renal injury, which can aid in decreasing iron-mediated injury in the kidney.  
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SAMENVATTING 
 
Het metaal ijzer (Fe) is essentieel voor een groot aantal processen in het menselijk 
lichaam. Echter, ijzer kan ook schadelijk zijn omdat het de vorming van reactieve 
zuurstofradicalen kan katalyseren. Inzicht in hoe ons lichaam omgaat met ijzer komt 
grotendeels van studies in levercellen (hepatocyten), voorloper rode bloedcellen 
(erytrocyten), darmcellen (enterocyten) en ontstekingscellen (macrofagen). We weten 
echter nog weinig van het ijzer metabolisme in de nier. De nier lijkt een cruciale rol te 
spelen bij het in stand houden van de hoeveelheid ijzer in het lichaam. Ondanks dat de 
aanwezigheid van vele eiwitten die betrokken zijn bij moleculaire en cellulaire ijzer 
processen in de nier zijn aangetoond, is de precieze lokalisatie van deze eiwitten in de nier 
onder normale omstandigheden nog niet opgehelderd. Bovendien lijkt de manier waarop 
de nier omgaat met ijzer anders te zijn dan deze processen in andere organen, door 
verschillen in de aanwezigheid van eiwitten die betrokken zijn bij ijzertransport of -
stapeling. Daarbij spelen de complexe organisatie van de nier en de aanwezigheid van 
nierspecifieke ijzer-gerelateerde eiwitten ook een rol.  
 Het menselijk lichaam neemt ijzer op vanuit de voeding in de darm. Echter, het 
lichaam heeft maar beperkte mogelijkheden om de uitscheiding van ijzer actief te 
reguleren. Dit heeft tot gevolg dat een te hoge ijzeropname in de darm kan leiden tot 
systemische ijzerstapeling, zoals bij de aangeboren aandoening hemochromatose. Ook 
frequente bloedtransfusies, die gegeven worden als behandeling van ?-thalassemie 
syndromen, kunnen leiden tot te veel ijzer in het lichaam. In deze ziektebeelden wordt de 
nier blootgesteld aan verhoogde ijzerconcentraties. Bevindingen van ijzerstapeling in de 
nier en verstoorde nierfunctie in patiënten met ?-thalassemie syndromen ondersteunen 
de gedachte dat verhoogde ijzerblootstelling in de nier door systemische ijzerstapeling kan 
leiden tot nierschade, waaronder ook in de nierbuisjes. Een relatie tussen ijzerstapeling en 
schade in de nier wordt ook gesuggereerd door bevindingen in patiënten met chronische 
nierziekten. De relatie tussen ijzerstapeling in de nier en nierschade is verder aangetoond 
in diermodellen van chronische nierziekten, waarbij het verlagen van de systemische 
ijzerconcentratie leidde tot een vermindering van ijzerstapeling en schade in de nier. In dit 
proefschrift zijn de processen van ijzermetabolisme in de gezonde nier in de mens nader 
onderzocht, alsmede in condities van systemische ijzerstapeling en chronische nierziekten. 
Op deze manier hebben we meer inzicht gekregen in de moleculaire mechanismen van 
ijzertransportprocessen in de nier en de mogelijke rol van ijzer bij het ontstaan van 
nierschade. 
 IJzer dat aanwezig is in de bloedbaan kan door de glomerulus van de nier worden 
gefilterd waarna het in het lumen van de nierbuisjes terechtkomt. Vervolgens wordt al het 
ijzer opgenomen door cellen van de proximale (PTs) en distale nierbuisjes (DTs) om 
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vervolgens getransporteerd te kunnen worden naar het bloed. Zo wordt voorkomen dat 
het lichaam dit schaarse metaal met de urine verliest. Bij verschillende ziektebeelden zijn 
verhoogde ijzerconcentraties in de urine gevonden, maar of dit komt door filtratie van 
verhoogde ijzerconcentraties in het bloed door de glomerulus en/of door verminderde 
opname door de nierbuisjes was nog onbekend. In Hoofdstuk 2 hebben we gekeken of 
beide processen kunnen bijdragen aan de uitscheiding van ijzer in de urine en aan het 
ontstaan van nierschade. Hiervoor hebben we de ijzerconcentraties in bloed en urine, 
maar ook markers voor nierschade in urine, vergeleken tussen patiënten met systemische 
ijzerstapeling, patiënten met verstoorde nierbuisfunctie en gezonde vrijwilligers. Zoals 
verwacht was de ijzerconcentratie in het bloed alleen verhoogd in patiënten met 
systemische ijzerstapeling; de ijzerconcentratie in de urine daarentegen was in beide 
patiëntengroepen verhoogd in vergelijking met gezonde vrijwilligers. We hebben laten 
zien dat glomerulaire filtratie van verhoogde ijzerconcentraties in het bloed bijdraagt aan 
de uitscheiding van ijzer in de urine, omdat de hoge ijzerspiegels in de urine geassocieerd 
waren met verhoogde ijzerconcentraties in het bloed in patiënten met systemische 
ijzerstapeling. Patiënten met een verstoorde nierbuisfunctie hadden verhoogde 
concentraties van glutathion s-transferase-pi-1-1 (GSTP-1-1) in de urine, een marker voor 
schade aan cellen van de DT. In deze patiënten waren deze concentraties geassocieerd 
met de hoge concentraties aan ijzer en transferrine in de urine. Bovendien waren ijzer en 
transferrine spiegels in urine van patiënten met systemische ijzerstapeling geassocieerd 
met de aanwezigheid van de nierschademarker 1 (KIM-1) in urine. Dit duidt op schade aan 
de cellen van de PTs. Deze resultaten laten zien dat zowel filtratie van verhoogde 
ijzerconcentraties in het bloed door de glomerulus als verminderde ijzeropname door de 
nierbuisjes kunnen bijdragen aan de uitscheiding van ijzer in de urine en nierschade.  
Bij systemische ijzerstapeling is het ijzertransporteiwit transferrine grotendeels 
verzadigd met ijzer (genaamd transferrine-gebonden ijzer, TBI) en bindt ijzer vervolgens 
ook aan andere moleculen. Dit wordt niet-transferrine-gebonden ijzer (NTBI) genoemd. 
Omdat de binding van ijzer aan deze andere moleculen mogelijk minder stabiel is dan in 
het geval van TBI, kan NTBI een schadelijk vorm van ijzer zijn. In Hoofdstuk 3?hebben we 
de moleculaire mechanismen van de opname van TBI en NTBI in humane conditioneel-
geïmmortaliseerde PT epitheel cellen (ciPTECs) bestudeerd. Hierbij hebben we specifiek 
gekeken naar de divalent-metaaltransporters ZIP8 en ZIP14. De ciPTECs bleken in staat het 
ijzer te metaboliseren, want deze cellen konden zowel het fluorescerend-gelabelde 
transferrine (als maat voor TBI) als het radioactief-gelabelde ijzer (55Fe, als NTBI) 
opnemen. Bovendien was het ijzerexporteiwit ferroportin aanwezig in de 
basaalmembraan van de ciPTECs (de zijde die in contact staat met het bloed). Ferroportin 
functioneerde als ijzerexporteiwit, aangezien een verlaging van de ferroportinconcentratie 
door genblokkade leidde tot een toegenomen hoeveelheid 55Fe in de cellen, terwijl de 
hoeveelheid 55Fe in het celkweekmedium was verminderd. Vervolgens hebben we NTBI 
opname bestudeerd. We konden de aanwezigheid van ZIP8 en ZIP14 op het ciPTEC-
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plasmamembraan aantonen. Echter leidde verlaging van de concentratie van ZIP8 of ZIP14 
afzonderlijk niet tot een verandering van de 55Fe concentratie in de cellen. Verlaging van 
beide transporters tegelijk leidde wel tot een afname van de concentratie 55Fe in de 
cellen. Dit betekent dat beide transporters betrokken zijn bij de opname van NTBI en 
elkaars functie (gedeeltelijk) kunnen overnemen. Tenslotte hebben we de opname van TBI 
bestudeerd. Het is bekend dat TBI door de niercel wordt opgenomen middels endocytose 
door transferrine receptor 1 (TfR1). De lokalisatie van de transporters TfR1 en ZIP14, maar 
niet ZIP8, kwam overeen met die van het endosoom antigeen 1 (EEA1), wat suggereert dat 
TfR1 en ZIP14 waarschijnlijk betrokken zijn bij de opname van TBI. Bovendien viel de 
aanwezigheid van zowel TfR1 als ZIP14 samen met de endosomen waarin fluorescerend-
gelabelde transferrine werd opgenomen. Ook vonden we dat een verlaagde concentratie 
van ZIP14 leidde tot een afname in 55Fe opname na blootstelling aan 55Fe-transferrine. Dit 
betekent dat ZIP14 betrokken is bij de opname van ijzer afkomstig van TBI vanuit het 
endosoom.  
In patiënten met systemische ijzerstapeling is ijzerstapeling in en schade aan de 
nier gevonden. Dit wekt de suggestie dat chronische ijzerblootstelling kan leiden tot 
niertoxiciteit. Dit wordt mogelijk veroorzaakt door schadelijke effecten van reactieve 
zuurstofradicalen, een proces wat ook wel oxidatieve stress wordt genoemd. Tijdens acute 
ijzerblootstelling beschermt de ??????????? ?antioxidant response? de cel tegen de 
schadelijke effecten van oxidatieve stress. Dit wordt gecoördineerd door de 
transcriptiefactor Nucleaire factor erythroid 2-gerelateerde factor 2 (Nrf2). Echter, het is 
bekend dat in condities van chronische stress de hoeveelheid Nrf2 in de nier uitgeput kan 
raken. Daarom hebben we in Hoofdstuk 4 bestudeerd of nierschade in ciPTECs bij 
chronische ijzerblootstelling kan ontstaan door Nrf2 uitputting als gevolg van ijzer-
gemedieerde oxidatieve stress. Chronische ijzerblootstelling leidde tot ijzerstapeling in de 
cel, productie van reactieve zuurstofradicalen en verhoogde aanwezigheid van het ?????
?????????? ?-gen (??????), wat een marker is voor oxidatieve stress in de cel. De 
ijzerblootstelling activeerde het eerder beschreven Nrf2 beschermingsmechanisme. We 
vonden namelijk verhoogde concentraties van Nrf2 in de celkern en een toename van het 
eiwit NAD(P)H chinon dehydrogenase 1 (NQO1), welke gestimuleerd wordt door Nrf2. Om 
Nrf2 uitputting in ciPTECs na te bootsen hebben we de Nrf2 remmer trigonelline gebruikt. 
Toevoeging van trigonelline aan de ijzerblootstelling verminderde de Nrf2 concentraties in 
de celkern en de hoeveelheid NQO1 in de cel. In tegenstelling tot wat we verwacht 
hadden, leidde Nrf2 remming tot een afname van de hoeveelheid van reactieve 
zuurstofradicalen in de cel, maar was de ?????? genexpressie nog steeds verhoogd. 
Blootstelling aan trigonelline en ijzer leidde tevens tot een toegenomen aanwezigheid van 
het gen ????, wat wijst op endoplasmatisch-reticulum stress. Daarbij was ook het eiwit 
ferritine verhoogd, welke een afspiegeling is van de hoeveelheid ijzer die opgeslagen is in 
de cel, maar ook kan worden verrijkt door andere stress-gerelateerde mechanismen. 
Samengevat, ondanks dat Nrf2 remming geen toename van oxidatieve stress in ciPTECs 
145
Samenvatting
7
527380-L-sub01-bw-vanRaaij
Processed on: 7-1-2019 PDF page: 146
veroorzaakt leidt dit wel tot andere stress-gerelateerde mechanismen die leiden tot een 
toegenomen cytotoxiciteit in PTs tijdens langdurige blootstelling aan hoge 
ijzerconcentraties.  
Hoofdstuk 5 beschrijft immunohistochemische studies omtrent de aanwezigheid 
en lokalisatie van verschillende eiwitten die betrokken zijn bij het ijzermetabolisme in 
nierbiopten van gezonde vrijwilligers en van patiënten met verschillende vormen van 
chronische nierziekten. Bovendien hebben we de aanwezigheid van deze eiwitten in 
relatie tot ijzerstapeling en nierschade in deze biopten bestudeerd. In 33% van de 
onderzochte biopten kwam ijzerstapeling voor in cellen van zowel PTs als DTs. Dit bleek 
vooral bij aandoeningen met schade aan de glomerulus. In de gezonde nier kon de 
aanwezigheid van de ijzeropnametransporters ZIP8, ZIP14 en divalent-metaaltransporter 1 
(DMT1), ijzeropslageiwitten L- en H-ferritine en de ijzerexporteur ferroportin in cellen van 
de PTs worden aangetoond. Dit betekent dat PTs zijn uitgerust om ijzer te recyclen vanuit 
het nierbuisje terug naar de bloedbaan. Daarentegen konden we in DTs alleen de 
ijzeropnametransporters ZIP8, ZIP14 en DMT1 detecteren. In biopten van verschillende 
chronische nierziekten bleek ijzerstapeling geassocieerd te zijn met een toegenomen 
aanwezigheid van de ijzerimporteurs ZIP8 en ZIP14 en de ijzeropslageiwitten L- en H-
ferritine, en/of afgenomen hoeveelheid van de ijzerexporteur ferroportin. Dit betekent 
dat ijzerstapeling in patiënten met chronische nierziekten veroorzaakt kan worden door 
een toegenomen ijzeropname en/of verminderde ijzerexport in de niercellen. 
IJzerstapeling liet ook een relatie zien met oxidatieve stress in de niercellen, aangezien het 
heem oxygenase 1 (HO-1) eiwit verhoogd aanwezig was in de nierbiopten. Dit betekent 
dat ijzerstapeling tijdens chronische nierziekten oxidatieve stress kan veroorzaken wat 
resulteert in nierschade. 
In Hoofdstuk 6 worden de bevindingen van dit proefschrift bediscussieerd en 
tevens worden suggesties gedaan voor toekomstig onderzoek naar het ijzermetabolisme 
in de nier. Samenvattend hebben de bevindingen uit dit proefschrift onze kennis van de 
moleculaire mechanismen van het ijzermetabolisme in de nier van de gezonde mens en 
tijdens systemische ijzerstapeling of chronische nierziekten vergroot. Bovendien hebben 
we meer inzichten gekregen in de potentiële rol van ijzer in het veroorzaken en/of 
verergeren van nierschade. Mogelijk kunnen deze inzichten in de toekomst bijdragen aan 
het ontwikkelen van nieuwe therapieën om ijzer-gemedieerde schade in de nier te 
verminderen.  
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ABBREVIATIONS  
 
546-Tf   Alexa546-labeled transferrin 
Apotransferrin  Iron deficient transferrin 
CHOP   CCAAT-enhancer-binding protein homologous protein 
CiPTEC   Conditionally immortalized proximal tubular epithelial cell  
CKD   Chronic kidney disease 
CM-H2DCFDA  ??????-dichlorodihydrofluorescein di-acetate 
CRP   C-reactive protein 
DAPI    4',6-diamidino-2-phenylindole 
DMT1   Divalent metal transporter 1 
DFX   Deferasirox 
DT   Distal tubule 
DTEC   Distal tubular epithelial cell 
DN   Diabetic nephropathy 
DNA   Advanced diabetic nephropathy 
DNE   Established diabetic nephropathy 
DFX   Deferasirox 
EEA1   Early endosome antigen 1 
eGFR   Estimated glomerular filtration rate 
ER   Endoplasmic reticulum 
FCS   Fetal calf serum 
Fe   Iron 
Fe-NTA   Ferric nitrilotriacetate 
Ferric citrate  FeC 
Ferric iron  Fe3+ 
Ferrous iron  Fe2+ 
FPN1   Ferroportin  
FSGS   Focal segmental glomerulosclerosis 
FTH   Ferritin heavy chain (H-ferritin) 
FTL   Ferritin light chain (L-ferritin) 
GBM   Glomerular basement membrane 
GCLM   Glutamate-cysteine ligase modifier subunit 
GFR   Glomerular filtration rate 
GSTP1-1   Glutathione s-transferase-pi-1-1 
Grz   Glutathione reductase 
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HFE   Human hemochromatosis protein 
HFE-HH   HFE-hereditary hemochromatosis  
HH   Hereditary hemochromatosis   
HMOX-1  Heme oxygenase 1 (mRNA) 
HO-1   Heme oxygenase 1 (protein) 
Holo-Tf   Holo-transferrin 
Holotransferrin  Diferric transferrin 
HPRT   Hypoxanthine-guanine phosphoribosyltransferase 
ICP-MS   Inductively coupled plasma mass spectrometry  
IgAN   IgA nephropathy  
IRE-IRP   Iron responsive element ? Iron responsive protein 
IQR   Interquartile range 
LPI   Labile plasma iron 
LN   Lupus nephritis 
LTCC   L-type voltage-dependent calcium channel 
KEAP1   Kelch like ECH associated protein 1 
KH-H   Krebs-Henseleit HEPES buffer 
KIM-1   Kidney injury molecule 1 
MDA   Malondialdehyde 
MDRD   Modifications of Diet in Renal Disease 
Monotransferrin  Ferric transferrin 
NAG   N-acetyl-?-D-glucosaminidase 
NF-?B   Nuclear factor kappa-light-chain enhancer of activated B cell 
NGALR   NGAL receptor 
NQO1   NAD(P)H quinone dehydrogenase 1 
Nrf2   Nuclear factor-erythroid 2-related factor 2 
NTBI   Non-transferrin-bound iron  
PAS   Periodic acid-Schiff 
PCBP   Poly(rC)-binding protein 
PT   Proximal tubule 
PTEC   Proximal tubular epithelial cell 
ROS   Reactive oxygen species 
siRNA   Small interfering RNA 
SEM   Standard error of the mean 
STEAP3   Six-transmembrane epithelial antigen of prostate 3 
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TBA   Thiobarbituric acid 
TBARs   Thiobarbituric acid-reactive substances 
TBI   Transferrin-bound iron 
TBMD   Thin basement membrane disease 
TIBC   Total iron binding capacity  
Tf   Transferrin 
TfR1   Transferrin receptor 1 
Trig   Trigonelline 
TRPV5 Transient receptor potential cation channel subfamily V 
member 5 
TSAT   Transferrin saturation  
TTCC   T-type voltage-dependent calcium channel 
TXNRD1   Thioredoxin reductase 1 
UPR   Unfolded protein response  
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RESEARCH DATA MANAGEMENT 
 
Appropriate research data management is important for safeguarding scientific integrity, 
open science, safekeeping of valuable datasets and the reuse of data. Research data 
presented in this thesis and obtained during this PhD trajectory at the Translational 
Metabolic Laboratory, department of Laboratory Medicine, at the Radboud university 
medical center (Radboudumc) were archived according to the Findable, Accessible, 
Interoperable and Reusable (FAIR) principles (Wilkinson ??? ???? 2016,? Scientific Data). 
Initially, raw and processed data was stored digitally on a local server of the department 
of Translational Metabolic Laboratory and on paper in the form of labjournals. Later, 
Labguru, a digital lab book, was introduced at this department that replaced the regular 
paper labjournals. Both the local server at the department and Labguru are supported by 
the Information and Communications Technology (ICT) of the Radboudumc. Labguru is 
daily backed up on the local server of the Radboudumc, while data stored on the local 
servers were replicated daily to servers of the Radboud University. The data files on 
Labguru and the local server are accessible by the associated scientific staff members. 
However, once the data are locked, the staff members can only view data files of the 
archive from Labguru and local servers, but not edit or remove any archived files. Studies 
in Chapter 3 and Chapter 4 used the patented cell line ciPTEC, which was developed from 
kidney tissue from an anonymous donor. Informed consent for use of this material was 
obtained. Human studies in Chapter 2 and Chapter 5 were conducted according to Dutch 
ethical guidelines and the principles of the Declaration of Helsinki. All participants gave 
written informed consent to participate in these studies, except when anonymized 
material left over from diagnostic care was used. In this case, in line with Dutch ethical 
guidelines, this material can be used without informed consent and approval from an 
ethical committee. The study protocol used in Chapter 2 was approved by the Medical 
Ethical Review Committee and the Board of Directors of the Radboudumc. All data 
generated or analyzed in this thesis are included in published articles and its additional 
files are available from the associated corresponding authors on request.  
 ?
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CURRICULUM VITAE 
 
Sanne Elisabeth Gerritje van Raaij werd geboren op 4 
februari 1990 te Nijmegen. In 2008 behaalde zij haar 
VWO-diploma aan het Stedelijk Gymnasium Nijmegen. In 
datzelfde jaar begon ze aan de opleiding Biomedische 
Wetenschappen aan de Radboud Universiteit in 
Nijmegen. Ze deed haar bachelorstage bij de afdeling 
Fysiologie van het Radboudumc in het toenmalige 
Nijmegen Center for Molecular Life Sciences (NCMLS), 
onder leiding van Prof. dr. Joost Hoenderop, waar zij 
onderzoek deed naar de rol van S100 eiwitten in het 
reguleren van calcium kanaal TRPV5 in de nier. Ook was 
Sanne betrokken bij het curriculum Biomedische Wetenschappen als studentlid van de 
opleidingscommissie (OLC) Biomedische Wetenschappen en het Onderwijs Management 
Team-1 (OMT-1). Ze vervolgde haar opleiding met de master Biomedical Sciences aan de 
Radboud Universiteit en richtte zich op de hoofdvakken Toxicology en Human 
?????????????? ????? ??????? ???????????? ????? ?????? ??? ??? ????????? ???????? ????
??????????????????????????Karolinksa Institutet in Stockholm in Zweden. Onder leiding van 
dr. Lena Sahlin bestudeerde ze de rol van de hormoonverstorende stof bisfenol A op 
oestrogeenreceptoren in de baarmoeder van de rat. Tijdens haar tweede masterstage, 
onder leiding van Prof. dr. Roos Masereeuw, op de afdeling Farmacologie-Toxicologie van 
het Radboudumc in het NCMLS, ontwikkelde Sanne een nieuw kweekmodel van de 
muizentestis waarin ze de rol van bisfenol A en transporteiwitten tijdens ontwikkeling van 
het weefsel onderzocht. Sanne rondde haar masteropleiding ???? ????? af, en ontving 
daarnaast de Universitaire Studieprijs van de Radboud Universiteit en de 2014 ????? ??????
?????? prijs van de Nederlandse Vereniging voor Farmacologie.  
 In februari 2014 startte Sanne haar promotieonderzoek bij het Translationeel 
Metabool Laboratorium, onderdeel van de afdeling Laboratorium Geneeskunde, van het 
Radboudumc in het Radboud Institute for Molecular Life Sciences (RIMLS) in Nijmegen. 
Onder leiding van Prof. dr. Dorine Swinkels, Prof. dr. Roos Masereeuw en dr. Rachel van 
Swelm verrichte ze onderzoek naar de processen van het ijzermetabolisme in de gezonde 
nier en in condities van systemische ijzerstapeling en chronische nierziekten. Tijdens haar 
onderzoek heeft Sanne zeven studenten begeleid en haar werk gepresenteerd op 
verschillende internationale congressen. Haar onderzoek heeft geleid tot meerdere 
artikelen die gepubliceerd zijn in wetenschappelijke tijdschriften en dit proefschrift. 
Gedurende haar promotietraject rondde ze tevens de postdoctorale opleiding tot 
toxicoloog en de Basiscursus Regelgeving en Organisatie voor Klinische Onderzoekers 
(BROK) succesvol af. Sanne is momenteel werkzaam als Country Approval Associate bij de 
contract research organisatie PPD in Bennekom en ondersteunt hier klinisch onderzoek.  
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PhD PORTFOLIO 
?
Oral and poster presentations are indicated with a * and # after the name of the activity, respectively.  
 
 
Name PhD student:  ????????????? 
Department:  ??????????????
???????????????????? 
Graduate school:  ??????????????????????
???????????????????????? ??????????????????????? 
 
PhD period:  ????????????????????????
Promotors:  ??????????? ???????????
?????????????? ?????????
Co-promotor: ??????????????????? ?
TRAINING ACTIVITIES Year(s) ECTS 
a) Courses & Workshops 
- Introduction day Radboudumc 
- RIMLS Graduation Course 
- ???????? ?????????????????????????? 
- ????????????????????????????? 
- ???????????????????????????? 
- ?????????????????????????? 
- ????????????????????????? 
- BROK course, exam and registration 
 
2014 
2014 
2015 
2015 
2015 
2016 
2016 
2016 
?
0.5 
2.0 
3.0 
1.0 
1.5 
3.0 
1.5 
1.5 
b) Seminars & Lectures 
- RIMLS Seminars and Technical forum  
- RIMLS Radboud Research Rounds (Plus) 
- Kidney research theme lunch meeting* 
- TML research meeting*** 
 
2014-2017 
2014-2017 
2015-2018 
2015-2018 
 
1.9 
1.1 
1.65 
2.95 
c) (Inter)national Symposia & Congresses 
- 2nd Benelux congress on Physiology and Pharmacology 
- European Iron Club Verona#  
- RIMLS PhD retreat##* 
- RIMLS New Frontiers 
- Seventh Congress of the International BioIron Society** 
 
2014 
2014 
2014, 2015, 2016, 2017 
2014, 2015 
2017 
 
0.25 
1.5 
2.75 
2.0 
2.25 
TEACHING ACTIVITIES Year(s) ECTS 
d) Supervision of internships 
- Master student A. Sebregts 
- Master student L. Miesen 
- Honours bachelor student K. Bouman 
- Master student C. van der Horst 
- Master student M. Platenburg 
- Bachelor student A. Geerlings 
- Master student M. Poppa 
 
2014-2015 
2014-2015 
2015-2016 
2016-2017 
2017 
2017 
2017-2018 
 
2.5 
2.5 
0.8 
2.0 
2.0 
1.0 
1.7 
TOTAL 42.85 
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DANKWOORD 
 
Het is echt zover; mijn proefschrift is af. Ik sluit hiermee een periode van 5 jaar af, waarin 
ik veel heb geleerd over onderzoek doen, de wetenschap en mezelf. Maar ik had alle 
voorbereidingen voor dit proefschrift ???????????????????????????? ?????????? ?????????????
had kunnen bouwen op heel veel mensen om mij heen. ???????????????????????????????????
heb de mooie momenten en mijlpalen mogen vieren met velen.  
 
Allereerst wil ik mijn promotoren en copromotor bedanken. Prof. dr. D.W. Swinkels, Beste 
??????. Wat heb je me een boel geleerd over de patiënt binnen wetenschappelijk 
onderzoek. Inmiddels vraag ik mezelf ook bij ieder onderzoeksidee af wat dit de patiënt 
daadwerkelijk gaat opleveren. Wat is het van fundamenteel belang? So what? Wat heeft 
de patiënt hier aan? Je kritische blik heeft het me soms niet makkelijk gemaakt, maar 
hierdoor hadden we heldere doelen in mijn onderzoek. Tijdens werkoverleg, maar ook 
menig keer aan het eind van de middag, kon ik bij je binnen lopen om vragen te stellen of 
(kort) iets te bespreken. Zodra mijn onderzoek vastliep omdat iemand niet reageerde, had 
je herinneringsmails snel verstuurd. Vooral binnen mijn klinische studie stimuleerde je me 
volop om door te gaan, en dat heeft een mooi artikel opgeleverd! Dank je wel! Prof. dr. R 
Masereeuw, Beste ????. Tijdens mijn studie heb je mijn interesse gewekt voor het 
onderzoeksgebied toxicologie. Ik ben nog steeds blij dat mijn masterstage met de 
testiskweek en bisfenol A, via ondersteuning bij onderwijsvernieuwing, heeft geleid tot 
het solliciteren op deze promotieplaats en nu dit proefschrift. Ook al is de samenwerking 
op sommige momenten wat minder intensief geweest, bij vragen van mij maakte je tijd in 
je agenda en kon ik bij je terecht. Naast het inhoudelijke werk kon ik ook met persoonlijke 
vragen bij je langskomen en dat is voor mij niet vanzelfsprekend. Want je liet me als geen 
ander zien dat je naast testes en later ciPTECs onder de microscoop ook interesse had in 
privézaken en mijn hobbies (gehaakte muisjes). Dank je wel! Dr. R.P.L. van Swelm, Beste 
??????. In het eerste jaar van mijn PhD deelde we een werkkamer op de gang van TML en 
een hotelkamer in Verona. Ook al hadden we een andere onderzoeksfocus, ik kon en kan 
je nog steeds altijd vragen hoe jij over resultaten, nieuwe experimenten, of vragen van 
reviewers denkt. Het heeft zo moeten zijn dat we allebei hebben ervaren hoe het leven 
kan lopen, en ook daarover konden we samen praten. Ook in lastige tijden. Ik waardeer 
het om te zien hoe hard je werkt voor je onderzoek maar daarnaast interesse hebt voor 
anderen en bereid bent die te helpen. Je kon kritisch zijn in welke elementen wel en niet 
nodig waren van mijn nieuwe onderzoeksideeën en je steekt dit niet onder stoelen of 
banken, maar je weet altijd een oplossing om het doel te bereiken. Hier ga je zelf 100% 
voor en zo kon je mij ook stimuleren om altijd door te blijven gaan met het doel scherp 
voor ogen. In mijn geval dit proefschrift, en dat is nu bereikt. Dank je wel! 
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?????????????????????????ep, lieve Coby, Erwin, Siem, Rian, Guus en Laura. Jullie hoorde mij 
goed op het lab als de muziek iets harder mocht (Erwin) of liever iets zachter (Siem). Ik kon 
gezellig komen kletsen, lachen, dropje eten (Rian) of er werd een grapje uitgehaald met of 
zonder droogijsbommetjes (Coby). Als ik hulp nodig had, dan kon ik bij jullie terecht. Hulp 
bij het uitvoeren van bepalingen, includeren van patiënten of praktisch tips voor een 
nieuw experiment. Ook als met spoed iets besteld moest worden, de vriezer weer niet 
goed dicht ging; jullie hebben ongetwijfeld verhalen genoeg. Maar ook was er tijd voor 
een serieus gesprek. Wat ik zeker zal onthouden als dé ijzergroep traditie: de appelkanjers 
van Looijenga. Ik had nog nooit van een appelkanjer gehoord maar wat was ik blij verrast. 
Ze kwamen terug bij de jaarlijkse verjaardagstraktaktie en de ijzergroep-uitjes en dat was 
iedere keer weer genieten. Daarom heb ik ze ook geïntroduceerd bij iedere keer dat een 
nieuw artikel geaccepteerd werd. De appelkanjers zijn echt een goede herinnering voor 
mij! De ijzergroep is een klein, hecht groepje waar ik met veel plezier deel van uit heb 
mogen maken en ik me ook altijd heel erg thuis heb gevoeld. Dank jullie wel! 
 
Ik heb lief en leed mogen delen met mijn medepromovendi, in het bijzonder Manon. 
Allebei waren we lange tijd de enige PhD student binnen onze onderzoeksgroep en dit 
heeft voor een hele speciale band gezorgd. Nu ben ik heel blij dat je mijn paranimf bent! 
Ook heb ik veel kunnen delen met Anke, Walinka, Lieke, Kioa en Anne. We hebben het 
allemaal zwaar gehad met ons onderzoek inhoudelijk, maar hadden we het ook menig 
keer ??????? tijdens de PhD retreats of in de Aesculaaf. We deelden een hoekje in de 
kantoortuin of een kantoor iets verderop in de gang. We deelden onze ervaringen over 
het onderzoek binnen het RIMLS, binnen TML, of binnen klinisch onderzoek, want we 
zaten allemaal in hetzelfde schuitje. Maar hierdoor heb ik mijn hart kunnen luchten bij 
jullie. Zeker niet onbelangrijk heb ik ook veel plezier gehad op het lab, de kantoortuin, de 
koffiekamer en de vele keren daarbuiten. Want jullie zorgen voor veel gezelligheid en daar 
kijk ik met heel veel plezier op terug. Succes met de afronding van jullie proefschriften en 
ik hoop jullie nog vaak te zien (inclusief de mannen)! Dank jullie wel! Federica, my 
kantoortuin-bench partner. I experienced no burden in helping you because you are a kind 
person who would always help me if I needed this. Good luck with finishing your thesis; 
you will definitely succeed! Thank you! Angel, I know you are not a PhD student in our lab, 
but it feels right to say my thanks to you in this section. You were among the PhD students 
with a lot of joy, and we received a lot of joy in return from you. I enjoyed our serious 
conversations and less serious talks with a drink. I also enjoyed seeing that you had 
several nice chats with Maarten, which I know he liked as well. Thank you! 
 
????? ???????????????????????????????Op de Q locatie, waar ik mijn werkplek had en mijn 
experimenten deed. In het bijzonder Bea, voor je oprechte interesse in mijn onderzoek; 
Alexandra, omdat je stiekem ook een beetje onderdeel bent van de ijzergroep en dit is 
heel fijn; en Jacintha, voor het overleggen over de centrifuges, de gezellige 
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kletsmomentjes maar ook voor je vragen over hoe het echt met me ging. Op de P locatie, 
waar ik dan wel geen vaste werkplek had, voelde ik me niet minder thuis. Want op P 
kwam ik meer dan dagelijks. Frans en Özlem, wat hebben jullie me vaak geholpen met 
vragen over de celkweek. Annelies en Thea, dank jullie wel voor de babbels en alle 
mentale ondersteuning. Jullie zorgde voor extra gezelligheid (in de celkweek). Voor qPCRs 
??????????????????????? ?????????????????????????????????????????????????????? ?????????
plekken. Maar ik werd met plezier verwelkomd en maakte gelijk een praatje met onder 
andere Fokje, Karin, Theo, Karina en Berendien. Ook al heeft TML twee locaties, ik heb 
me op allebei de plekken thuis gevoeld! Daarbij wil ik ook zeker even de secretaresses 
Sandra, Erna en Conny bedanken, want jullie hebben me veel geholpen en voorzien van 
gezellige momenten. Dank jullie wel! 
 
Bedankt ook aan ????? ??????? ??????????? Jitske en Carolien, jullie hebben mij de ciPTEC 
celkweek geleerd, inclusief de trucjes om het goed in de vingers te krijgen. FarmTox 
????????? Martijn, Tom, Jelle, en zeker ook Janny, ik heb jullie veel gevraagd bij problemen, 
nieuwe dingen, antilichamen, en nog heel veel meer rondom de ciPTECs. Ik heb deze 
cellen echt wel (meer dan) eens vervloekt, maar met veel proberen en tips van jullie heeft 
dit tot maarliefst twee hoofdstukken in mijn proefschrift geleid. Ik hoop dat er nog veel 
ciPTEC publicaties mogen volgen! Dank jullie wel! Milos and Michele, thank you for 
answering all my ciPTEC questions and the mental ciPTEC support! 
 
Ook al heeft mijn zebravis werk uiteindelijk niet tot een hoofdstuk in dit proefschrift 
geleid, ik heb veel geleerd van en kunnen bouwen op de zebravis community in het 
Radboud, in het bijzonder Erik, Selma, Tom en Ralph. Vissen klaarzetten, injecteren of 
dissectie, ik heb veel van jullie mogen leren en heb dit ook erg leuk gevonden. Thank you 
Paco for explaining many things to me in the zebrafish lab. I enjoyed working there!  
 
Ik wil hier ook zeker Vivienne en Jeanne vermelden. Want dit alles begon met het 
opgroeien van muizen testes in transwells. Dit heeft me veel gebracht, wat zich nu 
gedeeltelijk vertaalt in dit proefschrift. Want Vivienne, de dissectie van muizen testes 
onder de microscoop deed je alsof het de normaalste zaak van de wereld was. Ik wist dat 
??? ???? ?????????? ??????? ????? ??????????? ??? ????? ????????? ???? ????? ???? ???? ???????
bovenop. Ik vond het ontzettend interessant. Het heeft me gevoel voor precisie en 
doorzettingsvermogen bijgebracht! Jeanne, immunohistochemie sprong er tijdens mijn 
studie nou niet echt uit, maar daar ben ik in veranderd. Wat een ontzettend leuk vak vind 
ik dat! Je hebt me met veel enthousiasme het snijden, kleuren, en weer optimaliseren van 
de antilichamen bijgebracht. Ik kon tijdens mijn promotie nog steeds met veel vragen over 
de kleuringen bij je terecht. Ik ben erg blij dat een heel hoofdstuk in dit proefschrift 
bestaat uit kleuringen en de hypotheses daaruit. Maar daarnaast heb ik met jullie allebei 
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veel leuke gesprekken gehad. Tijdens mijn promotietraject dan wel met minder regelmaat, 
maar niet minder gezellig. Dank jullie wel!  
 
Ik ben dankbaar voor de hulp van mijn studenten Angela, Laura, Karlijn, Chiel, Merel en 
Alex. En hier wil ik ook zeker Maaike bij betrekken. Jullie hebben hard gewerkt om 
verschillende onderdelen van dit proefschrift tot stand te brengen. Maar ook heb ik het 
altijd leuk gevonden om met jullie de verschillende experimenten te doen en gezamenlijk 
tot nieuwe resultaten te komen. We hebben heel veel uren in de celkweek gezeten, niet 
?????????????? ???? ???? ??????? ???????? ?????? ???????? Dank jullie wel en succes met jullie 
verdere carrière! Thank you Madalina for your help as one of my students. You have 
worked hard to contribute to this thesis.  
 
Ook wil ik graag alle coauteurs bedanken voor de ondersteuning bij de verzameling van 
patiënten en data en jullie serieuze blik op mijn manuscripten. Dank je wel Harry van 
Goor, Marius van den Heuvel, Tom Nijenhuis, Ewout Hoorn, Alexander Rennings, Bart 
Biemond, Saskia Schols en Hennie Roelofs. I would like to thank all coauthors for their aid 
in patient inclusion and data collection as well as their critical views on my manuscripts. 
Thank you Kaila Srai, Robert Unwin, Paul Bass, Stephan Walsh and Dominic Patel. Zeker 
wil ik ook de ondersteuning van het tegenwoordige Radboud Technology Center for 
Clinical Studies (RCT-CT), in het bijzonder Fenna, bedanken voor het beantwoorden van al 
mijn vragen rondom klinisch onderzoek. Dat waren er nog al wat. Ook wil ik alle 
proefpersonen bedanken die deel hebben genomen aan mijn klinische studie (Hoofdstuk 
2) of toestemming hebben gegeven om hun materiaal te gebruiken in klinisch onderzoek 
(Hoofdstuk 5). Mijn inziens is deelname aan klinisch onderzoek essentieel voor het vooruit 
brengen van de medische wetenschap.  
 
Ik kan hier niet anders dan mijn vriendinnen Rianne, Hanna, Eva, Ilja en Bernadette 
bedanken. Wat heb ik vaak op maandagavond mijn hart gelucht over wat er wéér niet 
goed ging op het lab. Met ondersteunende woorden brachten jullie me er weer bovenop, 
al was er soms ook wat 43 voor nodig. Ik waardeer het dat jullie vroegen hoe het met mijn 
proefschrift ging, en dat ik kon zien dat ook jullie blij waren toen mijn eerste artikel was 
geaccepteerd of ik het manuscript van dit proefschrift had ingediend. Ook in moeilijke 
tijden zijn jullie er voor mij, dat weet ik nu heel zeker. Jullie vriendschap betekent veel 
voor mij! Dank jullie wel! Anouk, als er iemand altijd voor me klaar staat dan ben jij dat 
wel. Al heel veel jaren kunnen we kletsen over van alles en nog wat. Ik ga graag samen een 
lang weekend weg rond mei, borrelen met Licor maar ook even kort tussendoor een chai 
latte drinken. Want ik kan altijd van je op aan en altijd op je bouwen. Zoals beloofd zul je 
mijn lekenpraatje kunnen volgen! Dank je wel! 
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Lieve ???????, jullie zijn echt met te veel om iedereen hier allemaal bij naam te noemen, 
maar jullie weten allemaal dat ik ieder van jullie bedoel. Want jullie zorgen voor heel veel 
gezellige dagen en ondersteunen mij wanneer dan ook. Als het even wat lastiger is een 
stevige knuffel. Een por in de zij om even te sollen. Maar dikwijls een grote glimlach en 
een uitbundige lach. Dank jullie wel allemaal! 
 
Lieve ??????, ????, ????? en ??????, ik zie jullie ook als mijn familie. Ik val bij jullie in een 
warm bad en kan helemaal mezelf zijn. Jullie hebben me zien zwoegen de afgelopen jaren 
en hebben me echt ondersteund, wat ook ging in de vorm van macaroni of zelfgemaakte 
soep. En gewoon even kletsen, of een avondje gezellig met zijn allen. Ik hoop dit nog lang 
samen te doen. Dank jullie wel! 
 
Lieve ????, zonder al je hulp was dit proefschrift echt niet afgekomen. Je weet altijd te 
zeggen wat me stimuleert om door te gaan of me uit een dal te halen. Ik kan niet 
beschrijven hoeveel steun en liefde je me geeft en wat dit met me doet. Het heeft een 
hele bijzondere plaats in mijn hart. Dank je wel! Hetzelfde geldt voor mijn sissy. Lieve ????, 
je zorgt voor mij en ik zorg voor jou. Even knuffelen, even kletsen, of even samen een 
hapje eten. Ik ben blij dat ik veel met je kan delen en samen met je kan doen. Want samen 
kunnen we praten over serieuze dingen maar ook lol hebben om leuke kattenplaatjes. 
Tijdens mijn verdediging sta je naast me als mijn paranimf, dat betekent heel veel voor 
mij! Dank je wel! 
 
Lieve ???????, ik heb soms echt met je te doen hoeveel je juist voor mij doet. Het zijn 
soms maar kleine dingen, maar die komen uit een groot hart. Wat er ook is, wat ik ook 
heb meegemaakt, ik kan bij je aankloppen en je luistert. Want je hebt me nog al eens 
bijgestaan als het ging over mijn werk of papa. Ik kan niet anders dan zeggen dat ik blij ben 
dat je thuis bent als ik er bijna ben. Om even lekker te knuffelen. Even samen te kletsen. 
Of ergens een drankje te doen. Samen kunnen we de wereld aan, dat hebben we gemerkt. 
In de toekomst gaan we veel mooie dingen samen beleven! Dank je wel! 
 
Als laatste bedank ik ????. Het heeft niet zo mogen zijn dat ik deze woorden in het echt 
tegen je kan zeggen, maar je hebt me heel veel geleerd en liefde gegeven. Ik weet dat je 
beretrots op me bent dat mijn proefschrift nu af is. Ik denk graag terug aan je brede 
glimlach bij de uitreiking van mijn masterdiploma en het ritje in de Audi. Anders had je 
hier nu op precies dezelfde manier gestaan. Na afloop van mijn verdediging proost ik op 
jou. Proost op het leven. 
 
 
Liefs, Sanne  
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